

Index

Page numbers followed by “f” indicate figures, “t” indicate tables, and “b” indicate boxes.

A

- Abacavir, 643, 647b
and HLAB*5701, 135
unwanted effects, 707
- Abatacept, 330, 331t, 718t
- Abciximab, 69, 305
- ABC transporters, 21–23
- Absorption, drug, 106–110, 107f, 110b
effect of variation in rate of, 126
factors affecting gastrointestinal, 106–108
from the intestine, 106
methods for delaying, 109
pharmacokinetic interactions, 693
- Abstinence syndrome, 516, 595
- Acamprosate, alcohol dependence, 597b, 605b, 607
- Acarbose, 382, 383b
- ACAT (acyl coenzyme A: cholesterol acyltransferase), 286
- ACE *see* Angiotensin-converting enzyme (ACE)
- Aceclofenac, 319t
- A cells, 372
- Acemetacin, 319t
- Acetaldehyde, 605–606
- Acetaminophen *see* Paracetamol
- Acetazolamide, 109, 356
- Acetylation, 134–135, 228
- Acetylcholine (ACh), 141–143
in Alzheimer’s disease, 483
in the CNS, 468–470, 469f, 470b
effects on blood pressure, 151, 152f
functional aspects, 470
gastric acid secretion, 362
muscarinic actions, 151
nicotinic actions, 151
noise analysis, 27, 27f–28f
release, 154–156
inhibitors, 167–168
synthesis, 154–156
inhibitors, 167
vomiting, 365
- Acetylcholine (ACh) receptors, 151–154, 469–470
muscarinic *see* Muscarinic ACh receptors
nicotinic *see* Nicotinic acetylcholine receptors
- Acetylcholinesterase (AChE), 147–148, 155, 168, 171b
in Alzheimer’s disease, 483
inhibitors *see* Anticholinesterases
- Acetylcysteine, 325, 701
- N-Acetylcysteine, 678
- Acetyl-glycerol-ether-phosphorylcholine *see* Platelet activating factor (PAF)
- N-Acetyl-5-methoxytryptamine *see* Melatonin
- N-Acetyl-p-benzoquinone imine, 325, 701
- Acetylsalicylic acid *see* Aspirin
- Acetyltransferase, 135
- Aciclovir, 616b, 644–645, 646b
action/effects, 112–113, 613
unwanted effects, 645
- Acid-base balance, 352
- Acidic drugs
binding, 103
excretion, 120
ionization, 120
weak, 101, 102f–103f
- Acitretin teratogenicity, 706
- Acquired immune response *see* Adaptive (acquired) immune response
- Acquired immunodeficiency syndrome (AIDS) *see* HIV/AIDS
- Acridines, 613
- Acriflavine, 613
- Acrolein, 118–119, 678
- Acromegaly, 394–395, 397, 713
- ACTH *see* Adrenocorticotrophic hormone (ACTH)
- Actin, 59
- Action of drugs
cellular aspects, 49–65
in the central nervous system, 444–446, 445b
general principles, 6–19
molecular aspects, 20–48
sites of, 149
- Action potentials, 53–55, 57f, 246, 247f
- Activated partial thromboplastin time (APTT), 299
- Acute macular degeneration (AMD), 684
- Acute-phase proteins, 86
- Acyl coenzyme A: cholesterol acyltransferase (ACAT), 286
- N-Acyl-phosphatidylethanolamine (NAPE), 223
- Adalimumab, 330, 331t, 370, 718t
- Adaptation, physiological, 16
- Adapter proteins, 37
- Adaptive (acquired) immune response, 77, 82–86, 82b
antibody-mediated (humoral), 84–86
cell-mediated, 86
effector phase, 83f, 84–86
induction phase, 83–84, 83f
- Addiction *see* Dependence; *specific drugs*
- Addison’s disease, 401, 406–407
- Adefovir, 643
- Adenine deaminase deficiency, 722
- Adeno-associated virus, 720
- Adenohypophysis, 394, 399b, 402b, 403–404
- Adenosine, 258
actions/effects, 470–471
and asthma, 206
and the cardiovascular system, 205
in the central nervous system, 206
clinical uses, 255t
coronary blood flow, 251
ischaemic preconditioning, 249
as a mediator, 204–206
metabolism, 471
nociceptive pathway, 510
receptors *see* Adenosine receptors
vasodilatation, 272
- Adenosine deaminase, 681
- Adenosine diphosphate (ADP), 204, 205f
action/effects, 205b
as a mediator, 206
and platelets, 206
- Adenosine receptors, 204, 206t, 471
antagonists *see* Thienopyridines blockers, 205b
- Adenosine triphosphate (ATP), 21–23, 177, 204, 205f
action/effects, 205b, 470–471, 509
co-transmission, 147, 147f
in inflammation, 207
as a mediator, 207
metabolism, 471
NANC transmission, 145–147, 148t
as a neurotransmitter, 207
in nociception, 207
nociceptive pathway, 510
- Adenovirus, 719–720
- Adenylyl cyclase, 30, 32, 33f
- ADH *see* Antidiuretic hormone (ADH)
- ADHD *see* Attention-deficit hyperactivity disorder (ADHD)
- Adhesion molecules, 78, 80
- Adipose tissue, 388–389
- Administration, routes of, 106–110, 107f
drug dependence, 592
see also specific drugs; specific routes
- ADP *see* Adenosine diphosphate (ADP)
- Adrenal cortex, 400–407
- Adrenal hormone synthesis inhibitors, 683, 684b
- Adrenaline, 139, 174
action/effects, 7, 174, 182t–184t, 186, 256
cardiac arrest, 252
clinical uses, 255t
allergic emergencies, 344
shock, 281
delaying drug absorption, 109
efficacy, 13
hypoglycaemia, 184–186, 372
and local anaesthetics, 529
- Adrenal medulla, 140–141, 400
- Adrenal steroids, 84, 396, 399b, 402–406
action/effects, 343, 400–405
anti-inflammatory, 404–405
immunosuppressive, 404–405
metabolic and systemic, 402–403, 402b
negative feedback on anterior pituitary and hypothalamus, 403–404
unwanted, 343
bone metabolism and remodelling, 437
clinical uses, 401, 406b
anticancer drugs, 683, 684b
antiemesis, 367
asthma, 342–343, 344b
chronic bowel disease, 370
chronic obstructive pulmonary disease, 344–345
thyroid disorders, 415
drug interactions, 635, 695
in hypoglycaemia, 372
as immunosuppressants, 330
inhalation administration, 109
mechanism of action, 402, 405b
new directions, 407–408
pharmacokinetics, 406

- release, 402
 replacement therapy, 401
 secretion, 399b
 synthesis, 402
 unwanted effects, 406, 698
see also Mineralocorticoids; *specific adrenal steroids*
- Adrenoceptor agonists, 181–186, 186b
 actions, 181–186, 182t–184t, 185f
 clinical use, 186, 186b
- Adrenoceptor antagonists, 186–190
- Adrenoceptor(s)
 characteristics, 176t
 classification, 174–175, 175b
 drugs acting on, 181–190
 polymorphisms, 46
- Adrenocorticotrophic hormone (ACTH), 235t, 396, 398, 399b, 402, 565
 actions, 398
 antagonists, 280
 effect of glucocorticoids, 403–404
 receptors, 46
 role in inflammation, 86
 secretion, 398, 398f
- Adrenomedullin, 37, 267
- Adsorbent agents, 370
- Advanced glycation end products (AGE), 377–378
- Adverse drug reactions/harmful effects, 698–709
 classification, 698–699
 related to pharmacological action of drugs, 698–699
 unrelated to pharmacological action of drugs, 699
see also Carcinogens; Excitotoxicity; Hypersensitivity; Idiosyncratic reactions; Teratogenicity; Toxicity; *specific drugs*
- Aequorin, 49
- Affective disorders, 564
- Affinity, 8
- African sleeping sickness, 665
- After-depolarisation, 248, 248f
- Afterload, 249–250, 265
- Agar, 368
- Age and drug responsiveness/
 effectiveness, 690–691
 drug metabolism, 690–691
 renal excretion, 690
 sensitivity to drugs, 691
- AGEPC *see* Platelet activating factor (PAF)
- Aggregation, 476, 478t
- Aggression, 534
- Agomelatine, 471
- Agonist dose ratios, 18
- Agonists, 8, 14b
versus antagonists, 7
 full, 8, 11–13
 inverse, 13, 14f
 partial, 8, 11–15, 12f
 trafficking, 37
- Agouti-related peptide (AgRP), 388, 399
- Agouti-signalling protein, 399
- Agranulocytosis, 414, 561, 708
- AIDS *see* HIV/AIDS
- Akt, 39–40, 238–239
- Albendazole, 670
 action/effects, 616
 clinical uses, 669
- Albinism, 133
- Albumin, 103–105, 120, 694
- Alcohol *see* Ethanol
- Alcohol dehydrogenase, 605
- Alcohol-related neurodevelopmental disorder (ARND), 604–605
- Aldehyde dehydrogenase, 179, 605–606
- Aldesleukin, 686
- Aldose reductase inhibitors, 378
- Aldosterone, 64, 231, 350–351, 400–401, 401t, 406–407
 antagonists, 274t, 355–356
 pharmacokinetics, 355
 unwanted effects, 355–356
 escape, 280
 release, 407
 synthesis, 407
- Alemtuzumab, 684
- Alendronate, 438
- Alfentanil, 497, 510, 519
- Alginates, 364
- Alimemazine, 333t
- Aliskiren, 274, 274t
- Alkalinisation, urinary, 356–357
- Alkylating agents, 677, 677t, 678f
 action/effects, 615
 and related compounds, 678–679, 679b
 teratogenicity, 706
see also specific drugs
- Allergic bronchopulmonary aspergillosis, 649
- Allergy, 87
 antihistamines, 333–334
 emergencies, 344
see also Hypersensitivity
- ALLHAT trial, 96
- Allodynia, 503–505
- Allopathy, 2
- Allopurinol, 331–332, 357
 allergic reactions, 707
 drug interactions, 332, 695
- N-Allylnormetazocine, 511–512
- Almotriptan, 202t
- Alopecia, 676
- α -adrenoceptor agonists, 181
- α -adrenoceptor antagonists, 181, 182t–184t, 186–187, 187b
 action/effects, 174, 182t–184t, 561
 clinical uses, 187, 187b
 non-selective, 186–187
 unwanted effects, 187
- α -adrenoceptors, 143, 181
- α_1 -adrenoceptor agonists, 271
- α_1 -adrenoceptor antagonists
 clinical uses
 benign prostatic hypertrophy, 358
 hypertension, 277–278, 279t
 selective, 187
- α_1 -adrenoceptors, 174
 action/effects, 175, 176t, 181
 in the CNS, 461–462
- α_2 -adrenoceptor antagonists, 572–573
 clinical uses, 383
 selective, 187
- α_2 -adrenoceptors, 174
 action/effects, 176t, 181, 184–186
 in the CNS, 461–462
 downregulation, 571
 vasodilatation, 274
- α -bungarotoxin, 23
- Alphacalcidol, 357–358, 439
- α -endorphin, 232
- α -Glucosidase inhibitors, 382–383
- α -melanocyte-stimulating hormone (α -MSH), 388
- α -methylnoradrenaline, 190
- α -methyl-p-tyrosine, 182t–184t
- α -methyltyrosine, 177, 190, 193b, 584–585
- α -oxoglutarate, 448
- α -synuclein, 486
- α -tocopherol, 480
- α -toxins, 23
- Alphaxolone, 458, 492
- Alprazolam
 characteristics, 533t
 clinical uses, 534
- Alprenolol, 182t–184t, 187–188
- Alprostadil, 216b, 429
- Alteplase, 307, 481, 481b
- Alternative pathway, 79
- Alternative therapeutic principles, 2–3
- Aluminium hydroxide, 358, 364
- Aluminium salts, 364
- Alvimopan, 515, 520
- Alzheimer's disease, 476, 481–485, 483b
 animal models, 93
 loss of cholinergic neurons, 483
 pathogenesis, 481–483, 482f
 protein misfolding and aggregation, 478t
 in smokers, 601
 therapeutic approaches, 483–485
 cholinesterase inhibitors, 483–484, 484t
 memantine, 483–485
- Amanita phalloides, 700
- Amantadine, 645, 646b
 clinical uses
 bipolar disorder, 581
 Parkinson's disease, 486, 489
- Amascarine, 681
- Ames test, 703
- Amphetamine psychosis, 585–586
- Amphetamine(s), 191, 462, 584–586, 585t, 586b
 action/effects, 182t–184t, 193b, 554, 559–560
 behavioural effects, 465
 chemical use, 586
 chronic use, tolerance and dependence, 585–586
 clinical uses, 391
 dependence, 593t
 drug interactions, 578
 exhaustion of mediators, 16
 pharmacokinetics, 586
 pharmacological effects, 584–585
 related drugs, 584–586
 structure, 585f
 unwanted effects, 586
 use in sport, 712t, 713, 714b
- Amidation, 228
- Amikacin, 630
 antibacterial spectrum, 630
 resistance, 630
- Amiloride, 356
 excretion, 352–353
 pharmacokinetics, 356
 sodium channel blocking, 64
 unwanted effects, 356
- Amino acid(s)
 excitatory *see* Excitatory amino acids
 transmitters, 448–460, 449f
- Aminoglutethimide, 402, 683
- Aminoglycoside antibiotics, 167, 167b, 630–631
 action/effects, 631b
 antibacterial spectrum, 630
 elimination/excretion, 120
 inactivation, 619
 mechanism of action, 624t, 630
 ototoxicity, 135
 pharmacokinetics, 630
 resistance, 619, 630
 unwanted effects, 630–631, 704t
- Amino laevulinic acid (ALA), 134
- Aminophylline, 588
 clinical uses
 asthma, 341
 status asthmaticus, 343

- Aminopyridines, 172
 Aminosaliculates, 370
 5-Aminosalicylic acid, 327–328, 370
 Amiodarone, 257, 259
 action/effects, 256
 clinical uses, 257b
 drug interactions, 694
 mechanism of action, 255t
 partitioning into fat/tissues, 106
 repeated dosing, 126
 thyroid dysfunction, 413
 Amiphenazole, 713
 Amisulpride
 action/effects, 558
 clinical efficacy, 563
 clinical uses, 562b
 Amitriptyline, 567, 574, 576b
 characteristics, 568t–570t
 clinical uses, 581
 neuropathic pain, 521
 nocturnal enuresis, 358
 drug interactions, 365
 Ammonium chloride, 357
 Amnesia, 535
 Amodiaquine, 660
 Amoebapores, 664
 Amoebas, 655, 656t
 Amoebiasis, 664
 Amoebicidal drugs, 664
 Amorolfine, 653
 Amoxicillin, 627
 clinical uses, 627b, 630b
 drug interactions, 426
 AMP-activated protein kinase (AMPK), 380
 AMPAkinases, 455, 555
 Ampalex, 455
 AMPA receptors
 activation, 477
 effects of ethanol, 603
 glutamate, 449, 451, 454–455
 Amphenicols, 629–630
 antibacterial spectrum, 629
 clinical uses, 630b
 mechanism of action, 624t
 pharmacokinetics, 630
 unwanted effects, 630
 Amphotericin, 615, 617b, 650–651
 action/effects, 650
 clinical uses, 666
 packaging in liposomes, 113
 pharmacokinetics, 650
 unwanted effects, 651
 Ampicillin, 627
 resistance, 619
 Amprenavir, 643
 Amrinone, 259
 Amygdala, 388
 Amygdaloid nucleus, 463
 Amylin, 372, 377, 387t
 Amyl nitrite, 260–261, 589
 Amyloid, 377, 481–482
 Amyloid deposits, 476, 481–483
 Amyloid precursor protein, 93, 481–483
 Amyotrophic lateral sclerosis, 478t, 480
 Anabolic steroids, 423, 711–713
 Anabolism, 115
 Anacetrapib, 288
 Anaemia
 aplastic, 692, 699, 708
 haemolytic, 316–317, 708
 treatment, 309–314
 types of, 309
 Anaesthetics, general, 446t, 492–502
 clinical uses, 501b
 in combination with other drugs, 502
 dependence, 593t
 inhalation, 497–500, 499f
 characteristics, 498t
 clinical uses, 501b
 currently used, 500–501, 501b
 idiosyncratic reactions, 692
 induction and recovery, 498–499
 metabolism, 500
 pharmacokinetics, 497–500, 500b
 solubility, 498
 toxicity, 500
 intravenous, 495–497, 496t, 497b, 501b
 mechanism of action, 492–495
 effects, 495b
 effects on ion channels, 493–494
 effects on the cardiovascular system, 494–495
 effects on the nervous system, 494
 effects on the respiratory system, 494–495
 lipid solubility, 492–493
 muscarinic antagonists and, 163b
 theories of, 494b
 Anaesthetics, local, 525–530
 administration methods, 529t
 chemical aspects, 525
 history, 525–530
 mechanism of action, 525–526, 526f, 528b
 other therapeutic uses, 529–530, 530b
 pharmacokinetics, 528–529, 528b
 properties, 527t
 receptor, 7
 structure, 526f
 unwanted effects, 528, 528b, 707–708
 Anakinra, 330, 331t
 Analgesic drugs, 446t, 503–524
 bioassays, 92, 92f
 clinical uses, 523b
 effects of opioids, 514
 in general anaesthesia, 494
 new approaches, 522–523
 non-steroidal anti-inflammatory drugs, 321–322
 Analgesic nephropathy, 323, 702
 Anandamide, 223, 224f, 452, 472
 actions/effects, 473, 508
 biosynthesis, 223
 transport, 224
 Anaphase, 68
 Anaphylactic hypersensitivity/shock, 87, 699, 707–708, 708b
 Anaphylatoxin, 79
 Anaphylaxis, 344
 Anastrozole, 683, 726
 Androgens, 418–419, 422–423
 actions, 423
 clinical uses, 423b
 hormonal control of the male reproductive system, 423b
 mechanism of action, 423
 pharmacokinetics, 423
 preparations, 423
 sexual behaviour, 419–420
 unwanted effects, 423, 704t
 use in sport, 712t
 Androstane receptor (CAR), 42
 Androstenedione, 422–423
 Angel dust *see* Phencyclidine
 Angina, 253
 management *see* Antianginal drugs
 stable, 253
 unstable, 253
 variant, 253
 Angiogenesis, 66, 70, 99
 inhibitors, 75
 tumour cells, 687
 vascular endothelium in, 267
 Angio-oedema, 275, 344
 Angioplasty, 253–254
 Angiotensin, 62
 action, 231
 specificity, 7
see also Renin-angiotensin system
 Angiotensin-converting enzyme (ACE), 218, 270
 action, 275f
 inhibitors *see* Angiotensin-converting enzyme (ACE) inhibitors
 Angiotensin-converting enzyme (ACE) inhibitors
 atherosclerotic disease prevention, 288
 causing angio-oedema, 344
 clinical uses, 275b
 heart failure, 280
 hypertension, 277, 279t
 renal failure, 357–358
 myocardial infarction, 254
 pharmacological effects, 275
 unwanted effects, 275
 on the fetus, 704t
 kidneys, 701–702
 vasodilatation, 274–275, 274t, 276f
 Angiotensin I, 270
 Angiotensin II, 267, 270
 action, 270
 antagonists, 357–358
 receptor antagonists *see* Angiotensin receptor blockers (ARBs)
 vasoconstriction, 271
 Angiotensin III, 270
 Angiotensin IV, 270, 296–297
 Angiotensinogen, 270
 Angiotensin receptor blockers (ARBs)
 clinical uses, 276b
 heart failure, 280
 hypertension, 279t
 myocardial infarction, 254
 vasodilatation, 274t, 275–276
 Anidulafungin, 652
 Animal testing/models, 92–93
 Alzheimer's disease, 93
 anxiety, 531–532
 depression, 571, 571t
 disease, 92–93
 drug-induced reward, 594
 epilepsy, 542–543
 genetic and transgenic, 93
 obesity, 93
 Parkinson's disease, 93
 toxicity, 698–700
Ankylostoma duodenale, 668
 Annexin-1, 81, 343, 402
Anopheles mosquito, 655–658, 657f
 Anorexia, 488
 Anorexigenic neurons, 388
 Antacids, 364
 Antagonism
 chemical, 15
 competitive, 10–11, 10f–11f, 11b
 allosteric effects, 11
 irreversible, 10f, 11, 12f
 reversible, 10f, 11
 insurmountable, 10
 pharmacokinetic, 15
 physiological, 15
 surmountable, 10
 Antagonists, 8, 14b
versus agonists, 7
 allosteric, 11
 neutral, 13

- Antazoline, 332–333
- Antecedents of pharmacology, 1–2
- Anterograde amnesia, 535
- Anthracyclines, 681–682
- Anthroquinone laxatives, 368
- Antiandrogens, 423b, 424
clinical uses, 683, 684b
- Antianginal drugs, 259–263
- Antibacterial drugs, 622–637
affecting bacterial protein synthesis, 628–631, 631b
affecting topoisomerase, 631–632, 632b
interfering with folate synthesis or action, 622–625
mechanism of action, 624t
possible new, 636
resistance, 618b
biochemical mechanisms, 618–619, 619b
current status, 619–620
genetic determinants, 617–618
targets, 610
see also specific classes; specific drugs
- Antibiotics
aminoglycoside *see* Aminoglycoside
antibiotics
antifungal, 650–652
clinical uses
shock, 281
cytotoxic, 677, 677t, 681–682, 682b
intrathecal injection, 109–110
polyene, 615
and warfarin, 301
see also Chemotherapy
- Antibodies, 235t, 645
and basophils, 86
and cellular cytotoxicity, 85
and complement, 85
humanised, 234–235
and mast cells, 86
and the phagocytosis of bacteria, 85
- Antibody-dependent cytotoxic hypersensitivity, 87
- Antibody–drug conjugates, 113
- Antibody-mediated (humoral) response, 84–86
- Anticancer drugs, 673–688, 677t
drug interactions, 693
emesis, 686
future developments, 687
general principles, 676–677, 676b
myelosuppression, 686–687
resistance, 686
treatment schedules, 686
- Anticholinesterases, 168–171, 170t, 171b, 483–484, 484t
action, 169f
clinical uses, 171b
effects of, 170–171
irreversible, 169–170
medium-duration, 169
short-acting, 168–169
- Anticoagulants
factors that lessen the effect of, 301
factors that potentiate oral, 301
pulmonary hypertension, 282
unwanted effects, 302
- Anticonvulsants *see* Antiepileptic drugs
- Anticytokine drugs, 330–331
- Antidepressant drugs, 446t, 564–583
characteristics, 568t–570t
clinical effectiveness of, 580
clinical uses, 447, 581
anxiety, 532, 538b
fibromyalgia, 522
effects, 18, 445
future, 579
mechanism of action
chronic adaptive changes, 571–572
gene expression, 573
neurogenesis, 573
noradrenergic control of 5-HT release, 572–573, 572f–573f
testing, 571
tricyclic *see* Tricyclic antidepressants
types of, 567, 567b, 568t–570t
see also specific drugs; specific types
- Antidiarrhoeal agents, 369
- Antidiuretic hormone (ADH), 231, 235t, 350, 396, 399–400
actions, 399–400
administration routes, 109
clinical uses, 281, 400b
inhibition, 352
and nephrogenic diabetes insipidus, 351–352
pharmacokinetics, 400
physiological role, 399
receptors, 46, 399
regulation of secretion, 399
unwanted effects, 400
vasoconstriction, 271, 272b
- Antidysrhythmic drugs, 254–258
class I, 254–256
class Ia, 255–256, 257b
class Ib, 255, 257b
class Ic, 255, 257b
clinical uses, 257b
class II *see* β -adrenoceptor antagonists
class III, 255–257
clinical uses, 257b
class IV *see* Calcium channel antagonists/blockers
clinical use, 521
drug interactions, 693
mechanisms of action, 255–256
Vaughan William classification, 254, 255t
- Antiemetic drugs, 366–367, 368b
receptor antagonists, 366–367
- Antiepileptic drugs, 446t, 540–552
benzodiazepines, 535
clinical uses, 550, 551b
bipolar disorder, 582, 582b
fibromyalgia, 522
neuropathic pain, 521, 522b
drug interactions, 693–694
and HLAB*1502, 135
mechanism of action, 543–546, 546b
enhancement of GABA action, 545
inhibition of calcium channels, 546
inhibition of sodium channel function, 545–546
muscle spasm and muscle relaxants, 551
new drug development, 550
and pregnancy, 551, 706
properties, 544t–545t
unwanted effects, 706
see also individual drugs
- Antifungal drugs, 649–654
antibiotics, 650–652
future developments, 653
sites of action, 651f
synthetic, 652
- Antigen drift, 647
- Antigen presentation, 81
- Antigen-presenting cells (APCs), 82–84, 84f
- Anthelminthic drugs, 668–672
action/effects, 616, 617b
resistance, 671
- Antihistamines *see* Histamine H₁ receptor, antagonists
- Antihypertensive drugs, 132, 277–278, 279t
- Anti-IgE treatment, 343
- Anti-inflammatory drugs, 318–335
asthma treatment, 340, 342–343, 344b
atheromatous disease prevention, 288
- Antimalarial drugs, 655–663, 658t
acute attack, 658–659
affecting folate metabolism, 661–662
chemoprophylaxis, 659
as disease-modifying antirheumatic drugs, 328
drug targets of, 659t
and the parasite life cycle, 658b
pH partition, 101
potential new, 663
radical cure, 659
structure, 660f
transmission prevention, 659
- Antimetabolites, 677, 677t, 680–681, 681b, 706
- Antimotility agents, 369–370
- Antimycobacterial agents, 624t, 634–636
- Antioestrogens, 421, 421b
clinical uses, 421b, 683
- Antioncogens *see* Tumour suppressor genes
- Antioxidants, 288, 480
- Antiplatelet drugs, 302–305, 305b
clinical uses, 305b
peripheral vascular disease, 281
drug interactions, 695
unstable angina, 253
- Antiprogestogens, 422, 422b
- Antiproliferative agents, implantable, 113
- Antiprotozoal drugs, 655–667
- Antipsychotic drugs, 446t, 553–563
behavioural effects, 559–560
characteristics, 556t–557t
classification, 555, 558b
clinical efficacy, 562–563
clinical uses, 447, 562–563, 562b
antiemesis, 367
anxiety, 532
bipolar disorder, 582, 582b
effects, 445, 559–560
esterification, 109
future developments, 563
idiosyncratic reactions, 692
mechanism of action, 559b
pharmacokinetics, 562
pharmacological properties, 558–559
dopamine receptors, 558–559
hydroxytryptamine receptors, 559
muscarinic acetylcholine receptors, 559
unwanted effects, 560–561, 561b, 698
endocrine effects, 560
extrapyramidal motor disturbances, 560, 561b
- Antipsychotic malignant syndrome, 561
- Antipyretics, 321
- Antirheumatoid drugs, 326–330, 326f
disease-modifying, 326–328, 326f
- Antischizophrenic drugs *see* Antipsychotic drugs
- Antisense oligonucleotides, 687, 723–724, 724b
- Antithrombin III, 294, 299
- Antithrombotic drugs
drug interactions, 693
implantable, 113
- Anti-tumour necrosis factor agents, 330, 334, 717

- Antitussive drugs, 345
- Antiviral drugs, 638–648
- biopharmaceuticals, 644t
 - chemokine receptor antagonists, 644t
 - DNA polymerase inhibitors, 644t, 646b
 - drug interactions, 693
 - immunomodulators, 644t, 646b
 - inhibitors of HIV fusion with host cells, 644t, 646b
 - inhibitors of viral coat disassembly, 644t, 646b
 - integrase inhibitors, 644t
 - neuraminidase inhibitors, 644t
 - non-nucleoside reverse transcriptase inhibitors, 643, 644t, 646b
 - nucleoside reverse transcriptase inhibitors, 641–646, 644t, 646b
 - prospects for new, 647
 - protease inhibitors, 643–644, 644t, 646b
- Anturane Reinfection Trial Research Group, 97
- Anxiety
- animal models of, 531–532
 - disorders, 531
 - human tests, 532
 - nature of, 531
 - treatment *see* Anxiolytics
- Anxiolytics, 446t, 533b
- antiepileptic drugs as, 550
 - benzodiazepines, 533–538
 - bupirone, 538–539
 - dependence, 593t
 - measurement of anxiolytic activity, 531–532
 - potential, 539
- Apaf-1, 72
- Apathy, 560
- Aplastic anaemia, 692, 699, 708
- ApoA-I Milano, 288
- Apoferitin, 311
- Apomorphine, 488
- blood-brain barrier, 110
 - clinical uses, 429
- Apoptosome, 286
- Apoptosis, 50–51, 70–72, 477–478
- and cancer development, 674–675
 - excessive, 70
 - major players in, 71, 71f
 - morphological changes in, 71
 - pathways to, 72
 - promoters, 74–75
- Apoptosome, 71f, 72
- Apoptotic initiating factor (AIF), 71
- Apoptotic pathway inhibition, 640
- Appetite, 388, 468
- Appetite suppression, 586
- Aprepitant, 231, 367
- Aquaporins, 100, 351, 399
- Aqueous diffusion, 99
- Aqueous humour, 158–159
- Arachidonate, 212
- Arachidonic acid, 212, 214f, 374, 472, 472f
- metabolism, 472–473
 - metabolites, 63
- N-Arachidonyethanolamide, 223
- 2-Arachidonyl glycerol (2-AG), 223, 472
- biosynthesis, 223–224
 - transport, 224
- Arachis oil, 368
- Arcuate nucleus (ARC), 388
- Area postrema, 196, 467, 515
- Arecoline, 589
- Arenaviruses, 646
- Aripiprazole
- action/effects, 560
 - characteristics, 556t–557t
 - clinical uses, 581–582, 582b
- Aromatic hydrocarbon (Ah) receptor, 118
- Arousal, 462, 470
- Arsenic, 2
- Artemether, 661–662
- Artemisinin, 658, 662–663, 663b
- Artemisinin derivatives, 659
- Arterial thrombus, 294, 295f
- Arteries, 265–266
- Arterioles, 265
- Artesunate, 662, 663b
- Artether, 662
- Articaine
- properties, 527t
 - unwanted effects, 528
- Ascaris lumbricoides*, 668
- Ascorbic acid, 480, 711t
- Asparaginase, 235t, 685, 707–708
- Aspartate, 448
- Aspergillus*, 649, 650t
- Aspirin, 302–304, 319t, 323–325, 324b
- absorption, 101
 - action, 319
 - and Alzheimer's disease, 484
 - angina, 253
 - asthma, 339
 - causing angio-oedema, 344
 - clinical uses, 304f, 323–324
 - drug interactions, 325
 - metabolism, 118–119
 - pharmacokinetics, 130, 324
 - poisoning, 324–325
 - resistance, 304
 - sensitive asthma, 323
 - unwanted effects, 324–325, 699
 - urate secretion inhibition, 357
 - and warfarin, 301
- Astemizole, 652
- Asthma, 337–339, 340b
- adenosine and, 206
 - aspirin-sensitive, 323, 339
 - characteristics, 337
 - immediate phase, 338, 338f–339f
 - late phase, 338f–339f, 339
 - and nitric oxide, 243
 - pathogenesis, 337–339, 338f
 - status asthmaticus, 337, 343
 - treatment, 340–343
 - anti-inflammatory agents, 340, 342–343, 344b
 - β_2 agonists, 186
 - bronchodilators, 340–342, 341b
- Astrocytes, 443
- Asymmetric dimethylarginine (ADMA), 238, 242
- Asystolic arrest, 247–248
- Atavouquone, 663
- Atazanavir, 643
- Atenolol, 187–188
- Atherogenesis, 285–286, 601
- Atherosclerotic disease, 285, 289b
- prevention, 288
 - risk factors, 285
- Atherosclerosis, 285–293, 604
- Atomoxetine, 191, 567, 577
- action/effects, 193b
 - clinical use, 581, 586
- Atorvastatin, 289
- Atosiban, 428, 429b
- Atovaquone, 658, 663b
- ATP *see* Adenosine triphosphate (ATP)
- ATP-binding cassette (ABC), 21–23
- ATP-binding cassette (ABC) transporters, 101
- ATP-gated potassium channel, 44
- ATP-sensitive potassium channels, 43
- Atracurium, 164, 167b
- characteristics, 165t
 - pharmacokinetics, 165–166
 - unwanted effects, 164
- Atria, 246
- Atrial fibrillation, 247–248
- Atrial natriuretic peptide (ANP), 252, 270
- Atrioventricular (AV) node, 246
- Atropine, 139, 151, 159–160, 590
- clinical uses, 255t, 369
 - drug interactions, 693
 - effects
 - central nervous system, 161
 - tachycardia, 161
 - excretion, 352–353
 - lifestyle use, 710
- Attention-deficit hyperactivity disorder (ADHD), 586
- Auerbach's plexus, 360
- Augmerosen, 687
- Auranofin, 328
- Autoantibodies, 45–46
- Autoimmune disease, 87, 328
- Autoinhibitory feedback, 144, 178, 178f
- Autonomic efferent pathway, 140
- Autonomic ganglia, 140
- Autonomic nervous system
- basic anatomy and physiology, 140–141, 140f, 143b
 - chemical mediators in, 139–150
 - main effects of, 142t
 - respiratory system, 336–337
 - role in inflammation, 86–87
 - transmitters in, 141–143, 143b
 - see also* Enteric nervous system; Parasympathetic nervous system; Sympathetic nervous system
- Avermectins, 616, 617b, 671
- Azapropazone, 319t
- Azathioprine, 330
- clinical uses, 370
 - drug interactions, 332, 695
 - metabolism, 118–119
 - unwanted effects, 706
- Azelastine, 332–333
- Azithromycin, 631
- antimicrobial spectrum, 631
 - clinical use, 666
 - pharmacokinetics, 631
- Azoles, 615–616, 649–650, 652
- Aztreonam, 628, 629b
- ## B
- Bacillus*, 623t
- Bacitracin, 612, 622
- Baclofen, 458, 459b
- clinical uses
 - Huntington's disease, 489
 - muscle tone control, 551
 - intrathecal injection, 109–110
- Bacteria, 609
- clinically significant pathogenic, 623t
 - conjugation, 618
 - decreased drug accumulation in, 619
 - discovery of, 1
 - phagocytosis, 85
 - resistance genes, 617–618
 - transduction, 618
 - transformation, 618
- Bacterial envelope, 610
- Bad dreams, 189
- Bak, 72
- Balsalazide, 370

- Barbiturates
 as anaesthetics, 492
 dependence, 593t
 drug interactions, 430
 tolerance, 16
- Basic drugs
 binding, 103
 excretion, 120
 ionization, 120
 weak, 101, 102f–103f
- Basiliximab, 330, 331t
- Basophils
 antibodies and, 86
 histamine in, 211
 innate immune response, 81
- Batrachotoxin, 57
- Bax, 72, 74, 478
- BAY41-2272, 272
- Bayesian analysis, 96
- BAY K 8644, 262
- B cells, 82–83, 372, 380
- Bcl-2 protein family, 72, 478
- BCR-ABL1, 137
- Beclometasone, 343
- Bed wetting, 358
- Behaviour
 effect of antipsychotics on, 559–560
 effect of dopamine on, 465
 effects of ethanol, 603
 sexual, 419–420
- Bendroflumethiazide, 355
- Benefit and risk, clinical trials, 97–98
- Benign prostatic hyperplasia, 181, 187, 358
- Benserazide, 487
- Benzbromarone, 332
- Benzimidazoles, 670
 action/effects, 616, 617b
 resistance, 671
- Benznidazole, 665
- Benzocaine
 chemical aspects, 525
 pharmacokinetics, 529
- Benzodiazepines, 533–538, 538b
 antagonists, 537–538
 channel gating, 20–21
 characteristics, 533t
 clinical uses, 534–535
 aggression, 534
 alcohol dependence, 597b, 607
 anterograde amnesia, 535
 anticonvulsant effects, 535
 anxiety, 532, 534
 bipolar disorder, 581
 epilepsy, 548, 550b
 fibromyalgia, 522
 insomnia, 532
 reduction of muscle tone, 535
 sedation, 534–535
 sleep induction, 534–535
 dependence, 593t
 effect on GABA receptors, 458
 endogenous benzodiazepine-like mediator, 535
 inverse agonists, 537–538
 mechanism of action, 533–534
 pharmacokinetics, 536
 pharmacological effects, 534–535
 postsynaptic modulation, 145
 properties, 544t–545t
 unwanted effects, 536–537
 acute toxicity, 536
 during therapeutic use, 536–537
 tolerance on dependence, 537
- Benzomorphan series, 510
- Benzothiazepines, 262
- Benzylpenicillin, 622, 627, 627b, 629b
- Beractant, 345
- β -adrenoceptor agonists, 181, 261
 clinical uses
 asthma, 340–341
 thyroid disorders, 415
 unwanted effects, 341
- β -adrenoceptor antagonists, 181, 182t–184t, 187–190, 189b, 257
 action/effects, 174, 182t–184t, 188–189
 antidysrhythmic action, 254, 256
 clinical uses, 189, 189b, 257b
 angina, 259, 261–262
 anxiety, 532
 heart failure, 280
 hypertension, 277, 279t
 pathological tremor, 186
 tachycardia, 205
 and ethnicity, 689
 myocardial infarction, 254
 unwanted effects, 189–190, 257
 use in sport, 712t
- β -adrenoceptor kinase (BARK), 35
- β -adrenoceptors, 7, 9f, 143
 actions, 181
 molecular structure, 28
 respiratory system, 336
 translocation, 16
- β_1 -adrenoceptors, 174–175
 action/effects, 176t, 184–186
 agonists, 259
 antagonists, 174–175
 in the CNS, 461–462
 downregulation, 571
 effect on heart, 251–252
- Beta-blocker Heart Attack Trial Research Group, 96
- β_2 -adrenoceptor agonists, 174–175
 actions/effects
 unwanted, 186
 on the uterus, 428
 clinical uses, 186
 potentiation of nitric oxide, 243
 use in sport, 712t
- β_2 -adrenoceptors, 174–175
 action/effects, 175, 176t, 181
 in the CNS, 461–462
 mutations, 46
- β_3 -adrenoceptors, 174
 action/effects, 176t, 184–186
 agonists, 392
- β -alanine, 458
- β -Bungarotoxin, 167–168
- Betacarbolines, 535
- β -endorphin, 232, 513t
- β -globulin, 103
- β -lactamases, 618–619
- β -lactams, 616b, 625–628, 629b
 action/effects, 612
 inactivation, 618–619
 mechanism of action, 624t
 resistance, 619
see also specific types
- β -lipotrophin, 232
- Betamethasone, 401t
- Bethanechol, 157–158
- Bethanidine, 190–191
- Bevacizumab, 70, 75, 684, 685b
- Bezafibrate, 290
- Bezoar, 365
- Bias, 95
- Bicalutamide, 683
- Bicarbonate, 349
- Bicuculline, 456–458, 459b, 535
- Bid, 72
- Bifeprunox, 560
- Biguanides, 379–380
 actions, 379–380
 clinical uses, 380, 383
 mechanism of action, 379–380
 unwanted effects, 380
- Bile acid-binding resins, 290, 291b
- Bilharzia, 668
- Biliary colic, 370
- Biliary system
 drugs affecting, 370
 excretion, 119
- Bilirubin, 694
- Billy whizz *see* Amphetamine(s)
- Binding assays, 90
- Binding (of drugs)
 to plasma proteins, 103–105, 105f
 to proteins, 6–15
versus receptor activation, 8, 8f
 to receptors, 8–9, 9f, 16–18
 specificity, 7
- Bioassays, 89–92, 91b
 design of, 91–92
 general principles, 90–92
 standards, 90–91, 92f
 test systems, 89–90
- Bioavailability, 108, 110b, 123–124
- Biochemistry, emergence of, 2
- Bioequivalence, 108, 123–124
- Biologically erodible nanoparticles, 112
- Biological response modifiers, 686
- Biopharmaceuticals, 3, 89, 330–331, 331t, 715–718
 antiviral, 644t, 645–646
 definition, 716b
 development, 729
 first-generation, 716
 future developments, 334
 monoclonal antibodies, 717–718
 polypeptides, 716–717
 potential uses, 716b
 proteins, 716–717
 second-generation, 716, 716t
 third-generation, 716
- Biotechnology
 definition of, 4–5
 emergence of, 3
- Bipolar disorder, 550, 564
 drug treatment of, 581–582, 582b
- Bisacodyl, 368
- Bismuth chelate
 gastric mucosa protection, 365
 unwanted effects, 365
- Bisoprolol, 280
- Bisphosphonates, 438b
 clinical uses, 437–438, 438b
 mechanism of action, 438
 pharmacokinetics, 438
 structure, 437f
 unwanted effects, 438
- Bivalirudin, 300
- Blasomyces dermatides*, 650t
- Bleeding *see* Haemorrhage
- Bleomycin, 615, 682, 682b
- Blood
 coagulation *see* Coagulation
 flow, 265
 haemopoietic system, 309
 5-hydroxytryptamine in, 194
 reactions *see* Haematological reactions
- Blood-brain barrier, 110–111, 445–446
- Blood:gas partition coefficient, 498
- Blood glucose control, 372, 373f, 378
- Blood pressure
 ACh effects, 151, 152f
 and diabetes mellitus, 378
 and oral contraceptives, 426
 regulation, 462

- Blood vessels, 141
 autonomic nervous system effects on, 142t
 effects of 5-hydroxytryptamine on, 195
see also Vascular system
- B-natriuretic peptide (BNP), 252
- Body fluid compartments *see* Compartments, body fluid
- Body mass index (BMI), 385
- Body weight regulation
 hormones role in, 385–388, 386f–387f
 neurological circuits controlling, 388–389
- Bone
 composition, 432
 disorders, 437–440
 (*see also specific disorders*)
 metabolism, 432–441
 mineral turnover, 434, 435f, 437b
 remodelling, 432–437, 434b
 action of cells and cytokines, 432–434, 433f
 hormones involved in, 435–437
 important cells for, 432
 structure, 432
- Bone marrow, 309
 drug toxicity, 136
 toxicity of anticancer drugs, 676
- Bone morphogenic proteins (BMPs), 432–433
- Bordatella*, 623t
- Bortezomib, 74–75, 685
- Bosentan, 234
- Botox, 168
see also Botulinum toxin
- Botulinum poisoning, 168
- Botulinum toxin, 167, 167b, 458
 clinical uses, 168, 522
 lifestyle use, 711t
 potency, 167–168
- Bovine spongiform encephalopathy (BSE), 489–490
- Bowman's capsule, 347–349
- Boyle, Robert, 1
- Bradycardia, 247
 β -receptor antagonists, 189
 effects of opioids, 515
 suxamethonium-induced, 166
- Bradykinin, 217–219, 219b
 actions, 219
 antagonists, 218f
 and carcinoid syndrome, 202
 formation of, 218, 218f
 inactivation, 218
 metabolism, 218
 and pain, 508, 508f
 receptors, 218–219
 role in inflammation, 219
 source of, 218
 structure, 218f
- Brain-derived neurotrophic factor (BDNF), 455, 478, 543
 central facilitation, 505
 and depression, 565
- Brain stimulation, 579–580
 Parkinson's disease, 489
- Bran, 368
- BRCA1/BRCA2, 673
- Breast cancer, 673
- Breathing *see* Respiration
- Bretylum, 190–191
- Brivaracetam, 549
- Bromocriptine, 397
 action/effects, 199, 465–466, 554
 clinical use, 397, 398b, 465, 488
 effect on prolactin secretion, 397–398
 properties, 199t
- 4-Bromo-2,5-dimethoxyphenethylamine, 590
- Bronchial hyper-reactivity, 337
- Bronchial secretion
 effects of muscarinic agonists, 158
 effects of muscarinic antagonists, 161
- Bronchial smooth muscle, 141
- Bronchitis, 344
- Bronchoconstriction
 β -receptor antagonists, 189
 effects of muscarinic antagonists, 161
 effects of opioids, 515
 nitric oxide, 242
- Bronchodilators
 clinical uses
 asthma, 340–342, 341b
 chronic obstructive pulmonary disease, 345
 inhalation administration, 109
- Brucella*, 623t
- Brugia malayi*, 668–669
- Brussels sprouts, 117
- Buchheim, Rudolf, 1
- Budesonide, 343, 370
- Bulk laxatives, 368
- Bumetanide, 353–354
- Bundle of His, 246
- Bupivacaine
 action/effects, 528
 clinical uses, 530b
 intrathecal injection, 109–110
 properties, 527t
- Buprenorphine, 510, 518t–519t, 520
 administration, 108
 clinical uses
 gallstone pain, 370
 opioid dependence, 597b
- Bupropion, 567, 577, 577b
 characteristics, 568t–570t
 clinical uses, 581
 ethanol dependence, 605b
 smoking cessation, 597b, 601–602
 lifestyle use, 710, 711t
- Buserelin, 424, 683
- Buspirone, 468, 469b, 532, 538–539, 538b
- Busulfan, 678
- Butoxamine, 182t–184t
- Butyrylcholinesterase (BuChE), 168, 171b
- C**
- C1 esterase, 344
- C3, 79, 85
- C3a, 79–81
- C3b, 79–80
- C5, 79
- C5a, 79–81
- Cabergoline, 397–398, 465–466
- Cadmium, 706
- Caffeine, 52, 588
 action/effects, 206, 471, 588
 clinical use, 588
 lifestyle use, 710, 711t, 713b
 unwanted effects, 702
 use in sport, 712t, 713, 714b
- Calcifediol, 436
- Calciferol *see* Vitamin D
- Calcimimetics, 440
- Calcineurin, 329
- Calciphylaxis, 358
- Calcitonin, 235t, 410
 administration routes, 109
 bone metabolism and remodelling, 437
 clinical uses
 analgesia, 522
 bone disorders, 439, 439b
- Calcitonin gene-related peptide (CGRP), 37, 219, 504–505
 antagonists, 509
 central facilitation, 505
 discovery of, 229
 and migraine, 200
 NANC transmission, 148t
 nociceptive pathway, 509
- Calcitriol, 350, 434, 436
 clinical uses, 357–358, 439
- Calcium-activated potassium channels, 43
- Calcium (bone mineral), 434, 435f
- Calcium carbonate, 440
- Calcium channel antagonists/blockers, 257–258, 258b, 263b
 actions/effects, 262–263
 antidysrhythmic, 256
 cardiac, 254, 262
 ischaemic tissue protection, 263
 unwanted, 263
 vascular smooth muscle, 262–263
 clinical uses, 263b
 angina, 259, 262–263, 262f
 hypertension, 277, 279t
 mechanism of action, 262
 pharmacokinetics, 263
 vasodilatation, 272
- Calcium channels
 effect of antiepileptic drugs, 546
 functions, 51t
 heart, 246, 249
 ligand-gated, 50–51
 L-type *see* L-type calcium channels
 store-operated, 44, 51, 51t
 T-type *see* T-type calcium channels
 types, 51t
 voltage-gated, 44, 49–50, 51t
- Calcium chloride, 255t
- Calcium gluconate, 358, 439–440
- Calcium-induced calcium release (CICR), 52
- Calcium (ions)
 calmodulin, 52
 chemical mediators release, 62
 effect of glucocorticoids, 403
 entry mechanisms, 49–51
 epithelial ion transport, 64
 extrusion mechanisms, 51–52
 muscle contraction, 59–61
 regulation, 49–52, 50f, 53b
 release mechanisms, 52
 transport
 renal, 350
 and thiazide diuretics, 355
- Calcium lactate, 439–440
- Calcium polystyrene sulphonate, 358
- Calcium release channels, 43–44
- Calcium salts, 439–440, 440b
- Calmodulin, 52
- Calomel, 1
- cAMP, 32, 33f, 64
 effect on heart, 251–252
 vasodilatation, 272–273
- cAMP response element binding protein (CREB), 596–597
- Camptothecins, 682
- Campylobacter* spp., 369, 623t
- Canal of Schlemm, 158–159, 159f
- Cancer, 673
 drug therapy *see* Anticancer drugs
 effects of smoking, 600
 gene therapy for, 722–723, 723b

- growth, invasion and metastasis, 73
 pathogenesis, 673–676, 675f, 676b
 risk, oral contraceptives, 426
see also specific types
 Cancer cells, 609
 compartments, 676
 control of tumour-related blood vessels, 675
 dedifferentiation and loss of function, 675
 genesis, 673–674
 invasiveness, 675
 metastasis, 675–676
 resistance to apoptosis, 674–675
 special characteristics, 674–676
 telomerase expression, 675
 uncontrolled proliferation, 674–675
 Candesartan, 274t, 275–276
Candida albicans, 650t
 Candidiasis, 406, 649
 Cannabidiol, 221
 Cannabinoids, 221–227
 clinical uses, 226
 analgesia, 522
 antiemesis, 367
 obesity, 392–393
 plant-derived, 221–222
 adverse effects, 222
 analytical aspects, 222
 dependence, 222
 pharmacokinetics, 222
 pharmacological effects, 221
 tolerance, 222
 receptors, 222–223
 activation, 225
 agonists, 225, 226b, 369
 antagonists, 225–226, 226b
 CB₁, 222–223, 223f, 225, 473
 antagonists, 225–226
 CB₂, 222–223, 473
 cloning, 225
 depolarisation-induced suppression of inhibition, 225
 synthetic, 225–226
 Cannabinol, 221
 Cannabis, 221b
 adverse effects, 222
 analytical aspects, 222
 clinical uses, 551
 dependence, 222, 593t
 erectile dysfunction, 429
 lifestyle use, 710, 711t
 pharmacokinetics, 222
 pharmacological effects, 221
 tolerance, 222
 Canrenone, 355
 Capecitabine, 681
 Capillaries, 265
 Capreomycin
 clinical use, 634–635
 unwanted effects, 635
 Capsaicin, 43, 507–508, 522
 Capsid, 638
 Capsules, intestinal absorption, 107–108
 Captopril, 235t
 unwanted effects, 702
 vasodilatation, 274–275, 274t
 Carbachol, 154, 158
 Carbamazepine
 clinical uses
 bipolar disorder, 581–582, 582b
 epilepsy, 543, 546, 550b
 neuropathic pain, 521, 522b
 drug interactions, 342, 426, 430, 634, 694
 effect on antidiuretic hormone, 399–400
 and HLAB*1502, 135
 induction of microsomal enzymes, 118
 pharmacokinetics, 546
 in pregnancy, 551
 properties, 544t–545t
 unwanted effects, 546
 allergic reactions, 707
 on the fetus, 704t, 706
 Carbamyl esters, 169
 Carbapenems, 618, 624t, 628, 629b
 Carbenicillin, 111
 Carbenoxolone, 407
 Carbidopa, 182t–184t, 190, 193b, 487
 Carbimazole, 414, 414f, 415b
 unwanted effects, 699b, 708, 708b
 Carbohydrates, effect of glucocorticoids, 402–403, 402b
 Carbon dioxide, partial pressure, 336
 Carbonic anhydrase inhibitors, 356–357
 Carbonium ion, 678
 Carbon monoxide, 267, 472, 601
 Carboplatin, 679
 Carboprost, 216b, 428
 Carboxylation, 228
 Carcinogenesis, 702–704, 703b
 measurement of, 703–704
 Carcinogens, 673, 699, 704b
 Carcinoid syndrome, 202–203
 Cardiac depression, β -receptor antagonists, 189
 Cardiac failure, β -receptor antagonists, 189
 Cardiac glycosides, 258–259
 action/effects, 258
 clinical uses, 280
 effects of extracellular potassium, 259
 in mechanism, 258–259
 pharmacokinetic aspects, 259
 unwanted effects, 258
 Cardiac muscle *see* Heart muscle
 Cardiac natriuretic peptides, 252–253
 Cardiac output, 249
 Cardiotonic steroids (CTSs), 258
 Cardiovascular system
 adenosine and the, 205
 disease, gene therapy for, 723
 effect of glucocorticoids, 402b
 effects of β -receptor antagonists, 189
 effects of ethanol, 603
 effects of general anaesthetics on, 494–495
 effects of histamine, 211
 effects of leukotrienes, 216
 effects of local anaesthetics, 528
 effects of muscarinic agonists, 158
 effects of muscarinic antagonists, 161, 163b
 effects of non-steroidal anti-inflammatory drugs, 323
 effects of prostanoids, 216b
 see also Heart; Vascular system
 Carisbamate, 549
 Carmustine, 678
 Carrier-mediated transport, 101–103
 Carvedilol
 action/effects, 182t–184t, 187–188
 clinical uses, 189, 280
 Cascade superfusion, 89, 91f
 Caspases, 71, 71f
 inhibitors, 75
 Caspofungin, 652
 Catabolism, 115
 Catalase, 480
 Catalepsy, 559–560
 Catecholamines, 174, 178–179, 584–585
 actions/effects, 181–184
 biosynthesis, 177f
 degradation, 179, 180f
 hypothesis of depression, 462
 uptake, 178–179, 179t
 see also specific catecholamines
 Catechol-O-methyl transferase (COMT), 179
 Cathepsin K, 432–433
 Cathine, 589
 Cathinone, 589
 Cattle, transgenic, 717
 Caveolin, 237
 C cells, 437
 CCR5, 641, 645, 647
 CD95, 72
 Cdk inhibitory proteins, 68
 CD4⁺ T-helper lymphocytes, 84
 HIV/AIDS, 640–641, 642f–643f
 macrophage-activating, 86
 CD8⁺ T lymphocytes, 84, 86
 HIV/AIDS, 640–641
 Cefaclor, 627–628
 Cefadroxil, 627–628, 628b
 Cefalexin, 627–628
 Cefixime, 627–628
 Cefotaxime, 627–628, 628b
 Cefpodoxime, 627–628
 Cefradine, 627–628
 Ceftazidime, 627–628
 Ceftriaxone, 627–628, 628b
 Cefuroxime, 627–628, 628b
 Celecoxib, 319t, 325
 clinical uses, 687
 effects on gastrointestinal tract, 362
 unwanted effects, 698–699
 Cell cycle, 66–68, 68b
 check points, 68
 microRNAs and, 72
 negative regulators of, 68
 phases, 66, 67f
 positive regulators of, 66–68, 67f
 regulation, 75
 transducers, 674
 Cell-mediated hypersensitivity, 87
 Cell-mediated immune response, 86
 Cell(s)
 apoptosis *see* Apoptosis
 damage, 700–702
 death, 700–702
 division, 66
 host defence, 77–88
 interactions with growth factors and extracellular matrix, 69–70
 proliferation, 66–70
 regeneration, 73–74
 removal, 70–72
 repair, 73
 Cell theory, 1
 Cell wall, 609–610
 Central nervous system
 adenosine in the, 206
 body weight regulation, 388
 chemical signalling in, 442–443, 443f
 chemical transmission in, 442–447, 444b (*see also* Neurotransmission)
 drug action in, 444–446, 445b, 446t
 effects of anticholinesterases on, 171
 effects of antihistamines on, 333
 effects of ethanol on, 602–603
 effects of glucocorticoids on, 406
 effects of histamine on, 211
 effects of 5-hydroxytryptamine on, 195
 effects of indirectly acting sympathomimetic amines on, 191
 effects of local anaesthetics on, 528
 effects of monoamine oxidase on, 179
 effects of muscarinic antagonists on, 161, 163b

- effects of nicotine on, 598
 effects of opioids on, 514–515
 effects of quinolones on, 632
 effects of tetrahydrocannabinol on, 221
 5-hydroxytryptamine in, 194
 role in inflammation, 86
- Cephalosporins, 618, 627–628, 629b
 action/effects, 612
 clinical uses, 628b
 excretion, 352–353
 mechanism of action, 624t
 pharmacokinetics, 628
 unwanted effects, 628
- Cephamandole, 618
- Cephamycins, 627–628, 629b
- Certilizumab-pegol, 334
- Cestodes, 668, 670
- Cetirizine, 333t
- CETP *see* Cholesteryl ester transfer protein (CETP)
- Cetuximab, 684
- Cevimeline, 157–158
- CFTR gene, 64
- cGMP *see* cyclic GMP (cGMP)
- Channel modulators, 458
- Chaperone proteins, 476
- Cheese reaction, 578, 579b
- Chelating agents, 15
- Chem 23, 217
- Chemical antagonism, 15
- Chemical mediators
 and the autonomic nervous system, 139–150
 release of, 61–63
- Chemokines, 208, 210
 antagonists, 345, 644t
 innate immune response, 78
- Chemoprophylaxis, malaria, 659
- Chemoreceptor trigger zone (CTZ), 110, 365
- Chemotaxins, 78, 80
- Chemotherapy, 609–621
 background, 609
 for cancer *see* Anticancer drugs
 molecular basis, 609–616, 610b
 targets, 610–615, 616b–617b
 class III reactions, 611–615
 class II reactions, 610–611
 class I reactions, 610
 intracellular organelles, 616
 membrane, 615–616
 muscle fibres, 616
- Chickenpox, 639, 645b
- Chief cells, 360
- Chinese restaurant syndrome, 477
- Chirality, 115
- Chlamydia*, 623t, 628–629
- Chloral hydrate
 clinical uses, 532
 drug interactions, 694
 and warfarin, 301
- Chlorambucil, 678
 teratogenicity, 706
- Chloramphenicol, 616b, 629
 action/effects, 631b
 affect of age on, 690–691
 antibacterial spectrum, 629–630
 clinical uses, 630b
 idiosyncratic reactions, 692
 inactivation, 619
 pharmacokinetics, 630
 resistance, 619
 unwanted effects, 630, 690–691, 699, 708, 708b
- Chloramphenicol acetyltransferase, 619, 629
- Chlordiazepoxide, 533, 538b
 characteristics, 533t
 clinical uses, 607
- Chlorhexidine, 707–708
- Chloride transport, 64, 349
- Chloroform, 492, 500
- 7-Chloro-kynurenine acid, 453–454
- Chloroquine, 327
 action/effects, 619
 administration, 659–660
 clinical uses
 malaria, 655–656, 658–660, 663b
 malaria chemoprophylaxis, 659
 as a disease-modifying antirheumatic drug, 328
 partitioning into fat/tissues, 106
 pharmacokinetics, 659–660
 resistance, 659
 unwanted effects, 660
- Chlorphenamine, 344
- Chlorpromazine, 555
 action/effects, 555
 characteristics, 556t–557t
 clinical uses, 562b
 antiemesis, 367
 Huntington's disease, 489
 prion diseases, 490
 and Parkinson's disease, 485
 pharmacokinetics, 562
 unwanted effects, 560–561, 700–701, 701b
- Chlorpropamide, 380–381
- Chlortalidone, 355
- Cholecalciferol *see* Vitamin D₃
- Cholecystokinin (CKK), 360, 387t, 388
- Cholelithiasis, 370
- Cholera toxin, 30–32
- Cholesterol, 285, 402, 422–423
 drugs inhibiting absorption of, 290–291, 291b
 high-density *see* High-density lipoprotein (HDL) cholesterol
 low-density *see* Low-density lipoprotein (LDL) cholesterol
 transport, 286, 287f
- Cholesteryl ester transfer protein (CETP), 286, 288
- Choline acetyltransferase (CAT), 154–155, 483
- Cholinergic transmission, 139, 151–173
 drugs that enhance, 168–172
 effects of drugs on, 157–172
 electrical events, 156–157, 156f
 physiology of, 154–157, 155f
- Cholinesterase, 154–155, 171b
 distribution and function of, 168
 drugs inhibiting *see* Anticholinesterases
 reactivation, 171–172
- Christmas disease, 297
- Chromogranin A, 177
- Chromosomes, 610
- Chronic granulomatous disease, 722
- Chronic myeloid leukaemia (CML), 684
- Chronic obstructive pulmonary disease (COPD), 344–345
 acute exacerbations, 345
 clinical features, 344–345
 effects of smoking, 600
 and nitric oxide, 243
 pathogenesis, 344
 treatment
 principles, 344–345
 specific, 345
- Chylomicrons, 286
- Chymase, 275–276
- Ciclesonide, 343
- Ciclosporin, 21, 84, 235, 235t, 328–329, 727–728
 drug interactions, 652
 and dyslipidaemia, 288
 unwanted effects, 702
- Cidofovir, 357, 645
- Cigarette smoke, 117
see also Nicotine; Smoking; Tobacco
- Ciglitazone, 381
- Cilastatin, 628
- Ciliary muscle, 141
- Ciliates, 655, 656t
- Cilostazol
 clinical uses, 281
 vasodilatation, 272–273
- Cimetidine, 211
 action/effects, 363, 363t
 drug interactions, 430, 695
 unwanted effects, 363
- Cinacalcet, 440
- Cinchona bark, 1
- Cinchonism, 661
- Cinnarizine, 333t, 366
- Cinoxacin, 613–615
- CIP family, 68
- Ciprofibrate, 290
- Ciprofloxacin, 616b, 631, 632b
 action/effects, 613–615
 antibacterial spectrum, 632
 clinical uses, 630b
 diarrhoea, 369
 tuberculosis, 634
 drug interactions, 342
 pharmacokinetics, 632
 resistance, 620
- Circus movement, 248
- Cirrhosis (hepatic)
 effects of ethanol, 604
 and nitric oxide, 243
- Cisapride, 198, 368–369
- Cisplatin, 366–367, 679, 679b
- Citalopram, 567, 568t–570t, 573
- Citrate, 356–357
- CKK *see* Cholecystokinin (CKK)
- Cladribine, 681
- Clarithromycin, 631
 antimicrobial spectrum, 631
 clinical use
 toxoplasmosis, 666
 tuberculosis, 634
 drug interactions, 342
 pharmacokinetics, 631
- Clavulanic acid, 627
- Clearance, 123–124
- Clemastine, 333t
- Clenbuterol
 action/effects, 182t–184t, 186
 use in sport, 712t, 713, 714b
- Clindamycin, 633
 action/effects, 631b, 633
 clinical uses
 malaria, 659
 toxoplasmosis, 666
 unwanted effects, 633
- Clinical outcome measures, 96
- Clinical trials, 94–98, 95f
 avoidance of bias, 95
 balancing benefit and risk, 97–98
 clinical outcome measures, 96
 controls, 94
 errors, 95–96
 ethics, 94
 frequentist and Bayesian approaches, 96
 meta-analysis, 97
 placebos, 96
 power, 95–96

- randomised controlled, 94
Sample size, 95–96
- Clobazam
action/effects, 548
clinical uses, 543
- Clodronate, 438
- Clofarabrine, 681
- Clofazimine
action/effects, 636
clinical use, 635–636, 636b
pharmacokinetics, 636
unwanted effects, 636
- Clofibrate, 290
- Clofibrate analogue, 381
- Clomethiazole, 607
- Clomiphene, 421, 424–425
- Clomipramine, 567, 574, 576b
characteristics, 568t–570t
drug interactions, 579b
- Clonazepam, 533, 538b
action/effects, 546, 548
administration route, 548
characteristics, 533t
clinical use, 535, 543
- Clonidine, 190
action/effects, 182t–184t, 462, 571
clinical uses
alcohol dependence, 607
attention-deficit hyperactivity disorder, 586
hypertension, 277–278
opioid dependence, 597b
smoking cessation, 602
- Clopidogrel, 204, 205b, 206, 304
clinical use, 304–305, 305f
drug interactions, 695
pharmacokinetics, 130, 304
unstable angina, 253
unwanted effects, 304
- Clorphenamine, 333t
- Clostridium difficile*, 633
- Clostridium* spp., 623t
- Clotrimazole, 652
- Clotting factors, 235t
- Clozapine, 468, 555
action/effects, 560
characteristics, 556t–557t
clinical efficacy, 562–563
clinical uses, 562b
and HLA-DQB1*0201, 136
unwanted effects, 561, 708
- C-natriuretic peptide (CNP), 252, 267
- Coagulation, 294–297, 296f, 297b
defects, 297–298
drugs affecting, 297–302, 302b
innate immune response, 78–80, 80f
- Coagulation factors, 294
factor II, 297, 298f
factor IIa *see* Thrombin
factor Va, 294
factor V Leiden, 296–297
factor VII, 294, 297
factor VIIa, 294
factor IX, 294, 297
factor IXa, 294
factor X, 294, 297
factor Xa, 294
factor XIa, 294
factor XII, 294
factor XIIa, 294
factor XIII, 295–296
- Co-amoxiclav, 627b
- Coated implantable devices, 113
- Coaethylene, 592
- Cocaine, 585t, 587–588, 588b
action/effects, 182t–184t, 192, 193b
behavioural, 465
cardiovascular system, 528
on the CNS, 528
chronic use, dependence on tolerance, 587
dependence, 593t
history, 525
lifestyle use, 710, 711t
pharmacokinetics, 587
pharmacological effects, 587
properties, 527t
teratogenicity, 704
unwanted effects, 587–588, 704
use in sport, 712t
- Cocaine- and amphetamine-regulated transcript (CART), 388
- Coccidioides immitis*, 650t
- Codeine, 510, 513, 518t–519t, 519
actions/effects, 515
bioassays, 92, 92f
clinical uses
cough, 345
gastrointestinal motility, 369
pharmacokinetics, 516–517
use in sport, 712t
- Coenzyme B₁₂, 313
- Cognition enhancers, 446t
- Colchicine, 332, 352, 399–400
- Cold extremities, 189–190
- Cold sores, 639
- Colesevelam, 290–291
- Colestyramine, 330, 438
absorption, 108
drug interactions, 693
and warfarin, 301
- Colistin, 633, 634b
- Collagen species, 69
- Collecting ducts, 347, 350–352
- Collecting tubules, 350–352, 351f
- Colony-stimulating factors (CSFs), 37, 309, 314–315
administration, 315
clinical uses, 316b
unwanted effects, 315
- Combined pill, 425–426, 426b
beneficial effects, 426
common adverse effects, 426
considerations, 426
- Commensals, 609, 649
- Compartments
body fluid, 110–111, 110f
pH, 101
single-compartment model, 124–126, 125f–126f
two-compartment model, 127–128, 128f
well-stirred, 99
- Complement system
antibodies and, 85
innate immune response, 78–79, 80f
- Complex-mediated hypersensitivity, 87
- Concentration, drug, 124–125, 125f
bioassays, 89
relation between effect and, 9–10, 10f
- Concentration-effect curve, 9–10, 10f, 12f
- Conditioned place preference studies, 594
- Conivaptan, 280
- Conjugative plasmids, 618
- Conn's syndrome, 401, 406–407
- Constitutively active receptors, 36
- Constrictor pupillae, 158–159
- Construct validity, 92–93
- Contraception, 425–427
long-acting progestogen-only, 427
oral contraceptives, 425–426
postcoital (emergency), 427
- Contraction, muscle, 59–61, 60f, 62b
cardiac muscle, 59–60
skeletal muscle, 59
smooth muscle, 59–61, 61f
- Coronary artery disease *see* Ischaemic heart disease
- Coronary blood flow, 250–251, 251b
neural and humoral control, 251
physical factors, 250, 251f
vascular control, 251
- Corpus luteum, 417–418, 418f
- Corpus striatum, 463
- Cortical bone, 432
- Cortical spreading depression, 200
- Corticosteroid-binding globulin (CBG), 406
- Corticosteroids, 400–401
action/effects, 192
clinical uses
asthma, 340
shock, 281
comparison of, 401t
deficiency *see* Addison's disease
excess *see* Cushing's syndrome
teratogenicity, 704t
see also Adrenal steroids;
Mineralocorticoids; Steroids/steroid hormones
- Corticotrophin-releasing factor (CRF), 395t, 396, 399b, 403–404
- Corticotrophin-releasing hormone (CRH), 565
- Corticotrophs, 394
- Corticotropin, 707–708
- Cortisol *see* Hydrocortisone
- Cortisone, 400–401, 401t
- Corynebacterium* spp., 623t
- Cotinine, 599
- Co-transmission, 147, 147f, 149f
- Co-trimoxazole, 611, 622
clinical uses, 625b–626b, 630b
Pneumocystis, 666
toxoplasmosis, 666
interfering with folate action, 626b
- Cough, 345
reflex depression, effects of opioids, 515
treatment, 345
- Coxibs, 318–319, 325–326
asthma, 339
commonly used, 323–326
future developments, 334
unwanted effects, 322–323, 325–326
- C-peptide, 372
- Cranial nerves, 141
- Cranial outflow, 141
- Cravings, 595
- C-reactive protein, 86, 288
- Creeping eruption, 669, 669t
- Creutzfeldt-Jacob disease, 397, 478t, 489–490, 715–716
- Crisantaspase, 685
- Crohn's disease, 370, 601
- Cromakalim, 58
- Cromoglicate, 340, 343
- Cryptococcus neoformans*, 650t
- Cryptosporidium* spp., 369
- Crystal meth *see* Methamphetamine
- CSFs *see* Colony-stimulating factors (CSFs)
- CTOP, 513t
- Curare, 106, 139, 164
- Cushing's syndrome, 401–403, 405f
- Cutaneous administration, 108–109
- Cutaneous larva migrans, 669, 669t
- CX-516, 455
- CXCR4, 645, 647
- Cyanide poisoning, 261
- Cyclase activation, 272

- Cyclazocine, 510
 Cyclic 3',5'-adenosine monophosphate *see* cAMP
 Cyclic ADP-ribose (cADPR), 52
 Cyclic GMP (cGMP), 237, 240–241, 272–273
 Cyclic nucleotides *see* cAMP; cyclic GMP (cGMP)
 Cyclin-dependent kinases (cdks), 66–68, 67f, 75
 Cyclins, 66–68, 67f
 Cyclizine, 333t, 366
 Cyclo-oxygenase (COX), 213
 COX-1, 213, 318–320
 COX-2, 213, 318–320
 Cyclo-oxygenase (COX) inhibitors, 318–326, 320b
 actions/effects, 428
 clinical uses, 687
 comparison of, 319t
 unwanted effects, 323b, 698–699
see also Coxibs; Non-steroidal anti-inflammatory drugs (NSAIDs)
 Cyclopentolate, 159–160
 Cyclophilin, 329
 Cyclophosphamide, 678, 679b
 action, 112–113
 bladder toxicity, 118–119
 drug interactions, 332
 stereoselectivity, 117
 teratogenicity, 706
 Cycloplegia, 161
 Cyclopropane, 493
 Cycloserine
 action/effects, 612
 clinical use, 634–635
 unwanted effects, 635
 Cyclothiazide, 455
 CYP2C9 + VKORC1 genotyping, 137
 CYP2C19, 695
 CYP2D6, 136–137
 CYP enzymes *see* P450 monooxygenase system
 Cyproheptadine, 333, 333t
 carcinoid syndrome management, 202–203
 migraine management, 202t
 Cyproterone, 424, 683
 Cysteinyl leukotriene receptor antagonists, 340, 341b, 342
 Cysteinyl leukotrienes, 339
 Cysticercosis, 668, 670
 Cystic fibrosis, 715, 722
 Cystic fibrosis transmembrane conductance regulator (CFTR), 64, 719t
 Cytarabine, 613, 681, 681b, 681f
 Cytochrome *c* oxidase, 240
 Cytochrome P450 system *see* P450 monooxygenase system
 Cytokines, 208–210, 209t, 330–331, 444t
 bone remodelling, 432–434, 433f
 classification, 208
 innate immune response, 78
 receptors, 37, 210b
 role in inflammation, 86
 synthesis inhibition by viruses, 640
see also specific cytokines
 Cytoplasm, 610
 Cytoprotective agents, 365
 Cytosine arabinoside triphosphate, 681
 Cytotoxic drugs
 antibiotics, 677, 677t, 681–682, 682b
 as anticancer drugs, 677
 teratogenicity, 704t, 706
 Cytotoxicity, 241–242
 Cytotoxic T cells, 86
- D**
 Dabigatran, 300
 Dabigatran etexilate, 300
 Dacarbazine, 679
 Daclizumab, 330, 331t
 Dactinomycin, 613, 682, 682b
 Daidzin, 605–606
 Dale's principle, 143
 Dalfopristin, 631b, 633
 DAMGO, 513t
 D-amino acid oxidase (DAAO), 554
 D-amino acids, 234
 Danaparoid, 299–300
 Danazol, 344, 424–425, 425b
 Dantrolene, 52, 167, 500
 Dantron, 368
 Dapsone
 action/effects, 636
 clinical uses
 leprosy, 635–636, 636b
 malaria, 658, 661–662, 663b
 malaria chemoprophylaxis, 659
 drug interactions, 635
 metabolism, 135
 pharmacokinetics, 636
 unwanted effects, 636
 Daptomycin, 633
 Darbepoetin, 314
 Darifenacin, 154, 159–160
 DARPP-32, 464
 Darunavir, 643
 Dasatinib, 137, 684
 Daunorubicin, 681
Db gene, 385–386
 D cells, 362, 372
 DDT, 530
 Deadly nightshade, 159–160
 Death receptor pathway, 72
 Death receptors, 71
 Debrisoquine, 190–191, 692b
 Decamethonium, 163, 166
 Defasirox, 311
 Deferiprone, 311
 Deflazacort, 401t
 Dehydroepiandrosterone, 422–423
 Delirium tremens, 607
 Delivery systems, 111–113
 Demeclocycline, 628
 antidiuretic hormone inhibition, 352
 clinical uses, 629b
 effect on antidiuretic hormone, 399–400
 Dementia
 drugs used in, 484b
see also Alzheimer's disease
 Dendritic cells
 adaptive immune response, 82–83
 innate immune response, 81
 pathogen recognition, 78
 Denervation supersensitivity, 8–9, 143–144
 Denosumab, 440
 5'-Deoxyadenosylcobalamin, 313
 Deoxythymidylate monophosphate (dTTP), 312, 680
 Deoxyuridylate monophosphate (DUMP), 312, 680
 Dependence, 592–608, 593f, 596b
 drug administration, 592
 drug harm, 592–594
 drug-induced reward, 594–595
 mechanisms of, 595–597
 pharmacological treatment, 596t, 597
 physical dependence, 595
 psychological dependence, 595, 595f
 reward pathways, 594–595
 terminology, 593t
see also specific drugs
 Depolarisation block, 156–157, 157f, 166
 Depolarisation-induced suppression of inhibition (DSI), 225
 Depolarising blocking agents, 166–167, 167b
 comparison with non-depolarising blocking agents, 166
 unwanted effects, 166–167
 Depression (mood), 442
 animal models, 571, 571t
 bipolar disorder, 550, 564, 581–582
 catecholamine hypothesis of, 462
 endogenous, 564
 human tests, 571
 monoamine theory, 564–566
 nature of, 564
 reactive, 564
 treatment *see* Antidepressant drugs
 unipolar, 564
 Depression (synaptic transmission), long-term, 451–452, 472
 Dermatomycoses, 649
 Des-Arg9-bradykinin, 218–219, 219b, 508
 Descending inhibitory pathway, 505–506
 Desensitisation, 15–16, 16f, 35, 36f
 Desferrioxamine, 311
 Desflurane, 497, 500, 501b
 characteristics, 498t
 induction and recovery, 499
 pharmacokinetics, 500b
 Desipramine, 567, 574
 characteristics, 568t–570t
 clinical use, 521
 Desloratadine, 333t
 Desmopressin, 235t, 358, 400, 400b
 Desogestrel, 421, 425–426
 Desvenlafaxine, 567, 576–577, 577b
 Development, drug *see* Drug development
 Development (human)
 effect of thyroid hormones, 412
see also Growth
 Dexamethasone, 401t, 565
 clinical uses, 406
 anticancer drugs, 683
 antiemesis, 367
 Dexamethasone suppression test, 398, 406, 565
 Dexfenfluramine, 699
 Dexibuprofen, 319t
 Dexies *see* Dextroamphetamine
 Dextetropfen, 319t
 Dextrans, 707–708
 Dextroamphetamine, 584
 Dextromethorphan, 522
 actions/effects, 515
 clinical uses, 345
 Dextropropoxyphene, 513, 518t–519t
 Diabetes Control and Complications Trial, 378
 Diabetes insipidus, 399
 antidiuretic hormone, 400
 and drug responsiveness/effectiveness, 691
 nephrogenic, 351–352
 thiazide diuretics in, 355
 Diabetes mellitus, 372, 377–383
 treatment, 378–382
 type 1, 378
 type 2, 378
 Diabetic neuropathy, 377–378
 Diacylglycerol (DAG), 32–34
 Diacylglycerol lipase, 212
 Diacylglycerol lipases (DAGLs), 223–224

- Diamorphine, 510, 518t–519t, 519
administration, 592
dependence, 593t
- Diarrhoea
drugs for *see* Antidiarrhoeal agents
traveller's, 369
- Diazepam, 497, 538b
administration, 108, 548
affect of age on, 691
characteristics, 533t
clinical uses, 535, 543
excretion, 119–120
- Diazepam-binding inhibitor, 535
- Diazoxide, 58, 355
- Dibucaine, 133–134
- Dichloroisoprenaline, 187–188
- Diclofenac, 319t
- Dicycloverine, 369
- Didanosine, 613, 643
- Diet
and obesity, 391
see also Appetite; Food intake
- Diethylcarbamazine, 117–118, 670–671
- Diethylstilbestrol, 683
- Diffusion, 99–100
coefficient, 100
facilitated, 101–102
through lipid, 100–101
- Digitalis, 94
- Digitalis-like factors, 258
- Digoxin, 52, 258
affect of age on, 690
clinical uses, 255t, 280
drug interactions, 365, 693–694
elimination/excretion, 120
faecal elimination, 115
gastrointestinal absorption, 106–107, 107f
pharmacokinetics, 259
repeated dosing, 126
and verapamil, 257–258
- Dihydrocodeine, 519
- Dihydroergotamine, 197–198
action/effects, 199
properties, 199t
- Dihydrofolate, 312
- Dihydrofolate reductase, 312, 610–611, 619, 680
- Dihydro-oroate dehydrogenase, 330
- Dihydropteroate synthetase, 619, 622–623
- Dihydropyridines, 262
calcium channels and, 50
channel gating, 20
receptors, 52
unwanted effects, 263
vasodilatation, 272
- Dihydropyrimidine dehydrogenase (DPYD), 136
- Dihydrotestosterone, 423
- Dihydroxyphenylacetic acid (DOPAC), 463
- Dihydroxyphenylalanine (dopa), 175–177
- Di-iodotyrosine (DIT), 410
- Diloxanide, 664, 664b
- Diloxanide furoate, 664
- Diltiazem, 257–258
action/effects, 262
calcium channels and, 50
drug interactions, 342
vasodilatation, 272
- Dimaprit, 211
- 2,5-Dimethoxy-4-methylamphetamine (DOM), 590
- Dimethylarginine dimethylamino hydrolase (DDAH), 242
- Dimethyltryptamine (DMT), 590
- Dimorphic fungi, 649, 650t
- Dinitrophenol, 391
- Dinoprost, 428, 429b
- Dinoprostone, 216b, 428, 429b
- Diphenhydramine, 532, 686
- Diphenoxylate, 369
- Diphyllobothrium latum*, 668
- Dipivoxil, 643
- Dipyridamole, 205, 258
clinical uses, 304
vasodilatation, 260, 272–273
- Direct thrombin inhibitors, 300
- DISC-1, 554
- Discovery, drug *see* Drug development
- Disease
animal models, 92–93
and drug responsiveness/effectiveness, 691–692, 692b
and oral anticoagulants, 301
receptors and, 45–46
- Disease-modifying antirheumatic drugs (DMARDs), 326–328, 326f
- Disopyramide, 255t, 256
- Disposition, drug, 99–106
- Distal tubule, 350
- Distribution of drugs, 110–111, 112b, 693–694
- Disulfiram, 177, 679
action/effects, 605–606
clinical uses, 597b, 605b, 607
drug interactions, 695
metabolism, 118–119
- Diuresis, effects of ethanol, 603–604
- Diuretics, 347, 353–356, 357b
clinical uses, 269
drug interactions, 696
effects, 91–92
loop *see* Loop diuretics
osmotic, 356
potassium-sparing, 355–356, 356b
thiazide *see* Thiazide diuretics
use in sport, 712t
- Dizocilpine
action/effects, 554–555
NDMA receptor blockers, 450, 453–454
- DMT (dimethyltryptamine), 590
- DNA
damage, 72
plasmid, 720–721
replication, 66, 616f
sequence, 132–133
structure, 615f
synthesis, 612–615
transcription, 132–133
- DNAase, 235t
- DNA gyrase, 612
inhibition, 613–615, 615f
- DNA polymerase, 612
inhibition, 613, 644–645, 644t, 646b
- DNA viruses, 638, 640b
replication, 638
- Dobutamine, 252
action/effects, 182t–184t
clinical uses
heart failure, 280
shock, 281
effect on myocardial contraction, 259
- Docetaxel, 682
- Docusate sodium, 368
- Dolasetron, 366–367
- DOM (2,5-dimethoxy-4-methylamphetamine), 590
- Domoic acid, 478
- Domperidone, 427
blood-brain barrier, 110
clinical uses, 488
- antiemesis, 367
gastrointestinal motility, 368
- Donepezil, 483, 484b, 484t
- Dopa, 175–177
- Dopa decarboxylase, 177
- Dopamine, 174, 177
behavioural effects, 465
in the CNS, 463–466, 466b
functional aspects, 464–466
metabolism, 463, 463f
and motor systems, 464–465
NANC transmission, 145–147, 148t
neuroendocrine function, 465–466
in Parkinson's disease, 485
role in satiety signals, 388
schizophrenia, 554
transporter, 147–148
vasodilatation/vasoconstriction, 272
vomiting, 365, 466
- Dopamine agonists
clinical uses
fibromyalgia, 522
Parkinson's disease, 486, 488
- Dopamine antagonists
clinical uses, 367
effect on prolactin secretion, 397
- Dopamine- β -hydroxylase (DBH), 177
inhibition, 177
- Dopamine receptors, 464
antagonists, 464
D₁, 464–465, 558
D₂, 464, 554, 558
D₃, 464, 558
D₄, 464, 558
D₅, 464, 558
in Parkinson's disease, 485
in schizophrenia, 558–559
- Dopaminergic pathways in the CNS, 463–464, 463f
- Dorzolamide, 109
- Dose/dosing, effect of repeated, 126
- Dose ratio, 10
- Dose-response curve, 9–10, 91
- Double-blind clinical trials, 95
- Doxazosin
clinical uses
benign prostatic hypertrophy, 358
hypertension, 277–278
- Doxepin, 574–575
- Doxorubicin, 613–615, 681–682, 682b
- Doxycycline, 70, 628
clinical uses, 629b
malaria, 659
malaria chemoprophylaxis, 659
pharmacokinetics, 629
- DPDPE, 513t
- Dracunculus medinensis*, 668–669
- Dronabinol *see* Tetrahydrocannabinol (THC)
- Dronedarone, 257
- Droperidol, 497
- Drotrecogin alpha, 281, 296–297
- Droxidopa, 182t–184t, 190
- Drug, definition, 1
- Drug abuse, 592–597
see also Dependence; *specific drugs*
- Drug acetylation deficiency, 134–135
- Drug delivery systems, 111–113
- Drug development, 726–730
biopharmaceuticals, 729
clinical, 726, 727f, 728–729
commercial aspects, 729
discovery phase, 726–728, 727f
lead finding, 727–728
lead optimisation, 728
target selection, 726–727

- future prospects, 729–730
preclinical, 726, 727f, 728
- Drug-induced lupus, 135
- D-serine, 450
- Duloxetine, 567, 568t–570t, 576–577, 577b, 581
- Dutepilase, 307
- Dwarfism, pituitary, 397
- Dydrogesterone, 421
- Dyflos, 169–170, 170t, 171b
- Dynorphin, 232, 513t
- Dysbindin, 554
- Dyskinesia, 488
tardive, 560, 561b, 698
- Dyslipidaemia, 286–288, 287t, 288b, 292b, 357–358
- Dysmenorrhoea, 428
- Dysrhythmias, 247–249, 249b
 β_2 -adrenoceptor agonists effects, 341
treatment, 550
xanthine drugs adverse effects, 341
- Dystonias, acute, 560, 561b
- E**
- Eating behaviour, neurological circuits
controlling, 388–389
- Echinocandin B, 651–652
- Echinocandins, 649–652
- Echinococcus* spp., 669
- Eclampsia, 244
- Econazole, 652
- Ecothiophate, 169–170, 170t, 171b
- Ecstasy *see* MDMA
(methylenedioxymethamphetamine)
- Ectopic pacemaker activity, 248–249
- Eculizumab, 309, 316, 316f
- Edrophonium, 168–169, 170t, 171b
- Efalizumab, 330, 331t
- Efavirenz, 643, 646b
- Effector(s)
block of receptor-effector linkage, 15
controlled by G-proteins, 34b
- Efficacy, 8, 11–15, 14b
- Eflornithine, 665
- Ehrlich, Paul, 6
- Eicosanoids, 84, 212–217, 472
biosynthesis, 212–213
structure, 212–213
vasoconstriction, 271, 272b
- Eicosapentaenoic acid, 213, 217
- Eicosatrienoic acid, 213
- Elastin, 69
- Electroconvulsive therapy (ECT), 579–580
- Electroencephalography (EEG), 540, 541f
- Electrolytes, 369
- Eletriptan, 202t
- Elimination (and excretion), 119–121
definition, 115
drugs and metabolites, 119
expressed as clearance, 124
pharmacokinetic interactions, 696
- Elimination half-life, 125
- Elimination rate constant, 125
- Eliprodil, 450
- Emadastine, 332–333
- Emden-Meyerhof pathway, 610
- Embryogenesis, 70
- Emergency contraception, 427
- Emricasan, 75
- Emtricitabine, 643
- Enadoline, 513t
- Enalapril, 235t
metabolism, 118–119
vasodilatation, 274t
- Enalaprilat, 118–119
- Encainide, 255–256
- End-diastolic volume, 249–250
- Endocannabinoids, 223–225, 223t, 225b, 472–473
biosynthesis, 223–224, 224f
clinical use, 392–393
pathological involvement, 225
physiological mechanisms, 225
termination of signal, 224–225
- Endocrine gland-derived vascular endothelial growth factor (EG-VEGF), 99
- Endocrine system
effects of antipsychotic drugs, 560
effects of ethanol, 603
see also Neuroendocrine system
- Endogenous depression, 564
- Endoperoxides, 213
- Endorphins, 232, 512
- Endothelial nitric oxide synthase (eNOS), 237–240
- Endothelin, 267–269
biosynthesis, 267–268, 268f
discovery, 267–268
functions of, 269, 269f
receptors, 268–269, 268t
secretion, 267–268
vasoconstriction, 271, 272b
- Endothelium
dysfunction, 285
injury, 285
movement of drugs across, 99
vascular, 266–269, 266f
in angiogenesis, 267
endothelin, 267–269
in haemostasis and thrombosis, 296–297
- Endothelium-derived hyperpolarisation factors (EDHFs), 267
- Endothelium-derived relaxing factor, 237, 238f, 266–267
- Endotoxin, 622
- Endplate potential (epp), 156
- Energy balance, 385–390, 389b
- Energy expenditure control, 388–389
- Enflurane, 492, 500, 501b
characteristics, 498t
metabolism, 500
- Enfuvirtide, 235t, 645, 647, 647b
- Engineered proteins, 717
- Enkephalins, 512
descending inhibitory pathway, 506
vomiting, 365
- Enprofylline, 341
- Entacapone, 487
- Entamoeba histolytica*, 663
- Entecavir, 643
- Enteric nervous system, 140–141, 360
- Enterobius vermicularis*, 668
- Enterochromaffin cells, 194, 361
- Enterococci resistance, 620
- Enterohepatic circulation, 119
- Enuresis, 358
- Enzymes, 21, 21f, 22t
induction, 694–695, 694f
inhibition, 694t, 695–696
- Eosinophil cationic protein, 81, 339
- Eosinophil-derived neurotoxin, 339
- Eosinophil major basic protein, 81
- Eosinophils, 80–81
- Eotaxin, 209t
- Ephedrine, 191, 586
action/effects, 182t–184t, 193b
drug interactions, 578, 579b, 693
use in sport, 712t, 713, 714b
- Epibatidine, 162, 522, 598
- Epidermal growth factor (EGF), 37, 69
- Epidermophyton floccosum*, 650t
- Epidermophyton* spp., 649
- Epidural anaesthesia, 529t
- Epilepsy
animal models, 542–543
characteristics, 540
jacksonian, 541
Lennox-Gastaut syndrome, 542
nature of, 540–543, 543b
neural mechanisms, 542–543
psychomotor, 540–541
status epilepticus, 548
treatment *see* Antiepileptic drugs
types of, 540–542
complex, 540
generalised seizures, 541–542
partial seizures, 540–541
simple, 540
- Epinastine, 332–333
- Epinephrine *see* Adrenaline
- Epirubicin, 681
- Epithelium
as an administration route, 108–109
ion transport, 63–64, 64b, 64f
- Eplerenone, 355, 407
clinical uses, 280
pharmacokinetics, 355
vasodilatation, 274t
- Epoetin, 314, 315b, 347, 357–358
- Epoprostenol, 216b, 281, 305
- Epoxyeicosatrienoic acids (EETs), 267
- Eptifibatide, 305
- Equilibrium constant, 17
- Erectile dysfunction, 272–273, 429–430
effects of ethanol, 604
and nitric oxide, 244, 244f
and thiazide diuretics, 355
- Ergocalciferol *see* Vitamin D₂
- Ergometrine, 199t, 427–428, 429b
- Ergosterol, 615, 650
- Ergot alkaloids, 197–199, 198b
action/effects, 174, 199
clinical use, 199
poisoning, 198
properties, 199t
unwanted effects, 199
vasoconstriction, 271
- Ergotamine, 190
action/effects, 199
migraine management, 202t
properties, 199t
unwanted effects, 199
- Erlotinib, 75, 684, 685b
- Ertapenem, 628
- Erythromycin, 616b, 631
antimicrobial spectrum, 631
clinical uses, 369
drug interactions, 342
pharmacokinetics, 631
resistance, 619
- Erythropoietin, 235t, 309, 314–315
clinical use, 314
unwanted effects, 314
use in sport, 712t, 713
- Escherichia coli*, 369
- Escherichia* spp., 623t
- Escitalopram, 567, 568t–570t, 573
- Eslicarbazepine, 546
- Esomeprazole, 363
- Essential hypertension, 277–278
- Estramustine, 678
- Etanercept, 330, 331t, 717, 718t
- Etaquine, 662

- Ethambutol
clinical use, 634–635
unwanted effects, 635
- Ethanol
abstinence syndrome, 607
action/effects, 547
antidiuretic hormone secretion, 352
dependence, 593t, 597b, 602–607
treatment, 607
distribution, 111
drinks content, 602
drug interactions, 694
erectile dysfunction, 429
induction of microsomal enzymes, 118
lifestyle use, 710, 711t, 713b
metabolism, 117
pharmacokinetics, 605–607
genetic factors, 606
metabolism, 605–606, 606f, 607b
metabolism and toxicity of methanol and ethylene glycol, 606–607
pharmacological effects of, 602–605, 605b
atherosclerosis, 604
behavioural effects, 603
on the CNS, 602–603
on fetal development, 604–605
lipid metabolism, 604
on the liver, 604
neurotoxicity, 603
on other systems, 603–604
platelet function, 604
saturation kinetics, 128
teratogenicity, 704t
tolerance, 16, 607
vasodilatation, 273
- Ether, 501b
characteristics, 498t
induction and recovery, 498
- Ethinylestradiol, 119, 425, 683
- Ethnicity and drug responsiveness/effectiveness, 689
- Ethosuximide, 262
action/effects, 546
clinical uses, 543, 548, 550b
drug interactions, 634
properties, 544t–545t
- Ethylene glycol
metabolism, 606–607
toxicity, 118–119, 606–607
- Ethylene immonium, 678
- Ethynodiol, 421, 425–426
- Etidronate, 438
- Etodolac, 319t
- Etomidate, 496, 496t, 497b
- Etoposide, 682, 683b
- Etoricoxib, 319t, 325
- Etorphine, 510, 513, 520
- Etretinate, 706
- Eukaryotes, 609
- Euphoria, 514
- Excitation, 53–59, 54f, 56f–57f
- Excitatory amino acids, 448, 455b
as CNS transmitters, 448
metabolism, 448
release, 448
see also individual amino acids
- Excitotoxicity, 50–51, 477–478, 479f, 480b
- Excretion *see* Elimination (and excretion)
- Exemestane, 683
- Exenatide, 382–383
- Exendin-4, 382
- Exocytosis, 61–63, 62f
- Exons, 132–133
- Extracellular fluid, 110–111, 112t
- Extracellular matrix (ECM)
components, 69
interactions with cells and growth factors, 69–70
- Extraneuronal monoamine transporter (EMT), 178–179, 179t, 192
- Extrapyramidal motor disturbances, 560, 561b
- Eye drops, 109
- Eye(s)
autonomic nervous system effects on, 142t
effects of muscarinic agonists, 158–159, 159f
effects of muscarinic antagonists, 161, 163b
- Ezetimibe, 291, 291b
- F**
- Face validity, 92
- Facial nerve, 141
- Facilitating diffusion, 101–102
- Factor XII, 79–80
- Faecal elimination, 115
- Faecal softeners, 368
- Famciclovir, 112–113, 645, 646b
- Familial hypercholesterolaemia (FH), 286, 691–692
- Famotidine, 363
- Farnesoid (bile acid) receptor (FXR), 42
- Fas receptors, 72, 639
- Fast excitatory postsynaptic potential (fast epsp), 156
- Fast transmitters, 62–63, 63f
- Fat, body
brown, 388–389
partitioning of drugs into, 105–106
white, 388–389
- Fat (dietary), 390
- Fat* gene, 385–386
- Fatigue, β -receptor antagonists, 189
- Fatty acid amide hydrolase (FAAH), 224–225
- Fatty acid oxidation inhibitors, 383
- Fatty streaks, 285
- Fear, 531
- Felbamate, 549
clinical uses, 543
properties, 544t–545t
- Felypressin, 400, 400b, 529
- Fenbufen, 319t
- Fenfluramine
clinical uses, 391
unwanted effects, 699
use in sport, 713
- Fenofibrate, 290
- Fenoldopam, 277–278
- Fenopropfen, 319t
unwanted effects, 702
- Fentanyl, 109, 497, 510, 518t–519t, 519
- Fenticonazole, 652
- Ferritin, 310–311
- Ferrous succinate, 311
- Ferrous sulfate, 311
- Fetal alcohol syndrome (FAS), 604
- Fetal development, 604–605
- Fexofenadine, 333t
- Fibrates, 290
adverse effects, 290
clinical uses, 290b
nuclear receptors, 42
- Fibrin, 79–80, 294
- Fibrinogen, 294
- Fibrinolysis, 306–307, 306f
antifibrinolytic drugs, 307
fibrinolytic drugs, 306–307, 307b
choosing, 307
clinical use, 307, 307b
contraindications, 307
unwanted effects, 307
myocardial infarction, 253–254
- Fibrinolytic system, 78–80, 80f
- Fibroblast growth factor (FGF), 69
- Fibromyalgia, 522
- Filamentous fungi, 649, 650t
- Filariae, 668–670
- Filgrastim, 314–315
- Finasteride
antiandrogen activity, 424
clinical uses, 358
- First-order kinetics, 125
- First-pass metabolism, 108, 118, 118t
- Fish oils, 217, 288, 291–292, 711t
- FKBP (FK-binding protein), 329
- Flagellates, 655, 656t
- FLAP (five-lipoxygenase activating protein), 215
- Flatworms, 668
- Flavin adenine dinucleotide (FAD), 237
- Flavin mononucleotide (FMN), 237
- Flavopiridol, 75
- Flecainide, 255–256, 255t
- Fleming, Alexander, 622
- Flucloxacillin, 627, 627b
- Fluconazole, 652
drug interactions, 342
unwanted effects, 652
- Flucytosine, 611, 650, 653
- Fludarabine, 681, 681b
- Fludrocortisone, 401t, 407
- Fluid replacement
diarrhoea, 369
shock, 281
- Flukes, 668, 669t
- Flumazenil, 497, 533, 535–537, 538b, 602
- Flunitrazepam, 535
- Fluoride ions, 32
- Fluorinated pyrimidines, 649–650
- Fluorodeoxyuridine monophosphate (FDUMP), 681
- Fluoroquinolones
action/effects, 613–615
see also Quinolones
- Fluorouracil, 21, 616b, 681, 681b
action/effects, 611, 680f
intestinal absorption, 106
- 5-Fluorouracil (5-FU), 136
- Fluoxetine, 466–468, 469b, 567, 573
characteristics, 568t–570t
clinical use, 581–582
unwanted effects, 574
- Flupentixol
characteristics, 556t–557t
clinical uses, 562b
- Flupentixol decanoate, 562b
- Flurazepam, 533t
- Flurbiprofen, 319t
- Flushing, 291
- Flutamide, 424, 683
- Fluticasone, 343
- Fluvoxamine, 567, 568t–570t, 573
- Foam cells, 285
- Focal adhesion kinase, 69
- Folate/folic acid, 311–314
action/effects, 610–611
antimicrobial agents interfering with, 622–625, 626b
antagonists, 680–681, 681b
teratogenicity, 706

- antimalarial drugs affecting
 metabolism, 661–662
 clinical uses, 312b
 deficiency, 309
 mechanism of action, 312
 pharmacokinetics, 312
 during pregnancy, 705
 structure, 680f
 synthesis, antimicrobial agents
 interfering with, 622–625, 626b
 unwanted effects, 312
- Folinic acid, 312
- Follicle-stimulating hormone (FSH), 395, 425
 clinical use, 425
 male reproductive system, 418–419
 menstrual cycle, 417
 pharmacokinetics, 425
 preparations, 425
- Folliculostellate cells, 394
- Follitropin, 425
- Fomepizole, 606–607
- Food intake
 control of, 388
 effects of 5-hydroxytryptamine, 468
 and obesity, 390
- Food vacuoles, 616
- Forced expiratory volume in 1 s (FEV₁), 336
- Formaldehyde, 600, 606
- Formic acid, 606
- Formoterol
 asthma, 340–341, 341b
 chronic obstructive pulmonary disease, 345
- Formulation, 106–108
- Formyl peptide receptor (FPR), 234
- Forskolin, 32
- Fosamprenavir, 643
- Fosaprepitant, 367
- Foscarnet, 613, 616b, 645
- Foxgloves, 258
see also Cardiac glycosides
- FPR (formyl peptide receptor) family, 77–78
- Fraction, 125
- Frameshift mutation, 613
- Frank-Starling law, 249–250
- Free radicals, 480
- Frequentist analysis, 96
- Frovatriptan, 202t
- Frozen addict syndrome, 486
- Fulvestrant, 683
- Fumarate, 311
- Functionalisation, 115
- Fungal infections/fungi, 649, 650t
 treatment *see* Antifungal drugs
- Fungicidin, 651
- Fura-2, 49
- Furosemide, 353–354, 354f
 affect of disease on, 691
 excretion, 352–353
 use in sport, 712t
- Fusidic acid, 622, 627–628, 633
 action/effects, 631b
 resistance, 620
- Fusion proteins, 234–235
- G**
- G₀ phase of cell cycle, 66–68, 67f, 69f
- G₁ phase of cell cycle, 66, 67f, 68
- G₂ phase of cell cycle, 67f, 68
- GABA_A receptors
 drugs acting on, 457–458
 benzodiazepines, 533–534, 534f
- effect of antiepileptic drugs, 545
- effect of general anaesthetics on, 493–494
- effects of ethanol, 602
- pharmacology, 456, 457t
- presynaptic modulation, 144–145
- sites of drug action, 452f
- structure, 456
- GABA_B receptors, 36
 drugs acting on, 458
 pharmacology, 456, 457t
 structure, 456, 457f
- GABA (gamma-aminobutyric acid), 456–458, 459b
 in the brain, 448
 effect of antiepileptic drugs, 545
 function, 456
 NANC transmission, 145–147, 148t
 nociceptive pathway, 510
 receptors *see* GABA receptors
 storage, 456
 synthesis, 456
 transporter, 147–148
- Gabapentin
 action/effects, 545–546
 calcium channels and, 50
 clinical uses
 anxiety, 532
 bipolar disorder, 582
 epilepsy, 543, 549
 neuropathic pain, 521, 522b
 properties, 544t–545t
- GABA receptors
 drugs acting on, 457–458
 effects of ethanol, 602
 pharmacology, 456
 structure, 456
- Gabazine, 457–458
- Gaboxadol, 456–458
- Galanin, 397, 509
- Galantamine, 145, 483, 484b, 484t
- Gallamine, 154, 164
- Gallstones, 370
- Galvanic skin reactions, 532
- Gametocytes, 657–658
- Gametogenesis, 678
- Gamma-aminobutyric acid *see* GABA (gamma-aminobutyric acid)
- γ-endorphin, 232
- γ-hydroxybutyrate (GHB), 458
- γ-hydroxybutyric acid (GHB)
 clinical use, 607
 dependence, 593t
- Ganalozone, 550
- Ganciclovir, 645
- Ganglia/ganglion
 blocking drugs, 163
 clinical uses, 163, 277
 effects of, 163
 drugs affecting, 161–163
 stimulants, 161–162
- Ganglionic synapse, 156, 156f
- Gastric acid secretion, 360–365
 effects of histamine, 211, 361
 inhibition/neutralisation, 362–364
 antacids, 364
 histamine H₂ receptor antagonists, 362–363
 proton pump inhibitors, 363–364
 regulation of
 coordination of factors, 362
 by parietal cells, 360–362, 361f
- Gastrin, 360–362
- Gastrin-ECL-parietal cell axis, 362
- Gastrointestinal tract, 360–371
 drug absorption from, 106–108
- effect of non-steroidal anti-inflammatory drugs, 322, 322f
- effects of ethanol, 603
- effects of histamine, 211
- effects of 5-hydroxytryptamine on, 195
- effects of muscarinic antagonists, 161, 163b
- effects of opioids, 515
- gastric secretion *see* Gastric acid secretion
- histamine in, 211
- hormonal control, 360
- motility *see* Motility, gastrointestinal mucosa, drugs that protect, 365
- neuronal control, 360
- toxicity of anticancer drugs, 676
- Gastro-oesophageal reflux disease (GORD), 360, 362
- Gating, 43–44
 calcium release channels, 43–44
 ligand-gated channels, 43
 store-operated calcium channels, 44
 voltage-gated channels, 43
- G cells, 361
- GDP and G-proteins, 30
- Gefitinib, 75, 689
- Gemcitabine, 681
- Gemeprost, 216b, 422, 428
- Gemfibrozil, 290
- Gene amplification, 617
- Gene cassettes, 617–618
- Gene duplication, 617
- Gene expression, 573
 controlling, 721
 inducible system, 721
- Gene(s)
 influence on pharmacokinetics, 132
 mutation, 133
 and obesity, 390–391
 personalised medicine, 132–133
 polymorphisms, 133
 transcription, 42–43
- Gene silencing, 639–640
- Gene splicing, 232
- Gene tests
 combined (metabolism and target), 137
 drug metabolism-related, 136–137
 drug target-related, 137
 HLA, 135–136
- Gene therapy, 715, 718–721
 anticancer drugs, 687
 applications, 722–724
 cancer, 722–723, 723b
 cardiovascular disease, 723
 infectious disease, 723
 other gene-based approaches, 723–724
 single-gene defects, 722
 controlling gene expression, 721, 721b
 definition, 716b
 delivery, 718–721, 719t, 721b
 non-viral vectors, 720–721
 liposomes, 720
 microspheres, 720
 plasmid DNA, 720–721
 viral vectors, 719–720
 adenovirus, 719–720
 retroviruses, 719, 720f
 potential uses, 716b
 safety issues, 721–722, 722b
- Genetic animal models, 93
- Genistein, 420
- Genotoxic potential testing, 707
- Gentamicin, 630
 affect of age on, 690
 antibacterial spectrum, 630
 distribution, 111

- Gepirone, 538
 Gestodene, 117–118, 421, 425–426
 Ghrelin, 387t, 388
Giardia lamblia, 666
 Giardiasis, 666
Giardia spp., 369
 Gigantism, 397
 Glargine, 376, 379, 383
 Glaucoma
 drugs causing, 158–159
 drugs used for, 159t
 Glial cells, 443
 Glibenclamide, 380t, 381
 Glipizide, 380t
 Gliptins, 382–383, 383b
 Glitazones *see* Thiazolidinediones
 Glomerular filtration, 120, 347–349
 affect of age on, 690
 Glomerular filtration rate, 701–702
 Glomerulus, 347
 Glossopharyngeal nerve, 141
 Glucagon, 376–377
 actions, 376–377
 clinical uses, 377b
 effect on myocardial contraction, 259
 in hypoglycaemia, 372
 role in body weight regulation, 387t
 secretion, 372, 376
 synthesis, 376
 Glucagon-like insulinotropic peptide (GIP), 372–373, 377
 Glucagon-like peptide-1 (GLP-1), 372–373, 377, 387t
 Glucocerebrosidase, 235t
 Glucocorticoids *see* Adrenal steroids
 Glucokinase, 374
 Gluconate, 311
 Glucose
 blood *see* Blood glucose
 impaired tolerance, 355
 Glucose 6-phosphate dehydrogenase deficiency, 133, 662, 692
 Glucuronide conjugation reaction, 117, 117f
 Glut-2, 374
 Glut-4, 374
 Glutamate
 in the CNS, 448
 effects of ethanol, 603
 excitotoxicity, 477, 481
 and general anaesthetics, 494
 long-term potentiation, 451–453
 metabolism, 448
 nociceptive pathway, 509–510
 schizophrenia, 554–555
 synaptic plasticity, 451–453
 transport, 449f
 Glutamate receptors
 agonists, 455
 antagonists, 453–455, 523
 negative modulators, 453–455
 positive modulators, 455
 subtypes, 449–450, 451t, 452f–453f, 453t
 Glutamic acid, 680
 Glutamine, 448
 Glutathione, 117, 480, 700
 Glycerol, 368
 Glyceryl trinitrate (GTN), 242
 administration, 108
 clinical uses
 angina, 260
 gallstone pain, 370
 heart failure, 280
 pharmacokinetics, 261
 Glycine, 450, 453f, 458, 459b
 antagonists, 454–455
 receptor, 457t, 458, 602
 transporters, 147–148, 458
 Glycogen synthase kinase 3 (GSK3), 581
 Glycolysis, 374
 Glycopeptides, 624t, 633, 634b
 Glycophosphatidylinositol (GPI), 316
 Glycoprotein IIB/IIIA receptor antagonists, 305
 Glycosylation, 228
 Goitre
 diffuse toxic, 413
 simple, non-toxic, 413
 toxic nodular, 413
 Goitrogens, 413
 Gold compounds, 327–328
 Golimumab, 334
 Gonadorelin, 395, 395t, 424, 425b
 Gonadotrophin-releasing factor, 399b
 Gonadotrophin-releasing hormone (GnRH), 395, 395t, 425b
 administration routes, 109
 agonists and antagonists, 424–425
 clinical use, 424
 pharmacokinetics, 424
 unwanted effects, 424
 analogues, 235t, 683, 684b
 male reproductive system, 418–419
 menstrual cycle, 417
 NANC transmission, 148t
 translocation of receptors, 16
 Gonadotrophins, 425, 425b
 analogues, 425
 clinical use, 425
 pharmacokinetics, 425
 preparations, 425
 Gonadotrophs, 394
 Good Laboratory Practice (GLP), 728
 Goserelin, 424, 683
 Gout, 331–332, 331b
 G-protein coupled receptor kinases (GRKs), 35, 77–78
 G-protein coupled receptors, 24, 24f–25f, 24t, 28–37, 30b
 activation, 477
 agonist specificity, 37
 constitutively active, 36
 desensitisation, 16, 35, 36f
 dimerisation, 36
 families, 28, 29t
 further developments in biology, 35–37
 glutamate, 450–451, 453t, 455
 molecular structure, 28–29
 presynaptic modulation, 144–145
 protease-activated receptors, 29, 29f
 RAMPs and RGS proteins, 37
 G-protein(s), 9, 30–32
 independent signalling, 37
 mutations, 46
 role of, 30–32, 31f, 31t
 targets for, 31t, 32–35
 Graafian follicle, 417, 418f
 Gram-negative organisms, 610, 618–619, 622
 Gram-positive organisms, 610, 622
 Gram's stain, 610, 622
 Granisetron, 366–367, 686
 Granulocyte colony-stimulating factor, 315
 Granulocyte macrophage colony stimulating factor (GM-CSF), 653
 Grapefruit juice, 117, 430
 Graves' disease, 415
 Gregory, James, 2
 Grey baby syndrome, 630, 690–691
 Griseofulvin, 651
 Growth
 effect of thyroid hormones, 412
 toxicity of anticancer drugs, 676
 Growth factors, 229
 action of, 69
 in asthma, 339
 and cancer development, 674, 674f
 cell cycle, 66, 69f
 in hypertension, 277
 interactions with cells and extracellular matrix, 69–70
 Growth hormone, 235t, 396–397, 715–716
 actions, 396–397
 clinical use, 397
 effect of dopamine on, 465–466
 in hypoglycaemia, 372
 production disorders, 397
 secretion regulation, 396
 and thyroid hormones, 412
 use in sport, 712t, 713
 Growth hormone-releasing factor (GHRF), 395, 395t, 399b
 Growth hormone-releasing inhibiting factor, 395t
 GTP and G-proteins, 30
 Guanethidine, 191
 action/effects, 182t–184t
 clinical uses, 415
 Guanfacine, 586
 Guanidinium ions, 530
 Guanine nucleotides
 G-proteins and, 30
 see also GDP; GTP
 Guanylyl cyclase, 40, 240–241
 Guinea worm, 668–669
 Guvacine, 456
- ## H
- HAART *see* Highly active antiretroviral therapy (HAART)
 Haem, 239–240
 Haematinic agents, 309–314
 Haematological reactions, 696, 708
 Haemochromatosis, 311
 Haemoglobin, 310, 316
 Haemoglobinopathies, 715
 Haemolytic anaemia, 316–317, 708
 Haemophilia, 297
 Haemophilia B, 297
Haemophilus spp., 623t, 629
 Haemopoietic growth factors, 309, 314–315, 315f
 Haemopoietic system, 309
 Haemorrhage
 anticoagulants adverse effects, 302
 fibrinolytic agents adverse effects, 307
 heparin unwanted effects, 299
 Haemosiderin, 310–311
 Haemostasis, 294–308
 Haemostatic drugs, 307
 Hageman factor, 218, 294
 Hallucinations
 drugs causing *see* Psychotomimetic drugs
 effects of 5-hydroxytryptamine, 468
 Halofantrine, 661
 Halogenated hydrocarbons, 492
 Haloperidol, 555
 characteristics, 556t–557t
 clinical uses, 367, 562, 562b
 distribution, 111
 Halothane, 497, 500, 501b
 characteristics, 498t
 effect on respiratory system, 494
 induction and recovery, 498–499
 metabolism, 500
 pharmacokinetics, 500b

- unwanted effects, 167, 700–701, 701b, 708, 708b
- Haptens, 707
- Harmful effects of drugs *see* Adverse drug reactions/harmful effects; *specific drugs*
- Hashimoto's thyroiditis, 413
- Healing processes, 73
- Hearing loss, aminoglycoside-induced, 135
- Heart, 246–264
 - autonomic control, 142t, 251–252
 - parasympathetic, 252
 - sympathetic, 251–252
 - contraction *see* Heart muscle, contraction
 - coronary blood flow *see* Coronary blood flow
 - drugs affecting, 254–263
 - effects of adrenoceptor agonists, 181–184, 185f
 - effects of adrenoceptors, 176t
 - effects of calcium antagonists, 262
 - failure, 249–250, 278–280, 279f
 - muscle *see* Heart muscle
 - myocardial oxygen consumption, 250–251
 - rate, 246–249
 - control, 249
 - effects of cardiac glycosides, 258–259
 - effects of muscarinic antagonists, 161
 - rhythm, 246–249
 - disturbances of, 247–249
 - effects of cardiac glycosides, 258–259
- Heart attack *see* Myocardial infarction
- Heart block, 247–249
- Heart muscle
 - contraction, 59–60, 249–250, 250b
 - drugs that increase, 258–259
 - force of, 259
 - heart failure, 249–250
 - in heart failure, 280
 - myocardial contractility and viability, 249
 - ventricular function curves, 249–250, 250f
 - electrophysiological features, 246
 - excitation, 56–57
 - regeneration, 74
- Heavy metals
 - poisoning, 328
 - teratogenicity, 706
- Helicobacter pylori*, 362, 364–365
- Helicobacter* spp., 623t
- Helminth infections, 668–669
 - see also specific types*
- Hemicholinium, 167, 167b
- Henderson-Hasselbalch equation, 100–101
- Heparan sulfate, 296–297
- Heparin (and low-molecular-weight heparins)
 - administration, 299
 - clinical uses, 298–300
 - elimination/excretion, 120
 - mechanism of action, 299, 299f
 - pharmacokinetics, 299
 - plasma compartment, 111
 - repeated dosing, 126
 - unstable angina, 253
 - unwanted effects, 299–300, 707–708
- Heparin-induced thrombocytopenia (HIT), 299–300
- Hepatotoxicity, 700–701, 701b
 - paracetamol, 325
 - thiazolidinediones, 382
- Heptahelical receptors *see* G-protein coupled receptors
- HER2, 137
- Herbal ecstasy, 590
- Herbal preparations, 711t
- Herceptin *see* Trastuzumab
- Heroin *see* Diamorphine
- Herpes labialis, 639
- Herpes simplex, 645b
- Herpes viruses, 645b, 720
- Heterologous desensitisation, 35
- Heterotropic interactions, 144
- Hexamethonium, 163
- High-density lipoprotein (HDL) cholesterol, 285–286, 288, 290
- Highly active antiretroviral therapy (HAART), 646–647, 647b
- High-molecular-weight kininogen, 218, 218f
- Hill-Langmuir equation, 17
- Hiostidine decarboxylase, 211
- Hirudins, 300
- Histaminase, 211
- Histamine, 210–211, 211b, 360
 - action/effects, 8, 211
 - in asthma, 338
 - in the CNS, 471, 473b
 - gastric acid secretion, 361
 - inhibition by catecholamines, 186
 - innate immune response, 80–81
 - receptors, 211 (*see also specific histamine receptors*)
 - release, 211
 - effects of opioids, 515
 - storage, 211
 - synthesis, 211
 - triple response, 211
 - vomiting, 365
- Histamine H₁ receptor, 8, 471
 - antagonists, 211, 332–334
 - antiemesis, 366
 - clinical uses, 333b
 - allergic emergencies, 344
 - asthma, 342
 - insomnia, 532
 - comparison of commonly used, 333t
 - drug interactions, 693
 - pharmacokinetics, 333–334
 - pharmacological actions, 333
- Histamine H₂ receptor, 8, 471
 - agonists, 211
 - antagonists, 211, 332
 - inhibition/neutralisation of gastric acid secretion, 362–363
 - pharmacokinetics, 363
 - unwanted effects, 363
- Histamine H₃ receptor, 8, 471
 - agonists, 211
 - antagonists, 211, 332
- Histaminergic neurons, 211
- Histaminocytes, 211
- Histone deacetylase (HDAC), 341, 343–345, 408
- Histoplasma capsulatum*, 650t
- HIV/AIDS, 640–641, 642f–643f
 - combination therapy, 646–647, 647b
 - gene delivery vectors, 720
 - gene therapy for, 723
 - HIV-1, 640
 - HIV-2, 640
 - treatment, 647b (*see also* Antiviral drugs)
- HLAB*1502, 135
- HLAB*5701, 135
- HLA-DQB1*0201, 136
- HLA gene tests, 135–136
- HMG-CoA reductase inhibitors *see* Statins
- Homocysteate in the CNS, 448
- Homocysteine-methionine methyltransferase, 313
- Homoeopathy, 2
- Homologous desensitisation, 35
- Homotropic interactions, 144
- Homovanillic acid (HVA), 463
- Hookworms, 668
- Hormone replacement therapy (HRT), 422
- Hormone(s)
 - antagonists, 683
 - anterior pituitary, 396–399
 - anticancer drugs, 677, 677t, 682–683, 684b
 - gastrointestinal tract, 360
 - hypothalamic, 394–396, 395t
 - involved in bone metabolism and remodelling, 435–437
 - peptide, 228–229
 - role in body weight regulation, 385–388, 386f–387f
 - unwanted effects, 707–708
 - see also specific hormones*
- Host defence
 - cells, 77–88
 - nitric oxide, 241–242
- Human chorionic gonadotropin (HCG), 417–418, 425
 - clinical use, 425
 - pharmacokinetics, 425
 - preparations, 425
- Human genome, 28
- Human immunodeficiency virus *see* HIV/AIDS
- Humanised antibodies, 234–235
- Humoral response, 84–86
- Huntingtin, 489
- Huntington's disease, 478t, 489
- Hyaluronidase, 109
- Hybridoma, 717
- Hydatid tapeworm, 669
- Hydralazine
 - clinical uses, 280
 - effect of genetics on, 692b
 - metabolism, 135
 - unwanted effects, 708–709, 708b
 - vasodilatation, 273
- Hydrocarbons, 600
- Hydrochloric acid (HCl), 360
- Hydrocortisone, 400–401, 401t
 - clinical uses
 - allergic emergencies, 344
 - chronic obstructive pulmonary disease, 345
 - status asthmaticus, 343
 - pharmacokinetics, 406
- Hydrogen ion transport, 349, 352
- Hydrogen peroxide, 267
- Hydrogen sulphide, 267
- Hydrolytic reactions, 117
- Hydromorphone, 518t–519t
- 5-Hydroperoxytetraenoic acid (5-HPETE), 215
- Hydroxycarbamide, 309, 685
 - administration, 317
 - clinical uses, 316–317
 - mechanism of action, 317
 - unwanted effects, 317
- Hydroxychloroquine, 328
- Hydroxycobalamin *see* Vitamin B₁₂
- 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 468
- 6-Hydroxydopamine, 190, 193b, 463, 584–585
- Hydroxyicosatetraenoic acids (HETEs), 472–473, 472f, 508–509
- 5-Hydroxyindoleacetic acid (5-HIAA), 194
- Hydroxyprogesterone, 421
- 2-Hydroxysaclofen, 458

- 11 β -Hydroxysteroid dehydrogenase, 400–401, 407
- 5-Hydroxytryptamine (5-HT), 194–199
actions/effects, 196b, 509
biosynthesis, 194, 195f
and carcinoid syndrome, 202–203
clinically used drugs, 468
in the CNS, 466–468, 469b
degradation, 194
descending inhibitory pathway, 506
distribution, 194
feeding and appetite, 468
functional aspects, 467–468
hallucinatory effects, 468
metabolism, 466–467
and migraine, 199–201
mood, 468
NANC transmission, 145–147, 148t
nociceptive pathway, 510
pathways, 467, 467f
pharmacological effects, 195
and pulmonary hypertension, 203
receptors, 198b, 467 (*see also specific receptors*)
classification, 195–196
drugs acting on, 196–199, 197t
in schizophrenia, 559
release, control of, 572–573, 572f–573f
role in satiety signals, 388
sensory transmission, 468
sleep/wakefulness, 468
transporter, 147–148
vomiting, 365
- 5-Hydroxytryptamine (5-HT)₁ receptors, 196, 198b, 467
agonists, 197, 201, 469b
drugs acting on, 197t
type 1A, 559, 571–572
agonists
as anxiolytics, 538, 538b
expression, 538
- 5-Hydroxytryptamine (5-HT)₂ receptors, 196, 198b, 467
antagonists, 197–198, 469b
drugs acting on, 197t
type 2A, 559
- 5-Hydroxytryptamine (5-HT)₃ receptors, 196, 198b, 467
antagonists, 198, 366–367, 469b, 679, 686
drugs acting on, 197t
- 5-Hydroxytryptamine (5-HT)₄ receptors, 196, 198b, 467
agonists, 198
drugs acting on, 197t
- 5-Hydroxytryptamine (5-HT)₅ receptors, 196, 197t, 198b, 467
- 5-Hydroxytryptamine (5-HT)₆ receptors, 196, 197t, 198b, 467
- 5-Hydroxytryptamine (5-HT)₇ receptors, 196, 198b, 467
drugs acting on, 197t
- 5-Hydroxytryptamine (5-HT) reuptake inhibitors, 532
- Hydroxyzine, 333t
- Hygiene hypothesis, 671
- Hymenolepis nana*, 668
- Hyoscine, 159–160, 590
action/effects, 470
clinical uses
antiemesis, 366
gastrointestinal motility, 369
effects, 161
- Hyoscine butylbromide, 159–160
- Hyoscyamine, 590
- Hyperaldosteronism, 401
- Hyperalgesia, 503–505
- Hyperbola, rectangular, 17, 17f
- Hypercholesterolaemia, 243–244, 290–291
- Hyperglycaemia, 379
adrenaline-induced, 184–186
effect of glucocorticoids, 406
- Hyperimmune globulin, 645
- Hyperkalaemia, 355–356, 358
- Hyperlipoproteinaemia, 287t
- Hyperphagia, 385
- Hyperphosphataemia, 358
- Hyperplasia, 73
- Hyperprolactinaemia, 397–398
- Hyperpyrexia, malignant *see* Malignant hyperpyrexia
- Hypersensitivity, 707–709, 708b
clinical types of, 707–709
effects of local anaesthetics, 528
heparin unwanted effects, 300
immunological mechanisms, 707
type I (anaphylactic/immediate), 87
type II (antibody-dependent cytotoxic), 87
type III (complex-mediated), 87
type IV (cell-mediated), 87
- Hypertension, 188, 277–278, 278f
effects of MAOIs, 578
pulmonary, 195, 203, 282, 282b, 282f
in renal failure, 357–358
thiazide diuretics in, 355
- Hyperthermia, malignant *see* Malignant hyperthermia
- Hyperthyroidism, 413
and drug responsiveness/effectiveness, 692
treatment, 414–415, 415b
- Hyperuricaemia, 331b, 354
- Hyphae, 649
- Hypnotic drugs, 532–533, 533b
clinical use, 539b
dependence, 593t
see also Anxiolytics
- Hypnozoites, 657
- Hypoaldosteronism, 300
- Hypoglycaemia, 372
 β -receptor antagonists, 189
effects of insulin, 379
- Hypoglycaemic agents
clinical uses, 379b, 383b
see also Insulin; *specific types*
- Hypokalaemia, 354–355
- Hypokinesia, 485
- Hypomagnesaemia, 354
- Hyponatraemia, 355
- Hypoparathyroidism, 46, 439
- Hypophosphorylated Rb, 67–68
- Hypotension
effects of opioids, 515
orthostatic, 561
in Parkinson's disease, 488
postexercise, 163
postural, 163
- Hypotensive states, vasoactive drugs for, 280–281
- Hypothalamic hormones, 394–396, 395t
- Hypothalamic-hypophyseal tract, 399
- Hypothalamus, 399b
body weight regulation, 385, 388
effect of glucocorticoids, 402b, 403–404
- Hypothermia, 691
- Hypothyroidism, 413–414
congenital, 413–414
and drug responsiveness/effectiveness, 691
treatment, 415, 415b
- Ibandronate, 438
- Ibogaine, 590
- Ibuprofen, 319t
and Alzheimer's disease, 484
drug interactions, 693
- Icatibant, 219
actions/effects, 508
clinical uses, 344
- Ice *see* Methamphetamine
- Idarubicin, 681
- Idazoxan, 187, 462
- Idiosyncratic reactions, 689, 692, 692b, 699
see also Adverse drug reactions/harmful effects
- Idoxuridine, 645
- Ifenprodil, 450
- Ifosfamide, 678
- Imatinib, 40, 75, 685b, 730
and BCR-ABL1, 137
clinical uses, 684
- Imidazole N-methyltransferase, 211
- Imidazoline I₁ receptor, 274
- Imidazolines, 430
- Imidazoquinolones, 78
- Imipenem, 628, 629b
- Imipramine, 191, 567, 574, 576b
action/effects, 182t–184t, 192
characteristics, 568t–570t
pharmacokinetics, 575f
- Immediate hypersensitivity, 87
- Immune response
acquired/adaptive *see* Adaptive (acquired) immune response
apoptosis and, 70
innate *see* Innate immune response
subversion by viruses, 640
unwanted, 87
- Immune system
effect of glucocorticoids, 402b, 404–405
helminths, 671
mediators, 229
- Immunoglobulins, 84, 645, 646b, 683–684
- Immunomodulators, 644t, 646, 646b
- Immunosuppressant drugs, 328–330, 329b
clinical uses, 329b
cytotoxic, 84
drug interactions, 693
- Immunosuppression and ethanol, 604
- Incontinence, 358
- Incretin mimetics, 382
- Incretins, 372–373, 377
- Indapamide, 355
- Indinavir, 643, 646b
- Individual variation, 689–692, 689b
age, 690–691
disease, 691–692, 692b
ethnicity, 689
genetic factors, 692b
pregnancy, 691
- Indometacin, 319t
absorption, 107–108
and Alzheimer's disease, 484
drug interactions, 693
- Inducible expression system, 721
- Inducible NO synthase (iNOS), 219, 237, 239, 242
- Induction, enzyme, 118
- Infection
gene therapy for, 723
response to, 406
- Infiltration anaesthesia, 529t
- Inflammation
adenosine triphosphate in, 207
bradykinin role in, 219

- cytokines in, 208
 effect of glucocorticoids, 402b, 404–405, 407–408
 leukotrienes role in, 216–217
 neurogenic, 219, 337, 504–505
 nitric oxide role in, 219
 outcome, 87–88
 platelet activating factor role in, 217
 prostanoids in, 214–215
 role of nervous system in, 86–87
 systemic responses, 86–88
 unwanted, 87
- Inflammatory bowel disease (IBD), 370
 Inflammatory response, 77, 77b
 Infliximab, 330, 331t, 718t, 730
 chemical antagonism, 15
 clinical uses, 370
 Inhalation administration, 109
 Inhibitors of kinases, 68
 Injection of drugs, 109–110
 Injury, response to, 406
 Ink family, 68
 Innate immune response, 77–82
 cellular events, 80–82
 pathogen recognition, 77–82
 vascular events, 78–80
 Inosine monophosphate dehydrogenase, 330
 Inosine pranobex, 646, 646b
 Inositol monophosphatase, 581
 Inositol phosphate system, 32–34
 Inositol (1,4,5) trisphosphate (IP₃), 32–33, 43–44, 52
 Inositol trisphosphate receptor (IP₃R), 52
 Insecticides, 530
 Insomnia treatment *see* Hypnotic drugs
 Insulin, 235t, 372–376, 383, 715–716
 actions/effects, 372, 374–376, 374f
 long term, 376
 clinical uses, 379b
 diabetes mellitus treatment, 378–379
 mechanism of action, 376
 pharmacokinetics, 379
 preparations, 379
 role in body weight regulation, 387t
 secretion, 372–374, 373f
 drugs that stimulate, 381–382
 signalling pathways, 375f, 376
 synthesis, 372–374
 unwanted effects, 379
 use in sport, 712t
 Insulin glargine, 376, 379, 383
 Insulin-like growth factor (IGF)-1, 396
 Insulin lispro, 379, 383
 Insulin receptor substrate (IRS) proteins, 376
 Insulin-secreting cells, 74
 Integrase inhibitors, 644t
 Integrins, 69, 78
 Integrins, 617–618
 Interactions, drug, 692–696, 696b
 pharmacodynamic, 693
 pharmacokinetic, 693–696
 receptors, 8–10, 16–18
see also specific drugs
 Interferon- α , 210, 646
 action/effects, 209t
 clinical use, 210, 686
 Interferon- α -2a, 646
 Interferon- α -2b, 646
 Interferon- β , 210, 646
 Interferon- γ , 210, 646
 action/effects, 209t
 clinical use, 210
- Interferons, 37, 82, 210, 235t, 646
 action/effects, 209t
 clinical use, 210, 210b
 Interleukin (IL)-1, 78, 208
 Interleukin (IL)-2, 84
 Interleukin (IL)-3, 343
 Interleukins, 208
 action/effects, 209t
 anti-inflammatory, 208
 in asthma, 339
 International normalised ratio (INR), 301
 International Union of Pharmacological Sciences (IUPHAR), 8
 Interstitial cell-stimulating hormone (ICSH), 418–419
 Intestine
 drug absorption from, 106, 107f
 drug metabolism in, 117
 epithelial cells, pathogen recognition, 78
 5-hydroxytryptamine in, 194
 motility *see* Motility, gastrointestinal
 Intracellular fluid, 110
 Intramuscular injection of drugs, 109
 Intraocular pressure
 drugs that lower, 159t
 increased, suxamethonium-induced, 166
 regulation, 158–159
 Intrathecal injection, 109–110
 Intrauterine devices, 113
 Intravenous injection of drugs, 109
 Intravenous regional anaesthesia, 529t
 Intravitreal injection, 110
 Intrinsic efficacy, 13
 Intrinsic factor, 313, 360
 Introns, 132–133
 Inwardly rectifying potassium channels, 58, 58t
 Inward rectifier channels, 44
 Iodide/iodine, 415, 415b
 oxidation, 410
 plasma concentration, 412
 uptake, 410, 412
 Ion channels, 20–21, 21f, 22t
 as drug targets, 43–44
 effect of general anaesthetics on, 493–494, 493f
 excitation and, 55–59, 56f
 gating *see* Gating
 ligand-gated *see* Ligand-gated ion channels
 molecular architecture, 44, 45f
 pharmacology of, 44
 presynaptic modulation, 144–145
 selectivity, 43
 targets for G-proteins, 32, 34
 voltage-gated *see* Voltage-gated ion channels
see also specific ion channels
 Ionisation, 100–101, 120
 Ionotropic glutamate receptors, 449–450
 agonists, 455
 antagonists, 453–455
 Ionotropic receptors *see* Ligand-gated ion channels
 Ion transport, epithelial, 63–64, 64b, 64f
 Ion trapping, 101, 120
 Iopanoic acid, 413
 Ipratropium, 159–160
 clinical uses
 asthma, 342
 chronic obstructive pulmonary disease, 345
 status asthmaticus, 343
 inhalation administration, 109
 Iproniazid, 577, 700–701
 Ipsapirone, 538
- Irbesartan, 275–276
 Irinotecan, 137, 682, 683b
 Iron, 312b
 administration, 311
 balance, 310–311
 deficiency, 309
 distribution, 310, 310f, 310t
 intestinal absorption, 106
 overload, 311
 toxicity, 311
 turnover, 310–311, 310f
 unwanted effects, 311
 Irritable bowel syndrome, 369–370
 Irritant receptors, 337
 Ischaemic brain damage, 476, 480–481, 481b
 excitotoxicity, 478
 pathophysiology, 480–481
 therapeutic approaches, 481
 Ischaemic heart disease, 253–254
 effects of ethanol, 604
 effects of smoking, 600
see also Angina; Myocardial infarction
 Ischaemic preconditioning, 249
 Islet amyloid polypeptide, 372, 377
 Islets of Langerhans, 372
 Isocarboxazid, 568t–570t, 579b
 Isoflurane, 494, 497, 498t, 500, 501b
 Isoniazid
 action/effects, 634
 clinical use, 634
 drug acetylation deficiency, 134–135
 drug interactions, 634
 effect of genetics on, 692b
 pharmacokinetics, 634
 unwanted effects, 634
 Isophane insulin, 379
 Isoprenaline, 174
 clinical uses, 255t
 translocation of receptors, 16
 Isoproterenol, 182t–184t
 Isosorbide mononitrate
 clinical uses, 260
 pharmacokinetics, 261
 Isotretinoin, 288
 Ispaghula husk, 368
 Itching
 effects of histamine, 211
 effects of opioids, 515
 Itraconazole, 615–616, 652
 Ivabradine, 247, 259
 Ivermectin, 671
 clinical uses, 669
 pharmacogenomic tests, 135
- J**
 Jacksonian epilepsy, 541
 Jak, 39
 Jaundice, 561
 Juxtaglomerular apparatus, 270, 347, 348f
 Juxtamedullary nephrons, 347, 348f
- K**
 Kainate model, 542
 Kainate receptors, 449
 Kainic acid, 477
 Kallidin, 217, 508
 Kallikrein, 218, 219b, 306
 Kernicterus, 690–691, 694
 Ketamine, 493–494, 496, 496t, 497b, 522, 585t, 589–590, 591b
 action/effects, 495b, 554–555
 as an antidepressant, 579
 classification, 446

- clinical use, 454–455, 581
dependence, 593t
effect on cardiovascular system, 494
NDMA receptor blocker, 450, 453–454
pharmacological effects, 590
- Ketoconazole, 402, 652
P450 inhibition, 117–118
unwanted effects, 652
- Ketocyclazocine, 511–512
- Ketoprofen, 319t
- Ketorolac, 319t
- Ketotifen, 332–333
- Kidney(s), 347–359
acid-base balance, 352
diffusion across the renal tubule, 120, 120t
drugs acting on *see* Diuretics
effects of amphotericin on, 651
effects of antidiuretic hormone, 399–400
effects of non-steroidal anti-inflammatory drugs, 322–323
excretion via, 115, 119–121
 organic molecules, 352–353, 357
failure, drugs used in, 357–358
glomerular filtration, 120
natriuretic peptides, 353
nephron, 347–353
 blood supply, 347, 348f
 diuretics acting directly on cells of, 353–356
 glomerular filtration, 347–349
 juxtaglomerular apparatus, 347, 348f
renal clearance, 121
renal function, 347
 prostaglandins and, 353
toxicity *see* Nephrotoxicity
tubular function, 349–352, 352b
tubular secretion, 120, 120t
- Kinase inhibitors, 75, 484
- Kinase inhibitory proteins, 68
- Kinase-linked receptors, 24–25, 24f–25f, 24t, 37–40, 38f, 39b
 cascade mechanisms, 39–40, 41f
 protein phosphorylation, 39–40
- Kinases, 39
- Kindling model, 542
- Kininase II, 218
- Kininases, 218
- Kininogen, 219b
- Kinins, 62, 218, 508
- Kinin system, 78–80, 80f
- KIP family, 68
- Klebsiella*, 623t
- Kuru, 489–490
- Kynurenic acid, 453–454
- L**
- Labetalol, 182t–184t, 187
- Lacosamide, 522, 550
- Lacrimation
 effects of muscarinic agonists, 158
 effects of muscarinic antagonists, 161
- Lactic acidosis, 380
- Lactotrophs, 394, 397
- Lactulose, 368
- Lamivudine, 643, 646b
- Lamotrigine, 549
 clinical uses
 bipolar disorder, 581–582, 582b
 epilepsy, 543
 neuropathic pain, 521
 in pregnancy, 551
 properties, 544t–545t
 teratogenicity, 706
- Langerhans cells, 81
- Lanreotide, 395, 399b, 683
- Lansoprazole, 363
- L-arginine, 237–238
- L-arginine/nitric oxide pathway
 clinical conditions, 243
 inhibition, 243b
- Laropiprant, 291
- Lassa fever, 646
- Latanoprost, 216b
- Lateral horn, 140–141
- Law of Mass Action, 17
- Laxatives
 anthroquinone, 368
 bulk, 368
 osmotic, 368
 stimulant, 368
- LCAT (lecithin cholesterol acyltransferase), 286
- L-dopa *see* Levodopa
- Lead compounds
 finding, drug development, 727–728
 natural products as, 727–728
 optimisation, drug development, 728
 teratogenicity, 706
- Learning, 470
- Leber's congenital amaurosis, 722
- Lecithin cholesterol acyltransferase (LCAT), 286
- Leflunomide, 330
- Legionella*, 623t
- Leishmania major*, 241–242
- Leishmaniasis, 665–666
- Leishmania* spp., 655
- Lenalidomide, 685
- Lennox-Gastaut syndrome, 542
- Lenograstim, 314–315
- Lentivirus, 719
- Lepirudin, 300
- Lepra reactions, 636
- Leprosy, 635–636, 636b
- Leptin, 93, 184–186
 deficiency, 392
 role in body weight regulation, 386, 386f, 387t, 388, 390
- Letrozole, 683
- Leucocytosis, 86
- Leu-enkephalin, 232, 513t
- Leukocytes, 330–331
- Leukopenia, 561
- Leukotriene (LT)_{A₄}, 215
- Leukotriene (LT)_{B₄}, 338
- Leukotrienes, 212, 215–217, 217b
 actions, 215–217
 biosynthesis, 214f
 receptors, 215
 sulfidopeptide, 215
- Leuprorelin, 424, 683
- Levamisole, 616, 669, 671
- Levetiracetam, 549
 action/effects, 546
 clinical uses
 bipolar disorder, 582
 epilepsy, 543
 properties, 544t–545t
- Levobupivacaine, 528, 530b
- Levocetirizine, 333t
- Levodopa, 445–446
 absorption, 112–113
 clinical use, 486–488
 intestinal absorption, 106
 therapeutic effectiveness, 487–488
 unwanted effects, 488, 560
- Levofloxacin, 631
- Levomepromazine, 367
- Levonorgestrel, 425–427
- Levosimendan, 249
 clinical uses, 281
 vasodilatation, 272
- Levothyroxine, 415, 415b
- Lewy bodies, 486
- Lexatumumab, 74
- Lexipafant, 217, 217b
- Leydig cells, 418–419
- L-histidine, 177
- Lidocaine, 256
 action/effects, 528
 clinical use, 521, 522b, 526
 drug interactions, 696
 mechanism of action, 255, 255t
 properties, 527t
- Lifestyle drugs, 713b
 classification, 710
 commonly used, 711t
 definition, 710
- Ligand-activated transcription factors, 40
 see also Nuclear receptors
- Ligand-gated ion channels, 20, 23, 24f–25f, 24t, 26–27, 28b, 44
 calcium *see* Calcium channels
 gating, 43
 gating mechanism, 27, 27f
 molecular structure, 26–27, 26f
- Ligand specificity, 7
- Lincosamides, 624t
- Linezolid, 631b, 633
- Liothyronine, 415, 415b
- Lipid-lowering drugs, 288–292
- Lipid mediators, 444t, 472–473, 472f, 473b
- Lipids
 drug diffusion through, 100–101
 effect of glucocorticoids, 402b
 metabolism, effects of ethanol, 604
 peroxidation, 700
 transport, 286–288
 see also Cholesterol; Triglycerides
- Lipid solubility of general anaesthetics, 492–493, 493f
- Lipophilic drugs, 115
- Lipopolysaccharide, 239
- Lipoprotein
 high-density, 286, 288, 290
 low-density, 286, 288, 290
 transport, 286–288, 287f, 288b
 very low-density, 286, 290
- Liposomes
 gene delivery vectors, 720
 packaging in, 113
- Lipoxins, 212, 215, 217
- 5-Lipoxygenase, 215
- Lipoxygenases, 213, 267
- Liquid paraffin, 368
- Lispro, 379, 383
- Listeria*, 630
- Lithium, 32–33
 antidiuretic hormone inhibition, 352
 classification, 446
 clinical uses, 581–582, 582b
 drug interactions, 693, 696
 effect on antidiuretic hormone, 399–400
 mechanism of action, 581
 personalisation, 132
 pharmacokinetics, 129–130, 582
 pharmacological effects, 581
 toxicity, 582
- Liver
 allergic damage, 708
 anticoagulants adverse effects, 302
 drug toxicity, 136
 effects of ethanol, 604
 enterohepatic circulation, 119
 toxicity *see* Hepatotoxicity

- Liver oxysterol receptor (LXR), 42
 L-NAME (N^G-nitro-L-arginine methyl ester), 242
 L-NMMA (N^G-monomethyl-L-arginine), 242
Loa loa, 668–669
 Lobeline, 162
 Local anaesthetics *see* Anaesthetics, local
 Locus coeruleus, 444–445, 506
 Lofexidine, 597b
 Lomustine, 678, 679b
 Long QT syndrome, 59
 Long-term depression, 451–452, 472
 Long-term potentiation, 451–453, 454f, 472
 Loop diuretics, 353–354
 clinical uses, 269, 354b
 drug interactions, 696
 pharmacokinetics, 354
 unwanted effects, 354
 Loop of Henle, 347, 349–350, 351f
 Loperamide, 369, 520
 Lopinavir, 643
 Loratadine, 333t
 Lorazepam, 538b
 administration route, 548
 characteristics, 533t
 clinical uses
 antiemesis, 686
 insomnia, 532
 pharmacokinetics, 536
 Lormetazepam, 533t
 Losartan, 234, 274t, 275–276
 Lovastatin, 75, 289
 Low-density lipoprotein (LDL) cholesterol, 285–286, 288, 290
 Low-density lipoprotein receptor, 7
 Low-molecular-weight heparins *see* Heparin (and low-molecular-weight heparins)
 LSD *see* Lysergic acid diethylamide (LSD)
 LTBA, 215
 L-tryptophan, 177
 L-type calcium channels, 50, 51t
 blockers, 256
 heart, 246
 muscle contraction, 59–60
 smooth muscle contraction, 60–61
 L-tyrosine, 175–177
 Lugol's iodine, 415, 415b
 Lukasts, 342
 Lumefantrine, 659, 661, 663b
 Lungs
 disease, 337–345 (*see also specific diseases*)
 drug metabolism in, 117
 excretion via, 115
 see also Respiratory system; *entries beginning Pulmonary*
 Lupus, drug-induced, 135
 Luteinising hormone (LH), 395, 395t, 425
 clinical use, 425
 male reproductive system, 418–419
 menstrual cycle, 417
 pharmacokinetics, 425
 preparations, 425
 Lutropin, 425
 Lyme cycline, 628
 Lymphocytes, 85t, 216
 adaptive immune response, 82–84
 adrenoceptor expression, 186
 bone remodelling, 432
 see also B cells; T cells
 Lymphoma, 684
 Lypressin, 235t
 Lysergic acid diethylamide (LSD), 196, 221, 466, 585t, 589–590, 591b
 adverse effects, 589
 dependence, 589, 593t
 pharmacological effects, 589
 Lysoglyceryl-phosphorylcholine (lyso-PAF), 212
 Lysozyme, 610
 Lysyl bradykinin, 217
- ## M
- Macrogols, 368
 Macroheparin, 211
 Macrolide antibiotics, 622, 631
 action/effects, 631b
 antimicrobial spectrum, 631
 drug interactions, 430
 mechanism of action, 624t, 631
 pharmacokinetics, 631
 unwanted effects, 631
 Macrophage-activating CD4⁺ T-helper lymphocytes, 86
 Macrophage inflammatory protein (MIP)-1, 209t
 Macrophages, 216
 adaptive immune response, 82–83
 in apoptosis, 71
 bone remodelling, 432
 innate immune response, 81
 pathogen recognition, 78
 Macrovascular disease in diabetes mellitus, 377–378
 Macula densa, 270, 347
 Magnesium chloride, 255t
 Magnesium hydroxide, 364, 368
 Magnesium salts, 364
 Magnesium sulphate, 368
 Magnesium trisilicate, 364
 Major basic protein, 339
 Major histocompatibility complex (MHC), 82–83, 639
 Malaria, 655–663, 656b
 parasite life cycle, 656–658, 657f
 treatment *see* Antimalarial drugs
 Malignant hyperpyrexia, 133–134, 500
 Malignant hyperthermia, 500, 692
 suxamethonium-induced, 167
 Malnutrition, effects of ethanol, 604
 Mammalian cells, 716–717
 Mammary gland, 399b
 Mammothrophs, 394, 397
 Mapatumumab, 74
 Maraviroc, 645, 646b–647b, 647
 Mast cells
 antibodies and, 86
 histamine in, 211
 innate immune response, 80–81
 pathogen recognition, 78
 Matrix metalloproteinases (MMPs), 69–70
 inhibitors, 75
 Maximal response, 9–10
 Maximum plasma concentration, 123
 McNA343, 154
 MCP-1³, 81
 MDMA
 (methylenedioxymethamphetamine), 469b, 585t, 589–590, 591b
 actions/effects, 468
 dependence, 593t
 lifestyle use, 711t
 pharmacological effects, 590, 590f
 Measurement in pharmacology, 89–98
 see also specific tests
 Mebendazole, 670
 Mebeverine, 369
 Mecamylamine, 469–470, 598, 600b, 602
 Mecasermin, 397
 Mecillinam, 627
 Mediators
 definition, 208
 exhaustion of, 16
 types of, 444t
 Medicine, definition, 1
 Medroxyprogesterone, 421, 422b, 427, 683
 Mefenamic acid, 319t
 clinical uses, 428
 unwanted effects, 322
 Mefloquine
 clinical uses
 malaria chemoprophylaxis, 659
 malaria treatment, 658, 661, 663b
 pharmacokinetics, 661
 unwanted effects, 661
 Megaloblastic haemopoiesis, 311–312
 Megestrol, 683
 Meglumine antimoniate, 666
 Meissner's plexus, 360
 Melanin, 398–399
 Melanocortin receptors, 398–399
 Melanocortins, 392, 398–399
 Melanocytes, 398
 Melanocyte-stimulating hormone (MSH), 394, 398–399
 Melanocyte-stimulating hormone (MSH) release-inhibiting factor, 395t
 Melanocyte-stimulating hormone (MSH) releasing factor, 395t
 Melarprosol, 665
 Melatonin, 471, 473b
 lifestyle use, 711t
 metabolism, 471
 receptors, 471
 secretion, 471
 Meloxicam, 319t
 Melphalan, 678
 Memantine, 478, 522
 clinical use, 454–455
 Alzheimer's disease, 483–485
 bipolar disorder, 581
 NDMA receptor blocker, 453–454
 Membranes, cell, movement of drugs across, 99–103, 100f
 Membrane transporters, 148–149
 Memory, 470
 and benzodiazepines, 535
 Memory cells, 84
 Menadiol sodium phosphate, 298
 Menorrhagia, 428
 Menstrual cycle, 417, 418f
 Mepacrine, 328, 666
 Meperidine *see* Pethidine
 Mepivacaine, 527t
 Meprobamate, 532, 549
 Meptazinol, 520
 Mepyramine, 211, 363t
 Mercaptopurine, 118–119, 616b, 681, 681b
 action/effects, 611
 drug interactions, 332, 695
 teratogenicity, 706
 unwanted effects, 706
 6-Mercaptopurine, 117, 370
 Mercurous chloride, 1
 Mercury, teratogenicity, 706
 Meropenem, 628
 Merozoites, 657
 Mesalazine
 absorption, 108
 clinical uses, 370
 Mescaline, 585t, 589–590, 591b
 adverse effects, 589
 dependence, 589, 593t
 pharmacological effects, 589

- Mesna, 678
 Mesocortical pathway, 463
 Mesolimbic pathway, 463, 554
 Messenger RNA (mRNA), 132–133, 229
 splicing, 25–26
 Mestranol, 425
 Meta-analysis, 97
 Metabolism (drug), 115–119
 affect of age on, 690–691
 altered, 16
 definition, 115
 first-pass, 108, 118, 118t
 gene tests related to, 136–137
 induction of microsomal enzymes,
 118
 inhibition of P450, 117–118
 pharmacokinetic interactions, 694–696
 pharmacologically active drug
 metabolites, 118–119, 119t
 phase 1 reactions, 115–117, 116f
 phase 2 reactions, 116f–117f, 117
 stereoselectivity, 117
 Metabolism (human)
 effect of thyroid hormones, 412
 effects of adrenoceptor agonists,
 184–186, 185f
 Metabolites
 excretion, 119–121
 pharmacologically active drug,
 118–119
 Metabotropic receptors *see* G-protein
 coupled receptors
 Metalloproteinase inhibitors, 687
 Metaphase, 68
 Metastases, 673, 675–676
 Met-enkephalin, 232, 513t
 Metformin
 action, 103, 379–380
 clinical uses, 380, 383b
 mechanism of action, 379–380
 transport, 103, 105f
 unwanted effects, 380
 Methacholine, 158
 Methadone, 510, 513, 518t–519t, 519–520
 clinical use, 597b
 dependence, 593t
 lifestyle use, 711t
 Methadone series, 510
 Methaemoglobin, 261
 Methamphetamine, 584
 Methanamine, 633
 Methanol
 metabolism, 606–607
 toxicity, 118–119, 606–607
 Methaqualone, 532
 Methimazole, 414
 Methionine, 325, 701
 Method and measurement in
 pharmacology, 89–98
 see also specific tests
 Methotrexate, 327, 334, 616b, 680, 681b
 action/effects, 610–611, 680f
 administration, 680
 drug interactions, 694
 intrathecal injection, 109–110
 receptor, 7
 structure, 680f
 unwanted effects
 on the fetus, 705–706
 on the liver, 700–701
 Methotrimeprazine, 560
 Methoxamine, 182t–184t
 Methoxsalen, 703–704
 Methoxyflurane, 500, 500b
 3-Methoxy-4-hydroxyphenylglycol
 (MHPG), 179
 Methoxy polyethylene glycol-epoetin beta,
 314
 Methylcellulose, 368
 Methylcobalamin, 313
 Methyldopa, 190
 action/effects, 182t–184t, 193b, 462
 clinical uses, 277–278
 unwanted effects, 708, 708b
 Methylene-dioxymethamphetamine *see*
 MDMA
 (methylene-dioxymethamphetamine)
 Methylphenidate, 713
 Methylfolate, 579
 Methylnaltrexone bromide, 520
 action/effects, 515
 blood-brain barrier, 110–111
 Methylphenidate, 191, 584
 action/effects, 193b
 clinical use, 586
 lifestyle use, 710, 711t, 713b
 use in sport, 713
 1-Methyl-4-phenyl-1,2,3,6-
 tetrahydropyridine (MPTP), 486
 Methylphosphorate analogues, 723
 Methylprednisolone, 401t
 Methylxanthines, 32, 585t, 588, 588b
 clinical uses, 206, 588
 pharmacological effects, 588
 unwanted effects, 588
 vasodilatation, 272–273
 Methymalonyl-CoA, 313
 Methysergide, 197–198, 467
 action/effects, 199
 migraine management, 202t
 properties, 199t
 unwanted effects, 199
 Meticillin, 622, 627
 unwanted effects, 702
 Meticillin-resistant *Staphylococcus aureus*
 (MRSA), 617, 620
 Metoclopramide, 198
 clinical uses
 antiemesis, 367, 686
 gastrointestinal motility, 368
 drug interactions, 693
 Metoprolol
 action/effects, 182t–184t
 clinical uses, 280
 Metronidazole, 633
 action/effects, 605–606
 clinical uses, 633
 amoebiasis, 664, 664b
 giardiasis, 666
 trichomoniasis, 666
 drug interactions, 695
 unwanted effects, 664
 Metyrapone, 402
 Mianserin, 567, 568t–570t, 577, 579b
 Mibefradil, 262
 Micafungin, 653
 Miconazole, 652
 Microangiopathy, 377–378
 Microfilaments, 616
 MicroRNAs, 72, 74
 Microsomal enzymes, 115, 118
 Microspheres, gene delivery vectors, 720
Microsporium, 649, 650t
 Microtubules, 616, 617b
 Midazolam, 496t, 497, 533t, 538b
 Mifepristone, 422, 422b
 Migraine
 brain hypothesis, 200
 drug management, 199–201, 201b, 202t
 ergot alkaloids, 199
 inflammation hypothesis, 200
 pathophysiology, 200
 prophylaxis, antiepileptic drugs, 550
 vascular theory, 200
 Milk
 excretion via, 115
 production, 397
 Milnacipran, 567, 568t–570t, 576–577, 577b
 Milrinone, 32, 259
 Miltefosine, 666
 Minamata disease, 706
 Mineralocorticoid receptor, 407
 Mineralocorticoids, 399b, 406–407, 407b
 actions, 400–401
 antagonists, 407
 clinical uses, 407
 mechanism of action, 407
 see also Adrenal steroids
 Miniature endplate potentials, 62
 Minimal alveolar concentration (MAC), 492
 Minipumps, osmotically driven, 107–108
 Minocycline, 628
 antibacterial spectrum, 628–629
 pharmacokinetics, 629
 unwanted effects, 629
 Minoxidil, 117
 clinical uses, 277–278
 lifestyle use, 710, 711t
 vasodilatation, 272
 M2 ion channel, 645
 Mipomersen, 288
 Mirtazapine, 567, 568t–570t, 574, 577, 579b
 Misoprostol, 362, 428
 clinical uses, 216b, 322
 gastric mucosa protection, 365
 unwanted effects, 365
 Mitochondria, 610
 in apoptosis, 71f, 72
 calcium release, 52
 oxidative stress, 480
 Mitochondrial uncoupling proteins (UCP),
 388–390
 Mitogen-activated protein kinase (MAP
 kinase), 32, 34–35, 39
 Mitomycin, 615, 682, 682b
 Mitosis, 66, 68
 Mitoxantrone(mitoxantrone), 681
 Mivacurium, 167b
 characteristics, 165t
 pharmacokinetics, 165
 unwanted effects, 164
 Mizolastine, 333t
 Moclobemide, 567, 568t–570t, 578, 579b
 Modafinil
 clinical use
 attention-deficit hyperactivity
 disorder, 586
 narcolepsy, 586
 lifestyle use, 710, 711t
 Molecular biology and peptides, 229
 Molecular cloning, 8
 Molgramostim, 686–687
 Mometasone, 343
 Monoamine oxidase-A (MAO-A), 554,
 577–578
 Monoamine oxidase-B (MAO-B), 577–578
 inhibitors, 486, 488
 Monoamine oxidase inhibitors (MAOIs),
 567, 577–579, 577t, 579b
 and amfetamines, 584–585
 characteristics, 568t–570t
 chemical aspects, 578
 clinical uses
 anxiety, 532
 smoking cessation, 602
 drug interactions, 578–579, 693
 food interactions, 578–579
 pharmacokinetics, 130

- pharmacological effects, 578
 toxicity, 578
 unwanted effects, 578
 Monoamine oxidase (MAO), 117, 179, 191, 194, 577–578
 Monoamine receptor antagonists, 567, 568t–570t, 577
 Monoamines, 388
 Monoamine theory of depression, 564–566, 567b
 evidence supporting, 568t–570t
 neuroendocrine mechanisms, 565
 neuroplasticity, 565–566
 trophic effects, 565–566
 Monoamine uptake inhibitors, 567, 568t–570t, 573–577
 see also specific types
 Monobactams, 618, 624t, 628, 629b
 Monoclonal antibodies, 235t, 683–684, 685b, 685f, 717–718
 as anticancer drugs, 677, 677t
 chimeric, 717, 718f
 humanised, 717, 718f
 safety issues, 717–718
 second-generation, 718t
 unwanted effects, 707–708
 Monocyte chemoattractant protein (MCP)-1, 209t
 Monocytes
 bone remodelling, 432
 innate immune response, 81
 Monoiodotyrosine (MIT), 410
 Montelukast
 actions/effects, 215–216
 clinical uses, 340, 342
 Mood
 effects of 5-hydroxytryptamine, 468
 noradrenaline effects, 462
 Mood-stabilising drugs, 581, 582b
 Morbidly obese, 385
 Morphine, 272–273, 499, 510–513, 518t–519t
 actions/effects, 468, 516b
 affect of age on, 690–691
 analogues, 510
 bioassays, 92, 92f
 clinical uses
 cough, 345
 gallstone pain, 370
 gastrointestinal motility, 369
 dependence, 516, 593t
 distribution, 111
 enterohepatic circulation and, 119
 excretion, 352–353
 histamine release, 211
 overdose, 517
 partitioning into fat/tissues, 105
 pharmacokinetics, 516–517
 pharmacological actions, 514–516
 sites of action, 514
 synthetic derivatives, 510
 tolerance, 516
 unwanted effects, 164, 517
 use in sport, 712t
 Morphine-6-glucuronide, 117
 Motility, gastrointestinal, 367–370
 drugs decreasing, 369–370
 drugs increasing, 368–369
 effect on drug absorption, 106
 effects of muscarinic antagonists, 161
 Motor neuron disease, 478t, 480
 Motor systems, 464–465
 Moxifloxacin, 631
 Moxonidine
 actions/effects, 462
 clinical uses, 277–278
 M phase of cell cycle, 66, 67f, 68
 MPTP (1-methyl-4-phenyl-1,2,3,5-tetrahydropyridine), 190
 mRNA *see* Messenger RNA (mRNA)
 MRSA *see* Meticillin-resistant *Staphylococcus aureus* (MRSA)
 Multidrug resistance (MDR), 617–618, 620b
 reversal of, 687
 transporters, 21–23
 Multiple sclerosis (MS), 551
 Muscarine, 139, 151
 Muscarinic ACh receptors, 34, 141, 153–154, 469
 ACh actions, 151
 agonists, 153t, 154, 157–159, 158t, 470
 clinical use, 159
 effects, 158–159, 159f, 159t
 structure-activity relationships, 157–158
 antagonists, 153t, 154, 159–161, 160t
 clinical uses, 161, 162b
 antiemesis, 366
 asthma, 340, 342, 342b
 gastrointestinal motility, 369
 incontinence, 358
 Parkinson's disease, 486, 489
 effects of, 161
 drugs affecting, 157–161
 M₁ (neural), 153, 336
 M₂ (cardiac), 153, 156, 252, 336
 M₃ (glandular/smooth muscle), 154, 336
 M₄, 154
 M₅, 154
 respiratory system, 336
 in schizophrenia, 559
 subtypes, 153, 153t
 Muscimol, 457–458, 459b
 Muscle(s)
 contraction *see* Contraction, muscle
 effects of non-depolarising blocking agents, 164
 fibres, 616, 617b
 relaxation
 antiepileptic drugs, 551
 benzodiazepines, 535
 in general anaesthesia, 494
 rigidity, 485
 spasm, 551
 see also specific types
 Musculoskeletal system, effect of glucocorticoids, 402b, 406
 Mutagenesis, 702–704, 703b
 biomechanical mechanisms of, 703
 measurement of, 703–704
 site-directed *see* Site-directed mutagenesis
 Mutations
 antibiotic resistance, 617
 gene, 133
 Myasthenia gravis, 171–172, 172f
 and drug responsiveness/effectiveness, 691
 receptors and, 45–46
 Mycelium, 649
 Mycobacteria, 623t, 634
 Mycolic acids, 634
 Mycophenolate mofetil, 330
 Mycophenolic acid, 330
Mycoplasma, 609, 628–629
 Mycoses *see* Fungal infections/fungi
 Mydriasis, 161
 Myelosuppression, 686–687
 Myenteric plexus, 360
 Myocardial contractility *see* Heart muscle, contraction
 Myocardial infarction, 252–254, 698–699
 Myocardial oxygen consumption, 250–251
 Myocardial stunning, 249
 Myometrial cells, 427
 Myosin, 59
 Myosin light-chain, 61
 Myosin light-chain kinase (MLCK), 32, 61
 Myosin phosphatase, 61
 Myositis
 fibrates adverse effects, 290
 statins adverse effects, 290
 Myxoedema, 413
N
 Nabilone, 225
 adverse effects, 222
 clinical uses, 367
 Nabumetone, 319t
 Nafarelin, 424, 425b
 Naftifine, 653
 Nalidixic acid, 613–615, 631
 Nalorphine, 511–513
 Naloxone, 234, 506, 511–513, 520
 clinical uses, 367
 pharmacokinetics, 517
 Naltrexone, 234, 513, 520, 603
 clinical use
 ethanol dependence, 605b, 607
 opioid dependence, 597b
 Naltrindole, 513t
 Nandrolone, 423
 Nanoparticles, biologically erodible, 112
 Naproxen, 319t
 Naratriptan, 202t
 Narcolepsy, 586
 Nasal sprays, 109
 Natalizumab, 69, 330, 331t
 Nateglinide, 381
 Natriuretic drugs *see* Diuretics
 Natriuretic peptides, 353
 Natural killer (NK) cells, 639–640
 adaptive immune response, 82
 innate immune response, 82
 Nausea, 365
 effects of opioids, 515
 in Parkinson's disease, 488
 see also Vomiting
 N-demethylation, 576
 N-desmethyldiazepam, 536
 Nebivolol, 182t–184t, 187–188, 243
Necator americanus, 668
 Necrosis, 476–477
 Nedocromil, 343
 Nelarabrine, 681
 Nelfinavir, 643
 Nematodes, 668–669, 671
 Neomycin, 630
 Neostigmine, 169, 170t, 171b
 effects, 170
 reversing non-depolarising blockers, 166
 Nephron *see* Kidney(s), nephron
 Nephrotic syndrome, 354
 and drug responsiveness/effectiveness, 691
 Nephrotoxicity, 630, 701–702
 Nerve block anaesthesia, 529t
 Nerve endings/terminals
 effects of adrenoceptor agonists, 181
 effects of adrenoceptors, 176t
 effects of 5-hydroxytryptamine on, 195
 nociceptive, 507–509
 presynaptic *see* Presynaptic terminals

- Nerve growth factor (NGF), 37, 478
 central facilitation, 505
 clinical uses, 522–523
- Nervi erigentes, 141
- Nervous system
 effects of general anaesthetics on, 494
 peptides in, 229–231
 role in inflammation, 86–87
see also Autonomic nervous system;
 Central nervous system;
 Neuroendocrine system
- Nesiritide, 272
- Nesseria* spp., 623t, 628–629
- Neural transplantation, 489
- Neuraminidase inhibitors, 644t, 645, 646b
- Neuregulin, 554
- Neurodegeneration in schizophrenia, 555
- Neurodegenerative diseases, 476–491
 neuronal death, 476–480
 protein misfolding and aggregation,
 476, 477b, 477f, 478t
see also specific diseases
- Neuroendocrine system
 effects of dopamine on, 465–466
 mediators, 228
 monoamine theory of depression, 565
 role in inflammation, 86
- Neurofibrillary tangles, 481–483
- Neurogenesis, 573
- Neurogenic inflammation, 219, 337, 504–505
- Neurohypophysis, 399–400, 400b
- Neurokinin A, 219, 337
- Neurokinin B, 337
- Neuroleptanalgesia, 497
- Neuroleptic drugs *see* Antipsychotic drugs
- Neuromodulation, 139, 144–145, 149f,
 442–443
- Neuromodulators, 444b
- Neuromuscular-blocking drugs, 163–167,
 165t, 167b
see also Depolarising blocking agents;
 Non-depolarising blocking agents
- Neuromuscular junction, 171–172, 172f
 acetylcholine at, 155–156
 effects of anticholinesterases, 170–171
- Neuronal death, 476–480
- Neuronal nitric oxide synthase (nNOS), 237
- Neuropathic pain, 506–507, 509b
 treatment, 521–522, 522b, 550
- Neuropeptides, 219, 444t
 clinical uses, 522
- Neuropeptide Y, 388
 NANC transmission, 145–147, 148t
 and obesity, 392
 postsynaptic modulation, 145
- Neuroplasticity, 504
- Neuropsychological tests, 532
- Neurosteroids, 458
- Neurotoxicity, 603
- Neurotoxins, 486
- Neurotransmission
 basic steps, 149
 in the central nervous system, 442–447,
 444b
 general principles, 143–149
- Neurotransmitters, 21–23, 28, 228, 444b
 adenosine triphosphate, 207
 amino acid *see* Amino acid(s),
 transmitters
 in the autonomic nervous system,
 141–143, 143b
 termination of action, 147–149
- Neurotrophic factor, 444b
- Neurotrophins, 444t, 543
- Neutropenia, 414
- Neutrophil elastase, 306
- Neutrophilia, 86
- Neutrophils, 80, 216
- Nevirapine, 643, 647b
- N^G-monomethyl-L-arginine (L-NMMA), 242
- N^G-nitro-L-arginine methyl ester (L-NAME),
 242
- Niclosamide, 669–670
- Nicorandil, 261
 drug interactions, 430
 vasodilatation, 272
- Nicotinamide adenine dinucleotide (NAD),
 52, 605
- Nicotinamide adenine dinucleotide (NAD)
 phosphate, 52
- Nicotine, 139, 151, 162, 601
 absorption, 108–109
 action/effects, 470
 antidiuretic hormone secretion, 352
 dependence, 593t, 597–602, 597b (*see*
also Smoking)
 treatment, 601–602
 pharmacokinetics, 599, 600b
 replacement therapy, 601
 tolerance, 599
- Nicotinic acetylcholine receptors, 141,
 151–153, 469
 ACh actions, 151
 agonists, 151–153, 152t, 162t, 522
 antagonists, 151–153, 152t, 162t,
 469–470
 nicotine dependence, 598–599
 presynaptic modulation, 144–145
 structure, 25, 26f
 subtypes, 151, 152t
- Nicotinic acid, 291, 292b, 292f
- Nicotinic acid dinucleotide phosphate
 (NAADP), 52
- Nifurtimox, 665
- Nigrostriatal pathway, 463
- Nikethamide, 713
- Nilotinib, 684
- Nimodipine, 263
- Nipecotinic acid, 456
- Nitrate(s), 261b
 action/effects, 260–261
 clinical uses, 259–261, 261b
 dietary, 242
 pharmacokinetic aspects, 261
 tolerance, 261
 unwanted effects, 261
- Nitrazepam, 533t
- Nitric oxide (NO), 237–245, 444t
 actions/effects of, 240–242, 241b, 472
 biochemical and cellular, 240–241
 host defence, 241–242
 neuronal, 241
 vascular, 241
 and apoptosis, 72
 biosynthesis and its control, 237–239
 carriage, 239–240
 central facilitation, 505
 clinical conditions, 243–244
 in the CNS, 471–472, 473b
 degradation, 239–240
 donors/precursors, 242
 in haemostasis and thrombosis, 296–297
 inhibition, 243b
 metabolites, 63
 NANC transmission, 145–147, 148t
 in pathophysiology, 244b
 potentiation, 243
 release, 151
 role in inflammation, 219
 synthesis inhibition, 242–243
 therapeutic approaches, 242–243, 244b
 vascular endothelium, 266–267
- Nitric oxide synthase (NOS), 237, 472
 constitutive, 237–238, 239f
 endothelial, 237–240
 inducible, 208, 237, 239, 242
 neuronal, 237
- Nitrofurantoin, 633
- Nitrogen dioxide, 600
- Nitrogen mustards, 615, 678–679, 679b
- 7-Nitroindazole, 242
- Nitroprusside, 240, 272
- Nitrosureas, 615, 678, 679b
- Nitrous oxide, 492, 494, 497, 500–501, 501b
 action/effects, 495b
 characteristics, 498t
 effect on cardiovascular system, 494
 induction and recovery, 498
 pharmacokinetics, 500b
- Nitrovasodilators, 16, 242
- Nizatidine, 363
- NK₁ receptor antagonists, 367
- NMDA receptors
 activation, 477
 antagonists, 484b
 effects of ethanol, 603
 effects of general anaesthetics on, 494
 glutamate, 44, 50–51, 449, 451, 452f–
 453f, 453–454
 in schizophrenia, 554–555
 special features, 450, 452–453
- Nociceptin, 229, 513t
- Nociception
 adenosine triphosphate in, 207
 afferent neurons, 503, 504f
 chemical signalling in, 507–509
 mechanisms, 509b
 modulation in, 503–506, 504f, 506b
 modulators, 509–510
 and pain, 507
 transmitters, 509–510
- Nociceptive nerve endings
 chemosensitivity, 507–509
- Nocistatin, 229
- NOD-like receptors, 77–78
- Noise analysis, ligand-gated ion channels,
 27, 27f–28f
- Non-adrenergic non-cholinergic (NANC)
 transmission, 145–147, 148t
 nitric oxide, 241
 respiratory system, 336
- Non-depolarising blocking agents, 164–166,
 167b
 comparison with depolarising blocking
 agents, 166
 effects of, 164
 mechanism of action, 164
 pharmacokinetic aspects, 164–166
 recovery rate, 164f
 unwanted effects, 164
- Non-linear mixed effects modelling
 (NONMEM), 129
- Non-nucleoside reverse transcriptase
 inhibitors, 643, 644t, 646b–647b
- Non-steroidal anti-inflammatory drugs
 (NSAIDs), 318–319
 action/effects
 analgesia, 321–322
 on antidiuretic hormone, 399–400
 anti-inflammatory, 321
 antipyretic, 321
 on gastrointestinal tract, 362
 pharmacological, 321
 therapeutic, 321–323
 and Alzheimer's disease, 484
 asthma, 339
 clinical uses, 324b
 commonly used, 323–326

- drug interactions, 693
 future developments, 334
 mechanism of action, 319–321, 320f
 with opioids, 521
 and renal function, 353
 unwanted effects, 322–323, 323b, 698–699
 allergic reactions, 708
 cardiovascular, 323
 gastrointestinal, 322, 322f
 kidneys, 322–323, 701–702, 702t
 skin, 322
 and warfarin, 301
- Non-vesicular release mechanisms, 63
- Nootropic drugs *see* Cognition enhancers
- Noradrenaline, 139, 141–143, 174
 acetylcholine inhibition, 156
 action/effects, 182t–184t
 arousal and mood, 462
 blood pressure regulation, 462
 in the CNS, 461–462, 462b
 co-transmission, 147, 147f
 functional aspects, 461–462
 nociceptive pathway, 510
 release, 177–178
 drugs affecting, 182t–184t, 190
 regulation, 178, 178f
 role in satiety signals, 388
 storage, 177
 drugs affecting, 190
 synthesis, 175–177
 drugs affecting, 182t–184t, 190
 transporter, 147–148
 uptake
 drugs affecting, 182t–184t
 inhibitors, 192, 192f
 vasodilatation, 272
- Noradrenaline reuptake inhibitors, 567, 576–577, 577b
 characteristics, 568t–570t
 clinical uses, 532
- Noradrenergic neurons, 175–178
 drugs affecting, 190–192, 193b, 277
 noradrenaline release, 177–178
 noradrenaline storage, 177
 noradrenaline synthesis, 175–177
- Noradrenergic pathways in the CNS, 461
- Noradrenergic transmission, 174–193, 180b
 drugs acting on, 181–192, 182t–184t
 physiology, 175–179
- Nor-binaltorphimine, 513t
- Nordazepam, 536, 538b
- Norethisterone, 683
- Norepinephrine transporter (NET), 178–179, 179t
 inhibition, 192
- Norethisterone, 421, 422b, 425–426
- Norfloxacin, 631
 action/effects, 613–615
 clinical use, 632b
 pharmacokinetics, 632
 resistance, 620
- Norgestrel, 421
- Nortriptyline, 567, 574, 576f
 characteristics, 568t–570t
 clinical use, 521, 581
- Novobiocin, 622
- Nuclear factor kappa B (NFκB), 39
- Nuclear receptors, 24f–25f, 24t, 25, 40–43, 41f
 classification, 42, 42b
 control of gene transcription, 42–43
 structure of, 40–42
- Nucleic acid synthesis, 612–615
 inhibition, 612
- Nucleocapsid, 638
- Nucleoside analogues, 641, 646b
- Nucleoside reverse transcriptase inhibitors, 641–646, 644t, 647b
- Nucleus accumbens (NAc), 388, 463
- Nucleus basalis of Meynert, 468–469
- Nucleus tractus solitarius (NTS), 388
- Null hypothesis, 96
- Number needed to treat (NNT), 97–98
- Nystatin, 615, 651
- O**
- Obatoclox, 74
- Obesity, 385–393, 391b
 animal models, 93
 definition, 385
 as a disorder of homeostatic control of
 energy balance, 390
 energy expenditure control, 388–389
 food intake and, 390
 genetic factors, 390–391
 as a health problem, 389–391
 morbidly obese, 385
 neurological circuits controlling body
 weight and eating behaviour,
 388–389
 new approaches to therapy, 392–393
 pathophysiology of, 389–390
 pharmacological approaches to,
 391–392, 391f
 physical exercise and, 390
 role of hormones in body weight
 regulation, 385–388, 386f–387f
- Ob* gene, 385–386, 390
- Oblimersen, 74
- Obsessive-compulsive disorder, 531
- Occupancy (of receptors), 11–13
- Ocrelizumab, 334
- Octreotide, 235t, 394–395, 397, 399b
 action, 377
 clinical uses
 anticancer drugs, 683
 carcinoid syndrome management,
 202–203
 vasoconstriction, 271
- Oculomotor nerve, 141
- Odanacatib, 440
- Oedema, non-steroidal anti-inflammatory
 drugs effects, 321
- Oestradiol, 420
- Oestriol, 420
- Oestrogen(s), 420–421, 421b
 actions, 420
 administration routes, 109
 as an antidepressant, 579
 antiandrogen activity, 424
 atheromatous disease prevention, 288
 bone metabolism and remodelling,
 436
 clinical uses, 421b
 anticancer drugs, 683
 bone disorders, 438–439
 drug interactions, 635
 effect on prolactin secretion, 397
 mechanism of action, 420
 menstrual cycle, 417
 pharmacokinetics, 420
 preparations, 420
 receptor modulator, 420–421
 receptors, 420
 replacement *see* Hormone replacement
 therapy (HRT)
 teratogenicity, 704t
 unwanted effects, 420, 704t
- Oestrone, 420
- Ofatumumab, 334
- Ofloxacin, 631
 clinical use, 632b
 pharmacokinetics, 632
- Oil: gas partition coefficient, 498
- Olanzapine, 561
 action/effects, 559–560
 clinical efficacy, 563
 clinical uses, 562b, 581
 anxiety, 532
 bipolar disorder, 581–582, 582b
- Olapatadine, 332–333
- Olsalazine
 absorption, 108
 clinical uses, 370
- Omalizumab, 338, 343, 718t
- Omega-3, 291–292
- Omeprazole, 304
 clinical uses, 363
 drug interactions, 695
 pharmacokinetics, 363–364
- Onchocerca volvulus*, 668–669
- Onchocerciasis, 671
- Oncogenes, 673
- Ondansetron, 366–367, 467–468, 469b, 679, 686
- Onychomycosis, 649
- Oocyst, 656–657
- Opiates
 clinical uses, 369
 drug interactions, 693
 intrathecal injection, 109–110
 lifestyle use, 711t
- Opioid drugs, 510–520
 cellular actions, 513–514
 chemical aspects, 510
 clinical uses, 345
 dependence, 516, 593t, 597b
 effects, 18
 mechanism of action, 513–514
 with non-steroidal anti-inflammatory
 drugs, 521
 pharmacokinetics, 516–517
 pharmacological actions, 514–516
 structure, 511f
 terminology, 510b
 tolerance, 516
 unwanted effects, 517
- Opioid peptides, 232, 233f, 509, 513t
- Opioid receptors, 511–512, 513b
 agonists, 513, 513t
 antagonists, 513, 513t, 520
 functional effects, 512t
- Opium, 510
- Opportunistic infections, 649
- Opsonin, 79–80
- Orai1, 51
- Oral administration, 106–108
see also specific drugs
- Oral contraceptives, 425–426
 combined pill, 425–426
 drug interactions, 426
 lifestyle use, 711t
 pharmacokinetics, 426
 progestogen-only pill, 426
- Oral thrush, 406
- Orexigenic neurons, 388
- Orexins, 229
- Organic anion transporters (OATs),
 101–103, 119–120, 120t
- Organic cation transporters (OCTs),
 101–103, 104f–105f, 119–120, 120t
- Organophosphates, 108, 171
- Origins of pharmacology, 1–2
- Orlistat, 392
 clinical uses, 391
 lifestyle use, 711t

- pharmacokinetics, 392
 unwanted effects, 392
 Ornithine decarboxylase deficiency, 721
 Orphanin FQ, 513t
 Orphan receptors, 40
 Orthostatic hypotension, 561
 Oseltamivir, 645, 646b
 Osmotically driven minipumps, 107–108
 Osmotic diuretics, 356
 Osmotic laxatives, 368
 Ostabolin, 439
 Osteoblasts, 432, 434f
 Osteocalcin, 432
 Osteoclasts, 432–433, 434f
 Osteocytes, 432
 Osteoid, 432
 Osteomalacia, 437
 Osteonectin, 432
 Osteopenia, 437
 Osteopontin, 69
 Osteoporosis, 437, 698
 effect of glucocorticoids, 406
 heparin unwanted effects, 300
 treatment, 437, 438b
 Osteoprotegerin (OPG), 433–434
 Ototoxicity, 630
 Ouabain, 258
 Outcome measures, clinical, 96
 Overview analysis, 97
 Ovulation, 399b, 417–418
 Oxaliplatin, 679
 Oxazepam
 characteristics, 533t
 pharmacokinetics, 536
 Oxazolidinones, 624t, 633
 Oxcarbazepine, 546
 clinical uses
 epilepsy, 543
 neuropathic pain, 521
 Oxidase LDL (oxLDL), 285
 Oxidation, 117
 by P450 system, 115–116
 Oxidative stress, 480, 480b
 Oxotremorine, 154
 Oxprenolol, 187–188
 Oxybutynin, 159–160, 358
 Oxyntomodulin, 387t
 Oxycodone, 510, 518t–519t, 519
 dependence, 593t
 pharmacokinetics, 516–517
 Oxygen therapy
 allergic emergencies, 344
 chronic obstructive pulmonary disease,
 345
 status asthmaticus, 343
 Oxyntic cells, 360
 Oxytetracycline, 628
 Oxytocin, 235t, 397, 399, 427, 429b
- P**
- P21, 68, 72
 P2X ionotropic receptors, 204, 206t, 207,
 471, 509
 P2Y metabotropic receptors, 204, 206t, 207,
 471
 P450 monooxygenase system, 115–117, 116f,
 116t, 652
 and biological variation, 117
 inhibition, 117–118, 695
 P53, 68
 PABA *see* *P*-aminobenzoic acid (PABA)
 Pacemaker, ectopic activity, 248–249
 Pacemaker potential, 247
 Paclitaxel, 94–95, 682, 683b, 727–728
 PAF-acether *see* Platelet activating factor
 (PAF)
 Paget's disease, 437, 438b
 Pagoclone, 534
 PAG (periaqueductal grey), 505–506
 Pain
 mechanisms, 509b
 neural mechanisms of, 503–510
 neuropathic, 506–507, 509b, 521–522,
 522b, 550
 and nociception, 507
 transient receptor potential channels,
 507–508
 transmission to higher centres, 505
 Palivisumab, 646, 718t
 Palonosetron, 366–367
 Palpitations, 247–248
 Pamidronate, 438
P-aminobenzoic acid (PABA), 622–623, 661,
 680
 PAMPs *see* Pathogen-associated molecular
 patterns (PAMPs)
 Pancreatic islet hormones, 372–377
 Pancreatic polypeptide secretion, 372
 Pancuronium, 164, 167b
 characteristics, 165t
 unwanted effects, 164
 Pancytopenia, 630
 Panic disorder, 531
 Panitumumab, 684, 685b
 Pantoprazole, 363
 Papaverine, 272–273, 429
 PAR-2, 29
 Paracalcitol, 439
 Paracelsus, 698
 Paracetamol, 117, 325, 325b, 521, 522b
 action, 319
 asthma, 339
 combination therapy, 521
 drug interactions, 694–695
 hepatotoxicity, 118–119
 overdose, 323
 pharmacokinetics, 325
 unwanted effects, 325, 699–700, 699b
 liver, 700–701, 701b
 Parallel line assays, 91
 Paralysis
 aminoglycosides, 630–631
 prolonged, suxamethonium-induced,
 166–167
Para-methoxyamphetamine, 590
 Parasympathetic nervous system, 140–141
 control of the heart, 252
 respiratory system, 336–337
 Parasympatholytics *see* Muscarinic ACh
 receptors, antagonists
 Parasympathomimetics *see* Muscarinic ACh
 receptors, agonists
 Parathion, 169–170, 170t
 Parathormone, 350
 Parathyroid hormone
 bone metabolism and remodelling, 435,
 437b
 clinical use, 439
 Paraventricular nucleus, 388, 399
 Paravertebral chains, 140–141
 Parecoxib, 319t, 326
 Pargyline, 578
 Parietal cells, 360–362, 361f
 Parkin, 485–486
 Parkinson's disease, 476, 485–489
 animal models, 93
 drug treatment, 486–489, 489b
 acetylcholine antagonists, 489
 amantadine, 489
 dopamine agonists, 488
 levodopa, 487–488
 MAO-B inhibitors, 488
 features, 485–486, 485f
 neural transplantation and brain
 stimulation, 489
 neurochemical changes, 485–486
 pathogenesis, 486
 molecular aspects, 486
 neurotoxins, 486
 protein misfolding and aggregation,
 478t
 in smokers, 601
 Paroxetine, 567, 568t–570t, 573
 Paroxysmal depolarising shift (PDS),
 542–543, 542f
 Paroxysmal nocturnal haemoglobinuria
 (PNH), 316, 316f
 Particle size and intestinal absorption,
 106–107
 Partition coefficients, 498
 Partitioning (of drugs), 105–106
 Pasteur, Louis, 1
 Patch clamp recording technique, 27, 28f
 Pathogen-associated molecular patterns
 (PAMPs), 77–78
 Pathogen recognition, 77–82
 Pattern recognition receptors (PRRs), 77–78,
 79t
P-chlorophenylalanine (PCPA), 466–468
 PD-1 death receptor, 75
 Peak expiratory flow rate (PEFR), 336
 PECAM (platelet endothelium adhesion
 molecule), 80
 Pegfilgrastim, 314–315
 Pegvisomant, 397
 PEGylation, 717
 Pelvic ganglia, 141
 Pemetrexed, 681
 Penciclovir, 112–113, 645
 Pendred's syndrome, 413–414
 Pendrin (PDS), 410
 Penicillamine, 327–328
 unwanted effects
 on the fetus, 704t
 kidneys, 702
 Penicillin-binding proteins, 612, 626
 Penicillin G *see* Benzylpenicillin
 Penicillin(s), 328, 357, 616b, 618, 625–627,
 629b, 727–728
 action/effects, 612
 antimicrobial activity, 627
 blood-brain barrier, 110
 clinical uses, 627b
 discovery of, 622
 drug interactions, 693, 696
 elimination/excretion, 120
 excretion, 119–120, 352–353
 mechanism of action, 624t, 626–627
 pharmacokinetics, 627
 types of, 627
 unwanted effects, 627, 699
 allergic reactions, 707–708, 708b
 kidneys, 702
 Penicillin V *see* Phenoxymethylpenicillin
Penicillium griseofulvum, 651
 Pentamidine, clinical uses
 leishmaniasis, 665
 trypanosomiasis, 664–665
 Pentazocine, 510, 513, 518t–519t, 520
 Pentosan polyphosphate, 490
 Pentostatin, 681, 681b
 Pentylene tetrazol, 535, 542
 Pepsinogen, 360
 Peptic cells, 360
 Peptic ulcer, 360, 362
 Peptide hormones, 386

- Peptides
agonists, 234
antagonists, 234
biosynthesis, 231–233, 232f, 233b
blood-brain barrier, 110–111
diversity, 232–233
gene splicing, 232
post-translational modification, 232–233
as drugs, 234–235, 234b, 235t
historical aspects, 228
molecular biology, 229
multiple physiological roles of, 231
in the nervous system, 229–231
precursors, 231–232
regulation, 231–233
release, 233b
secretion, 233
structure, 228, 231b
trafficking, 233
types of, 228–229
vascular endothelium, 267
vasoconstriction, 271, 272b
- Peptidoglycan, 609
synthesis, 611–612
- Peptidomimetics, 228
- Peptoids, 234
- Pergolide, 488
- Periaqueductal grey (PAG), 505–506
- Pericyazine, 559
- Pericytes, 99
- Perifosine, 75
- Peripheral sensory neurons
effects of smoking, 598–599
role in inflammation, 87
- Peripheral vascular disease, 281, 600
- Permeability coefficient, 100
- Permethrin, 658
- Peroxisome proliferator-activated receptor- γ (PPAR γ), 381–382
- Peroxisome proliferator-activated receptors (PPARs), 23, 42, 390
- Peroxytrite anion, 239–240
- Perphenazine, 367
- Personalised medicine, 132–138
- Pertussis toxin, 30–32
- Pethidine, 510, 518t–519t, 520
affect of disease on, 691
clinical uses, 370
drug interactions, 579, 579b
- P-glycoprotein, 259, 686
- P-glycoprotein transporters, 103, 119
- pH, 100–101
partition, 101, 102f
- Phaeochromocytoma, 186–187
- Phagocytosis, 85
- Pharmacodynamics, 123
- Pharmacoeconomics, 4–5
- Pharmacoepidemiology, 4
- Pharmacogenetics, 4, 132–138
- Pharmacogenomics, 4, 132–138
- Pharmacokinetic antagonism, 15
- Pharmacokinetic disorders, single-gene, 133–135
- Pharmacokinetics, 99–114, 123–131
complicated models, 126–129
definition, 123–124
drug elimination expressed as
clearance, 124
limitations of, 129–130
population, 129
saturation kinetics, 128–129, 129f
single-compartment model, 124–126, 125f–126f
two-compartment model, 127–128, 128f
- uses of, 130b
see also *individual drugs; individual parameters*
- Pharmacological studies in humans, 93–94
see also *Clinical trials; specific studies*
- Phase inversion nanoencapsulation, 112
- Phenacetin, 323, 702
- Phencyclidine, 496, 589–590, 591b
action/effects, 554–555, 560
NDMA receptor blocker, 450, 453–454
pharmacological effects, 590
- Phenelzine, 567, 568t–570t, 577, 579b
- Phenindione, 300
- Phenobarbital, 703
action/effects, 547
clinical uses, 543, 548
drug interactions, 695
nuclear receptors, 42
pharmacokinetic antagonism, 15
pharmacokinetics, 548
properties, 544t–545t
unwanted effects, 548
- Phenobarbitone, 605
- Phenoxymethylamine, 182t–184t, 186–187, 192
- Phenoxymethylpenicillin, 627, 627b
- Phentolamine
action/effects, 182t–184t, 186–187
clinical uses, 429
- Phenylalkylamines, 262
- Phenylbutazone
drug interactions, 694
unwanted effects, 708
- Phenylephrine, 11–13, 12f
action/effects, 182t–184t
clinical uses, 429
- Phenylethanolamine *N*-methyl transferase (PNMT), 177, 462
- Phenylpiperidine series, 510
- Phenytol, 256
action/effects, 546
clinical uses, 543, 546–547, 550b
distribution, 111
drug interactions, 342, 426, 634, 694
hypersensitivity, 135
pharmacokinetics, 547
in pregnancy, 551
properties, 544t–545t
saturation kinetics, 128
unwanted effects, 547
allergic reactions, 708b
on the fetus, 704t, 705–706
liver, 700–701
- Phobias, 531
- Pholcodine
actions/effects, 515
clinical uses, 345
- Phosphatases, 39
- Phosphate (bone mineral), 434
binding preparations, 358
excess see *Hyperphosphataemia*
- Phosphatidylinositol (4,5) bisphosphonate (PIP₂), 32–33, 34f
- Phosphatidylinositol-3-kinase (PI₃), 39–40
- Phosphatidyl inositol pathway, 581
- Phosphodiesterase inhibitors, 588
clinical uses
asthma, 341
chronic obstructive pulmonary disease, 345
erectile dysfunction, 429–430, 430f
heart failure, 280
drug interactions, 430
effect on myocardial contraction, 259
mechanism of action, 429
pharmacokinetics, 430
unwanted effects, 430
vasodilatation, 272–273
- Phosphodiesterases (PDEs), 32
- Phosphodiesterase type V inhibitors, 243
- Phosphoinositides (PIs), 32–33, 35f
- Phospholipase A₂, 212–213
- Phospholipase C, 32–34, 212
- Phospholipase C β , 32–33
- Phospholipase D, 212
- Phospholipases, 374
- Phospholipids
cleavage, 472
mediators derived from, 212f, 213b
structure, 213f
- Phospholipid transfer protein (PLTP), 286
- Phosphoramidon, 267–268
- Phosphorylation, 35, 39–40, 228
- Phosphothiorate analogues, 723
- Physical exercise, 390–391
- Physicochemical factors affecting drug
absorption, 108
- Physiological antagonism, 15
- Physostigmine, 139, 161, 169, 170t, 171b
- Phytomenadione, 298
- Picrotoxin, 458, 459b
- Pilocarpine, 157–158
- Pimecrolimus, 329
- PIN, 243
- Pindolol, 571–572
- Pinocytosis, 100
- Pinworm, 668, 669t
- Pioglitazone, 381–382, 390
- Piperacillin, 627, 627b
- Piperazine, 616, 670
- Piracetam, 455, 549
- Pirenzepine, 154, 159–160
- Piroxicam, 319t
- Pituitary dwarfism, 397
- Pituitary gland, 394–400
anterior, 394, 399b
effect of glucocorticoids, 402b, 403–404
hormones, 396–399
hypothalamic hormones, 394–396, 395t
posterior, 399–400, 400b
- Pivmecillinam, 627
- Pizotifen, 202t
- Placebos, 96
- Plant derivatives, 677, 677t, 682, 683b, 717
- Plant extracts, 1–2
- Plasma
drug concentrations in, 123
drug distribution, 111, 112t
drug metabolism in, 117
- Plasma cells, 84
- Plasma cholinesterase deficiency, 133–134
- Plasma membrane, 609, 615–616, 617b
- Plasma proteins, 103–105, 105f
- Plasmid DNA, 720–721
- Plasmids
antibiotic resistance, 617
conjugative, 618
promiscuous, 618
- Plasmin, 286, 306
- Plasminogen, 286
- Plasminogen activator inhibitor-1, 270, 296–297
- Plasminogen activators, 306
- Plasmodium falciparum*, 658–660
- Plasmodium malariae*, 658
- Plasmodium ovale*, 658
- Plasmodium spp.*, 655
- Plasmodium vivax*, 658–659
- Platelet activating factor (PAF), 212, 217, 217b
actions, 217
role in inflammation, 217

- Platelet-dependent growth factor (PDGF), 69
- Platelet endothelium adhesion molecule (PECAM), 80
- Platelet(s)
and adenosine diphosphate, 206
adhesion and activation, 302–305, 303f
effects of antidiuretic hormone, 400
effects of ethanol, 604
effects of 5-hydroxytryptamine on, 195
function, 304b
5-hydroxytryptamine in, 194
innate immune response, 82
- Platinum compounds, 679, 679b
- Platyhelminths, 668
- PLTP (phospholipid transfer protein), 286
- Pneumocystis carinii*, 649, 655, 666
- Pneumocystis* spp., 666
- PNMT (phenylethanolamine *N*-methyl transferase), 177, 462
- Polyclonal antibodies, 717
- Polycyclic aromatic hydrocarbons, 118
- Polycythaemia rubra vera, 316–317
- Polyene antibiotics, 615, 649–650
- Polymixin B, 633
- Polymixins, 615, 624t, 633, 634b
- Polymodal nociceptors (PMNs), 509b
- Polymorphisms, 133
see also Single nucleotide polymorphisms (SNPs)
- Polymorphonuclear leucocytes, 20
- Polypeptides, 716–717
- Polyproteins, 643
- Polysaccharides, complex, 622
- Polyunsaturated fatty acids (PUFAs), 291–292
- Population pharmacokinetics, 129
- Poractant alpha, 345
- Porins, 619
- Porphobilinogen deaminase (PBGD), 134
- Porphyrias, acute intermittent, 134
- Posconazole, 652
- Positive reinforcement, 594
- Positron emission tomography (PET), 9
- Postcoital contraception, 427
- Postexercise hypotension, 163
- Postganglionic neurons, 140
- Postsynaptic modulation, 145
- Post-translational modification of peptides, 232–233
- Post-traumatic stress disorder, 531
- Postural hypotension, 163
- Potassium channel activators, 261, 272, 273f
- Potassium channels
ATP-gated, 44
ATP-sensitive, 43, 374
calcium-activated, 43
classes, 57, 58t
effects of general anaesthetics on, 494
excitation and, 54, 55f, 57–59
inherited abnormalities, 59
inwardly rectifying, 58, 58t
two-pore domain, 58–59, 58t, 494
voltage-gated, 44, 54, 57–59, 58t
- Potassium competitive acid blocker, 370–371
- Potassium (ions)
balance, 352
effects of cardiac glycosides, 259
excitation and, 54
loss, and thiazide diuretics, 355
release, suxamethonium-induced, 166
transport, renal, 350
- Potassium-sparing diuretics, 355–356, 356b
- Potential, long-term, 451–453
- PPADS, 207
- PPARs *see* Peroxisome proliferator-activated receptors (PPARs)
- PP cells, 372
- Practolol, 187–188
- Prader-Willi syndrome, 388
- Pralidoxime, 171, 172f
- Pramipexole, 488
- Pramlintide, 377
- Prasugrel, 304
clinical use, 304–305
unstable angina, 253
- Pravastatin, 289
- Praziquantel, 669–670
- Prazosin, 182t–184t, 187
- Pre-Bötzinger complex, 514–515
- Precocious puberty, 692
- Predictive validity, 92–93
- Prednisolone, 401t
and Alzheimer's disease, 484
clinical uses
anticancer drugs, 683
chronic bowel disease, 370
chronic obstructive pulmonary disease, 345
status asthmaticus, 343
pharmacokinetics, 406
- Prednisone, 401t, 406
- Pregabalin
calcium channels and, 50
clinical uses
anxiety, 532
bipolar disorder, 582
epilepsy, 543, 549
neuropathic pain, 521, 522b
properties, 544t–545t
- Preganglionic neurons, 140
- Pregnancy
and antiepileptic drugs, 551
and drug responsiveness/effectiveness, 691
effects of smoking in, 600
- Pregnenolone, 402
- Preload, 249, 265
- Prenylation, 30
- Preprodynorphin, 232
- Preproenkephalin, 232
- Preprohormone, 231, 233b
- Preproinsulin, 372
- Prepro-opiomelanocortin (POMC), 232
- Presenilins, 93
- Presynaptic modulation, 144–145, 145f, 156, 178
- Presynaptic terminals, 144
- Pre-systemic metabolism, 108, 118, 118t
- Prevertebral ganglia, 140–141
- Prilocaine, 400
action/effects, 528
properties, 527t
- Primaquine
action/effects, 659
clinical use, 662, 663b
pharmacokinetics, 662
unwanted effects, 662
- Primidone, 548
- Prion diseases, 489–490, 609
- Probenecid, 332
action, 357
clinical uses, 627b
drug interactions, 325, 696
elimination/excretion, 120
- Procainamide, 256
action/effects, 255
effect of genetics on, 692b
metabolism, 135
unwanted effects, 708–709
- Procaine, 168, 496, 622–623
action/effects, 528
clinical uses, 627b
history, 525
pharmacokinetics, 529
properties, 527t
- Procaine penicillin, 109
- Procalcitonin, 232
- Pro-calcitonin gene-related peptide (pro-CGRP), 232
- Procarbazine, 679
- Prochlorperazine, 367
- Procholecystokinin (pro-CCK), 232–233
- Prodrugs, 112–113, 118–119
- Proflavine, 613
- Progesterone, 417
- Progestogen-only pill, 426, 426b
beneficial effects, 426
unwanted effects, 426
- Progestogens, 421–422, 422b
actions, 421
antiandrogen activity, 424
clinical uses, 422b, 683
pharmacokinetics, 422
preparations, 421
unwanted effects, 422
- Proglumide, 361
- Programmed cell death receptors, 70
- Proguanil
action/effects, 610–611, 661
clinical uses
malaria chemoprophylaxis, 659
malaria treatment, 658, 663b
pharmacokinetics, 662
structure, 662
- Prohormone, 231
- Prohormone convertases, 231
- Prokaryotes, 609
- Prolactin, 397–398, 465
actions, 397
secretion
modification of, 397–398
regulation of, 397, 397f
- Prolactin release-inhibiting factor, 395t
- Prolactin-releasing factor (PRF), 395t
- Proliferation, cell, 66–70
- Prolonged QT syndrome, 256
- Promethazine, 333t
action/effects, 555
clinical uses
antiemesis, 366
insomnia, 532
drug interactions, 693
- Promiscuous plasmids, 618
- Pronethalol, 699
- Prontosil, 622
- Pro-opiomelanocortin (POMC), 388, 398
- Propanidid, 168
- Propantheline, 159–160, 369
- Prophase, 68
- Propiverine, 358
- Propofol, 495, 496t, 497b
- Propranolol, 257
action/effects, 182t–184t, 187–188
clinical trials, 96
clinical uses
alcohol dependence, 607
thyroid disorders, 415
drug interactions, 696
efficacy, 13
and ethnicity, 689
mechanism of action, 255t
migraine management, 202t
use in sport, 712t
- Propylthiouracil, 414, 415b
- Prorennin, 360

- Prostacyclin (PGI₂), 213–214, 428
 action/effects, 214
 in haemostasis and thrombosis, 296–297
 in inflammation, 214–215
 and renal function, 353
 vascular endothelium, 266
 vasodilatation, 272
- Prostaglandin D₂, 213
 action/effects, 214
 in asthma, 338
 in inflammation, 214–215
- Prostaglandin E₁, 213, 429
- Prostaglandin E₂, 213, 428
 action/effects, 214
 in inflammation, 214–215
 and renal function, 353
 vascular endothelium, 266
- Prostaglandin E₃, 213
- Prostaglandin F_{2α}, 213–214, 428
- Prostaglandin G₂, 213, 266
- Prostaglandin H₂, 213, 266
- Prostaglandins, 212
 actions/effects, 428
 and carcinoid syndrome, 202
 gastric acid secretion, 362
 and pain, 508–509, 508f
 preparations, 428
 and renal function, 353
 unwanted effects, 428
- Prostanoids, 213–215, 216b
 action/effects, 214
 catabolism, 213–214
 clinical uses, 216b
 receptors, 214, 215t
 role in inflammation, 214–215
 vascular endothelium, 266
- Protamine sulfate, 299
- Protean agonism, 37
- Protease-activated receptors (PARs), 29, 29f
- Protease inhibitors, 288, 643–644, 644t, 646b–647b
- Proteases, 66
- Protein C, 296–297
- Protein kinase A, 35, 238–239
- Protein kinase B, 39–40, 238–239
- Protein kinase C, 33–35, 238–239
- Protein kinase inhibitors, 383, 677, 677t, 684, 685b, 685f
- Protein kinases, 32
- Protein(s)
 designer, 234–235
 as drugs, 234–235, 234b, 235t, 716–717
 effect of glucocorticoids, 402–403, 402b
 engineered, 717
 fusion, 234–235
 historical aspects, 228
 manufacturing problems, 716–717
 misfolding, 476, 477b, 477f, 478t
 phosphorylation, 39–40
 synthesis, 610
 as targets for drug binding, 6–15
 as therapeutic agents, 715–716
see also Peptides
- Proteoglycans, 69, 432
- Prothrombin, 298f
- Prothrombin time (PT), 301
- Protirelin, 395–396, 395t, 399b, 410–412
- Proton pump inhibitors
 clinical use, 363–364
 drug interactions, 695
 pharmacokinetics, 363–364
 unwanted effects, 363–364
- Proto-oncogenes, 673
- Protozoa, 655, 656t
 host-parasite interactions, 655
 treatment *see* Antiprotozoal drugs
- Provirus, 638–639
- Proximal convoluted tubule, 349, 349f
- PRRs *see* Pattern recognition receptors (PRRs)
- Pseudocholinesterase *see* Butyrylcholinesterase (BuChE)
- Pseudohypoparathyroidism, 692
- Pseudomembranous colitis, 633
- Pseudomonas aeruginosa*, 622, 630
- Pseudomonas* spp., 623t
- Pseudoreceptors, 640
- Psilocybin, 585t, 589–590, 591b
 adverse effects, 589
 dependence, 589
 pharmacological effects, 589
- Psoriasis, 700–701
- Psychedelic drugs *see* Psychotomimetic drugs
- Psychiatric disorders, 442
- Psychodysleptics *see* Psychotomimetic drugs
- Psychomotor epilepsy, 540–541
- Psychomotor stimulants, 446t, 584–589, 585t
 clinical uses, 447
 dependence, 593t
- Psychostimulants *see* Psychomotor stimulants
- Psychotomimetic drugs, 446t, 585t, 589–590, 591b, 593t
- Psychotropic drugs
 classification of, 446–447
 effects, 445
- Pulmonary artery pressure, 282
- Pulmonary emboli, recurrent, 282
- Pulmonary hypertension, 195, 203, 282, 282b, 282f
- Pulse pressure, 265–266
- Pupillary constriction, effects of opioids, 515
- Purgatives, 368
- Purines, 204–207, 470–471, 473b
 analogues, 611, 681, 681b
 future prospects, 207
 as mediators, 204–206, 205b, 205f
 receptors *see* Adenosine receptors; P2X ionotropic receptors; P2Y metabotropic receptors
- Purkinje fibres, 246
- Pyrantel, 616, 617b
- Pyrazinamide
 clinical use, 634–635
 unwanted effects, 635
- Pyrethrins, 530
- Pyridostigmine, 169, 170t
 blood-brain barrier, 110–111
 effects, 170
- Pyrimethamine, 616b, 625
 action/effects, 610–611, 661
 clinical uses, 625b
 malaria chemoprophylaxis, 659
 malaria treatment, 611, 658, 663b
 toxoplasmosis, 666
 pharmacokinetics, 662
 structure, 662
 unwanted effects, 703–704
- Pyrimidines, 204
 action/effects, 611
 analogues, 681, 681b
 fluorinated, 649–650
- Pyrimidinoceptors, 204
- Pyronaridine, 663
- Q**
- Quality-adjusted life years (QALYs), 96
- Quaternary ammonium compounds, 159–160
- Quetiapine
 action/effects, 559
 characteristics, 556t–557t
 clinical use, 581–582, 582b
- Quinacrine, 490
- Quinagolide, 397–398
- Quinidine, 256
 action/effects, 255
 drug interactions, 694
- Quinine
 clinical use, 658, 660–661, 663b
 excretion, 352–353
 pharmacokinetics, 661
 unwanted effects, 660–661, 708, 708b
- Quinolones, 631–632
 antibacterial spectrum, 632
 clinical use, 632, 632b
 mechanism of action, 624t, 632f
 pharmacokinetics, 632
 resistance, 620
 unwanted effects, 632
- Quinupristin, 631b, 633
- R**
- Rabeprazole, 363
- Radioiodine, 413–414, 415b
- Radiological contrast agents, 707–708
- Raf, 39
- Ralbinamide, 522
- Raloxifene, 420–421, 438–439
- Raltitrexed, 681
- Ramelteon, 471
- RAMPs *see* Receptor activity-modifying proteins (RAMPs)
- Randomisation (clinical trials), 95
- Randomised controlled clinical trials, 94
- Ranibizumab, 110
- Ranitidine, 363
- RANK (receptor activator of nuclear factor kappa B), 432–434, 434f
- RANTES, 81, 209t
- Rapamycin *see* Sirolimus
- Ras, 39, 376
- Rasagiline, 488
- Rasburicase, 332
- Ratelgravir, 645, 646b–647b, 647
- Raynaud's disease, 281–282
- Rb protein, 67–68
- Reactive depression, 564
- Reactive oxygen species (ROS), 480, 700
- Reboxetine, 567, 568t–570t, 577
- Receptor activator of nuclear factor kappa B (RANK), 432–434, 434f
- Receptor activity-modifying proteins (RAMPs), 37
- Receptor(s), 6–7, 20, 21f, 22t
 activation, 8, 8f
 constitutive, 13
 agonists *see* Agonists
 antagonists *see* Antagonists
 binding of drugs to, 8–9, 9f
 block of receptor-effector linkage, 15
 change in, 15–16
 classification, 8
 control of expression, 44–45
 death, 71–72
 definition of, 6–7
 and disease, 45–46
 drug interactions, 8–10
 quantitative aspects, 16–18
 heterogeneity, 25–26
 history of, 2
 ionotropic *see* Ligand-gated ion channels

- isolation and cloning, 23
 kinase-linked and related *see* Kinase-linked receptors
 metabotropic *see* G-protein coupled receptors
 molecular structure, 25–26
 nuclear *see* Nuclear receptors
 occupancy *see* Occupancy (of receptors)
 orphan, 23, 40
 in physiological systems, 7
 proliferation of, 144
 spare, 8–9, 11, 13–15
 subtypes, 25–26
 translocation of, 16
 two-state model, 13, 14f
 types of, 23–25
see also specific types
- Receptor tyrosine kinases (RTKs), 37, 78
 Rectal administration, 108
 Rectangular hyperbola, 17, 17f
 Red blood cells, 309
 Re-entry rhythm, 248, 248f
 Refractoriness, 15
 Regeneration, 73–74
 Regulators of G-protein signalling (RGS) proteins, 37
 Relative potency, 90–91, 92f
 Remacemide, 453–454
 Remifentanyl, 510, 517, 518t–519t, 519
 Remoxipride, 558
 Renal artery stenosis, bilateral, 701–702
 Renin, 347
 Renin-angiotensin-aldosterone system, 271, 273–274, 274t
 inhibition, 280
 Renin-angiotensin system, 270–271, 270f
 Renin inhibitors, 274, 274t
 Repaglinide, 381
 Repair processes, 73
 Reproductive system, 417–431
 drugs affecting, 420–425
 endocrine control of, 417–420
 female, neurohormonal control, 417–418, 418f, 419b
 male, neurohormonal control, 418–419, 419f, 423b
- Reserpine, 177, 190
 action/effects, 182t–184t, 193b, 554
 and amfetamines, 584–585
 clinical uses
 gastrointestinal motility, 369
 hypertension, 277
 and Parkinson's disease, 485
- Resistance, drug, 15
see also specific drugs; specific organisms
- Resistance arteries, 141
 Resolvins, 217
 Respiration, 336–337
 afferent pathways, 337
 blood vessels, 336–337
 control of breathing, 336
 efferent pathways, 336–337
 glands, 336–337
 physiology of, 336–337
 regulation of musculature, 336–337
 sensory receptors, 337
- Respiratory distress syndrome, 242, 345
 Respiratory syncytial virus, 646
 Respiratory system, 336–346
 effects of general anaesthetics on, 494–495
 effects of leukotrienes, 216–217
 effects of muscarinic antagonists, 163b
 effects of opioids, 514–515
 physiology of respiration, 336–337
- Resting cell, 53–54, 54f
 Reteplase, 307
 Retigabine, 522, 550
 Retinoic acid receptor (RAR), 42
 Retinoids, 704t, 706
 Retroviruses, 613, 640b
 gene delivery vectors, 719, 720f
 replication, 638–639
- Reversed transcriptase enzyme, 638–639
 Reward pathways, 594–595
 Reye's syndrome, 324
 RGS proteins *see* Regulators of G-protein signalling (RGS) proteins
- Rheumatoid arthritis, 326
 Rho A/Rho kinase, 32, 34
 Rhodopsin, 28
 Rho kinase inhibitors, 34
 Ribonucleotide reductase, 317
 Ribosomes, 610
 Rickets, 437
Rickettsiae, 623t, 628–629
- Rifabutin
 clinical use, 634
 drug interactions, 426
- Rifampicin, 613, 622
 action/effects, 634
 clinical use
 leprosy, 635–636, 636b
 tuberculosis, 634–635
 drug interactions, 342, 426, 430, 635, 652, 694–695, 695f
 excretion, 119
 induction of microsomal enzymes, 118
 pharmacokinetics, 634–635
 resistance, 619
 unwanted effects, 635
- Rifamycin, 613
 Riluzole, 478, 582
 Rimantadine, 645
 Rimonabant, 225–226
 actions/effects, 473
 clinical use, 392–393
- Ring hydroxylation, 576
 Ringworm, 649
 Risedronate, 438
 Risk, clinical trials, 97–98
 Risperidone, 555
 action/effects, 559
 characteristics, 556t–557t
 clinical efficacy, 563
 clinical uses, 562b
 anxiety, 532
 bipolar disorder, 581–582, 582b
- Ritalin *see* Methylphenidate
 Ritodrine, 182t–184t, 428, 429b
 Ritonavir, 430, 643
 Rituximab, 330, 331t, 334, 684, 685b
 Rivaroxaban, 300
 Rivastigmine, 483, 484b, 484t
 Rizatriptan, 202t
 (R)-methylhistamine, 211
- RNA
 synthesis, 612–615
 translation, 132–133
 types of, 612
- RNA polymerase, 638
 inhibition, 613
- RNA viruses, 638, 640b
 replication, 638
- Ro64-6198, 513t
 Rofecoxib, 323, 698–699
 Rolipram, 32
 Ropinriole, 488
 Ropivacaine, 528
 Rosiglitazone, 381–382, 390
 Rosuvastatin, 289
- Rotenone, 486
 Rotigotine, 488
 Roundworms, 668–671, 669t
 Routes of administration, 106–110, 107f
see also specific drugs; specific routes
- R plasmids, 617
 Rubella, 704–705
 Ruboxistaurin, 383
 Rufinamide, 550
 clinical uses, 543
 properties, 544t–545t
- Rupatidine, 217
 RXR, 40
 Ryanodine, 52
 Ryanodine receptor (RyR), 43–44, 52, 692
 cardiac muscle contraction, 59–60
 mutations, 59–60
 skeletal muscle contraction, 59

S

- Sacral outflow, 141
 Safety of drugs, 698
 Safety pharmacology, 728
 St Anthony's fire, 198–199
 St John's wort, 117, 567, 568t–570t
- Salbutamol, 428
 action/effects, 182t–184t
 clinical uses
 asthma, 341, 341b, 343
 chronic obstructive pulmonary disease, 345
 hyperkalaemia, 358
 drug interactions, 693
 use in sport, 712t
- Salcatonin, 439, 439b
 Salicylate, 324
 drug acetylation deficiency, 134–135
 drug interactions, 694
 excretion, 352–353
 saturation kinetics, 128
see also Aspirin
- Salicylism, 324
 Salivary glands, 141
 Salivation
 effects of muscarinic agonists, 158
 effects of muscarinic antagonists, 161
- Salmeterol
 action/effects, 182t–184t
 clinical uses
 asthma, 340–341, 341b
 chronic obstructive pulmonary disease, 345
- Salmonella* spp., 369, 623t
Salmonella typhimurium, 703, 704b
- Salt balance, 353
 Salvinorin A, 585t, 589–590
 Saquinavir, 643, 646b
 Sarafotoxin S6c, 268–269
- Sartans
 clinical uses, 276b
 vasodilatation, 275–276
- Sativex, 522
 Saturation kinetics, 128–129, 129f
 Saxitoxin, 530
 SB 612111, 513t
- Scandinavian Simvastatin Survival Study, 289
 Scatchard plot, 17
 Schild equation, 18
 Schild plot, 18
Schistosoma haematobium, 668
Schistosoma japonicum, 668
Schistosoma mansoni, 668
 Schistosomiasis, 668, 670

- Schizont, 657
- Schizophrenia, 442
 aetiology, 554–555
 environmental factors, 554
 genetic factors, 554
 nature of, 553–555, 555b
 negative symptoms, 553
 neuroanatomical and neurochemical basis, 554–555
 pathogenesis, 554–555
 positive symptoms, 553
 treatment *see* Antipsychotic drugs
- Sclerostin, 432
- Scopolamine, 159–160, 366
- Scrapie, 489–490
- Second messengers, 52
- Sedatives, 446t
- Seizures, 540
 absence, 541–542
 generalised, 541–542
 partial, 540–541
 tonic-clonic, 541–542
 xanthine drugs adverse effects, 341
- Selective attention, 553
- Selective oestrogen receptor modulator (SERM), 420–421, 438
- Selective serotonin reuptake inhibitors (SSRIs), 194, 466–467, 469b, 567, 573–574, 574b
 characteristics, 568t–570t
 clinical uses
 anxiety, 532
 smoking cessation, 602
 pharmacokinetics, 574
 unwanted effects, 574
- Selegiline, 486, 488, 577–578
- Senna, 368, 670
- Sepsis, 243
- Septohippocampal nucleus, 468–470
- Serine/threonine kinases, 37
- Sermorelin, 395, 395t, 399b
- Serotonin *see* 5-Hydroxytryptamine (5-HT)
- Serotonin syndrome, 574
- Serotonin uptake transporter (SERT), 195, 203
- Sertindole
 action/effects, 560
 characteristics, 556t–557t
- Sertoli cells, 418–419
- Sertraline, 567, 568t–570t, 573–574
- Sertürner, Friedrich, 1–2
- Sevelamer, 358
- Severe combined immunodeficiency (SCID), 721–722
- Sevoflurane, 497, 500, 501b
 characteristics, 498t
 induction and recovery, 499
 metabolism, 500
- Sex hormones, 399b, 417
 behavioural effects of, 419–420
- Sex pili, 618
- SH2 domain proteins, 39
- Shear stress, 238–239
- Shigella*, 369, 623t
- Shingles, 639, 645b
- Shock, 280–281, 281f
- Sibutramine
 clinical uses, 391–392, 581
 lifestyle use, 711t
 pharmacokinetics, 392
 unwanted effects, 392
- Sickle cell anaemia, 282
- Signalling, chemical
 in the central nervous system, 442–443, 443f
 in nociceptive pathway, 507–509
- Sildenafil, 32, 240, 429–430
 clinical uses, 711t
 drug interactions, 693
 lifestyle use, 710, 711t, 713b
- Silver sulfadiazine, 625b
- Simeticone, 364
- Simvastatin, 289
- Single-compartment model, 124–126, 125f–126f
- Single-gene defects, 722
- Single-gene pharmacokinetic disorders, 133–135
- Single nucleotide polymorphisms (SNPs), 103, 133
- Sinoatrial (SA) node, 246
- Sirolimus, 113, 329, 727–728
- Sitagliptin, 382
- Site-directed mutagenesis
 G-protein coupled receptors, 29
 ligand-gated ion channels, 26
- Skeletal muscle
 contraction, 59
 effects of adrenoceptor agonists, 186
 excitation, 56–57
- Skin
 as an administration route, 108–109
 autonomic nervous system effects on, 142t
 as a defence against viruses, 639
 effects of non-steroidal anti-inflammatory drugs, 322
- Sleep
 and benzodiazepines, 534–535
 effects of 5-hydroxytryptamine, 468
- Slow excitatory postsynaptic potential (slow epsp), 156
- Slow inhibitory (hyperpolarising) postsynaptic potential (slow ipsp), 156
- Slow-reacting substance of anaphylaxis (SRS-A), 215
- Slow transmitters, 62–63, 63f
- S-methyl-L-thiocitrulline, 242
- Smoking, 598b
 annual cigarette consumption, 598f
 effects of, 598–599
 on the central nervous system, 598
 harmful, 600–601, 601b
 peripheral effects, 598
 pharmacological approaches to cessation, 601–602
 withdrawal syndrome, 599
- Smooth muscle
 bronchial, 141
 cAMP-dependent protein kinase, 32
 contraction, 59–61, 61f
 effects of adrenoceptor agonists, 181
 effects of adrenoceptors, 176t
 effects of antidiuretic hormone, 400
 effects of calcium antagonists, 262–263
 effects of ergot alkaloids, 199
 effects of ethanol, 604
 effects of histamine, 211
 effects of 5-hydroxytryptamine on, 195
 effects of muscarinic agonists, 158
 effects of muscarinic antagonists, 161
 effects of opioids, 515
 vascular *see* Vascular system, smooth muscle; Vasoconstrictor drugs; Vasodilator drugs
- SNAREs, 63
- S-nitrosoacetylpenicillamine (SNAP), 240
- S-nitrosoglutathione (SNOG), 240, 242
- Social anxiety disorder, 531
- Sodium aurothiomalate, 328
- Sodium bicarbonate, 358
- Sodium channel blockers, 55, 57, 255–256, 530
 antidysrhythmic action *see* Antidysrhythmic drugs, class I
 clinical uses, 257b, 522
 use-dependent, 255
see also Anaesthetics, local
- Sodium channels
 activation, 255
 agents affecting gating of, 530
 effect of antiepileptic drugs, 545–546
 epithelial, 64
 excitation and, 54–57, 55f, 57f
 inactivation, 255
 voltage-gated, 44, 54
- Sodium cromoglicate, 370
- Sodium (ions)
 excitation and, 54
 transport, 64
 renal, 349–350
- Sodium oxybate, 586
- Sodium picosulfate, 368
- Sodium polystyrene sulphonate, 358
- Sodium pump, 21–23
- Sodium stibogluconate, 666
- Soft tissue necrosis, 302
- S oligomers, 723
- Solute carrier, 100
- Solute carrier (SLC) transporters, 101
- Solvents, 593t
- Somatomedins, 396
- Somatorelin, 395, 395t
- Somatostatin, 235t, 377, 394–395, 399b, 412
 analogues, 683
 clinical use, 522
 gastric acid secretion, 362
 secretion, 372
 unwanted effects, 395
- Somatotrophin, 396–397
- Somatotrophs, 394
- Somatotropin, 399b
- Somogyi effect, 379
- Sorafenib, 684, 685b
- Sotalol, 257
 action/effects, 256
 clinical uses, 257b
 mechanism of action, 255t
 stereoselectivity, 117
- Spare receptor hypothesis, 8–9, 11, 13–15
- Spasmolytic agents, 369–370
- Special drug delivery systems, 111–113
- Special K *see* Ketamine
- Specificity of drugs, 7–8
- Speed *see* Amphetamine(s)
- Spermatogenesis, 399b, 418–419
- S phase of cell cycle, 66, 67f, 68
- Spinal anaesthesia, 529t
- Spiramycin, 631
- Spironolactone, 259, 355
 clinical uses, 407
 heart failure, 280
 hypertension, 277–278
 pharmacokinetics, 355
 vasodilatation, 274t
- Spongiform encephalopathy, 489–490
- Sporozoa, 655, 656t
- Sporozoites, 656–657
- Sport, drugs in, 710–713, 712t, 714b
 anabolic steroids, 711–713
 human growth hormone, 713
 stimulants, 713
- Squalene epoxidase, 653
- Staphylococci, 618, 623t
 resistance, 619–620
- Staphylococcus aureus*, 611–612
 resistance, 619–620

- Stat, 39
- Statins, 285, 289–290
action/effects, 289–290
adverse effects, 290
clinical uses, 281, 290b
pharmacokinetics, 289–290
- Status asthmaticus, 337, 343
- Status epilepticus, 548
- Stavudine, 643
- Steal, vascular, 260
- Stem cells, 73–74
- Stents, 113
- Sterculia, 368
- Stereoselectivity, 117
- Steroids/steroid hormones, 444t
as anaesthetics, 492
delaying absorption of, 109
effect of ethanol on, 605
esterification, 109
receptors, 42
- Sterols, 609
- Stevens Johnson syndrome, 135, 707–708
- Stilbestrol, 704t, 705
- Stim1, 51
- Stimulant drugs, use in sport, 713
- Stimulant laxatives, 368
- Stiripentol, 550
- Storage vesicles/granules, 61–62
- Store-operated calcium channels, 44, 51, 51t
- Stratified randomisation, 95
- Straub tail reaction, 515
- Streptococci, 623t, 630
- Streptogramins, 624t, 633
- Streptokinase, 235t, 307
- Streptomyces*, 627–629, 650
- Streptomycin, 622, 630, 727–728
clinical use, 634
resistance, 619
- Stress, 110–111
- Stretch receptors, respiratory system, 337
- Stroke *see* Ischaemic brain damage
- Stroke volume, 249
- Strongyloides infestation*, 670
- Strongyloides stercoralis*, 668
- Strontium ranelate, 437, 439
- Strychnine, 458, 459b, 713
- Subcutaneous injection of drugs, 109
- Sublingual administration, 108
- Submucous plexus, 360
- Substance P, 219, 504–505
and carcinoid syndrome, 202
central facilitation, 505
NANC transmission, 145–147, 148t
nociceptive pathway, 509
postsynaptic modulation, 145
respiratory system, 337
vomiting, 365
- Substantia gelatinosa (SG), 506
- Substantia nigra, 464
- Succinyl-CoA, 313
- Sucralfate
gastric mucosa protection, 365
unwanted effects, 365
- Sufentanil, 510, 519
- Sugammadex, 166, 167b
- Suicide and antidepressants, 580
- Sulconazole, 652
- Sulfadiazine, 622, 666
- Sulfadoxine, 611, 661–662, 663b
- Sulfamethoxazole, 622, 626b
- Sulfanilamide, 622–623
- Sulfapyridine, 327–328, 370
- Sulfasalazine, 327–328, 622
clinical uses, 370, 625b
urate secretion inhibition, 357
- Sulfation, 228
- Sulfhydryl groups modification, 700
- Sulfinpyrazone, 332
action, 357
clinical trials, 97
drug interactions, 325
- Sulfonamides, 327–328, 356–357, 622–623
action/effects, 610, 661
binding, 105
clinical uses, 625b
discovery of, 2
drug interactions, 693–694
interfering with folate action, 626b
mechanism of action, 622–623, 624t
metabolism, 135
pharmacokinetics, 623
resistance, 619
unwanted effects, 623, 708
- Sulfones, 661
- Sulfonyleurea receptor (SUR), 44
- Sulfonyleureas, 58, 380–381, 380t
channel gating, 21
clinical uses, 381, 383
drug interactions, 381
mechanism of action, 380
pharmacokinetics, 381
unwanted effects, 381
- Sulindac, 319t, 322
- Sulpiride
action/effects, 558
characteristics, 556t–557t
clinical use, 562
- Sumatriptan, 196, 468, 469b
migraine management, 202t
vasoconstriction, 271
- Sunitinib, 684
- Superoxide anion, 239–240
- Superoxide dismutase (SOD), 480
- Supraoptic nucleus, 399
- Supraventricular tachycardia (SVT), 247–248
- Suramin, 207
clinical uses, 665
unwanted effects, 665
- Surface anaesthesia, 529t
- Surfactants, 345
- Survival curves, 94–95, 95f
- Survivin, 74–75
- Suxamethonium, 156–157, 166, 167b, 168
characteristics, 165t
effect of genetics on, 692b
idiosyncratic reactions, 692
pharmacokinetics, 165
sensitivity, 133–134
unwanted effects, 166–167, 167f
- Sweat glands, 141
- Sweating
effects of muscarinic agonists, 158
effects of muscarinic antagonists, 161
excretion via, 115
- Sympathetic nervous system, 140–141
control of the heart, 251–252
insulin release, 374
respiratory system, 337
role in energy expenditure control, 388–389
- Sympathomimetic amines
directly acting *see* Adrenoceptor agonists
indirectly acting, 182t–184t, 191–192
actions, 192
mechanism of action, 191
structure-activity relationships, 191
vasoconstriction, 271, 272b
- Synapse
cholinergic
effect of anticholinesterases, 170
electrical events, 156–157, 156f
ganglionic, 156, 156f
- Synaptic plasticity, 451–453, 472
- Synaptobrevin, 63
- Synaptotagmin, 63
- Synaptotaxin, 63
- Syndrome of inappropriate ADH secretion (SIADH), 399–400
- Synuclein, 93, 485
- Systemic lupus erythematosus, 708–709, 708b
- T**
- Tachycardia, 247
atropine-induced, 161
 β_2 -adrenoceptor agonists effects, 341
- Tachyphylaxis, 15–16
- Tacrine, 483, 484t
- Tacrolimus, 329–330
- Tadalafil, 240, 429
- Taenia saginata*, 668
- Taenia solium*, 668, 670
- Tafenoquine, 659, 662
- Tamoxifen, 286
antioestrogenic action, 420–421
clinical uses, 683, 684b
and CYP2D6, 136–137
and dyslipidaemia, 288
- Tamsulosin, 424
action/effects, 182t–184t, 187
clinical uses, 358
- Tapeworms, 668, 670
- Tardive dyskinesias, 560, 561b, 698
- Target concentration strategy, 123
- Targets for drug action, 6–15, 7b, 20–23, 21f, 22t, 444
in drug development, 726–727
gene tests related to, 137
- Tau, 483
- Taurine, 713
- Taxanes, 682
- T cells
adaptive immune response, 82–84, 84f
in asthma, 337–338, 338f
clonal proliferation, 329, 329b
cytotoxic *see* CD8⁺ T lymphocytes
helper *see* CD4⁺ T-helper lymphocytes;
T-helper cells
- Tegafur, 681
- Tegaserod, 198, 368–369
- Teicoplanin, 633
- Telbivudine, 643
- Telcagepant, 200
- Telithromycin, 631
- Telomerase, 674–675, 687
- Telophase, 68
- Temazepam, 538b
characteristics, 533t
clinical uses, 532
- Temocillin, 627
- Temozolomide, 679
- Tenofovir, 643
- Tenoxicam, 319t
- Teratogenicity, 704–707, 704t, 707b
anticancer drugs, 676
anticoagulants, 302
definite and probable human teratogens, 705–706
genotoxic potential testing, 707
mechanism of, 705
nature of drug effects, 705t

- testing for, 705
see also specific drugs
- Terazosin, 424
- Terbinafine, 653
- Terbutaline
 action/effects, 182t–184t
 clinical uses, 341
- Teriparatide, 439
- Terlipressin, 400, 400b
- Testosterone, 418–419
 administration, 109, 423
 pharmacokinetics, 423
 synthesis, 422–423
- Tetanic fade, 166
- Tetanus toxin, 458
- Tetrabenazine, 136–137, 489
- Tetracaine, 527t
- Tetracosactide, 398
- Tetracycline(s), 628–629
 absorption, 108
 action/effects, 631b
 antibacterial spectrum, 628–629
 clinical uses, 629b
 drug interactions, 365, 693
 mechanism of action, 624t, 628
 partitioning into fat/tissues, 106
 pharmacokinetics, 629
 resistance, 619
 teratogenicity, 704t
 unwanted effects, 629, 704t
- Tetraethylammonium, 172
- Tetrahydrobiopterin (H₄B), 237
- Tetrahydrocannabinol (THC), 221–222, 222f, 551, 585t, 589, 710
- Tetrahydrofolate, 312–313, 610–611, 680
- Tetrahydrogestrinone (THG), 711–713
- Tetrodotoxin, 55–56, 530
- Thalassaemia, 311
- Thalidomide, 685, 704–706, 704t
- Thapsigargin, 51–52
- Thebaine derivatives, 510
- T-helper cells, 208
 in asthma, 337–338
 CD4⁺ *see* CD4⁺ T-helper lymphocytes
 clonal proliferation, 329, 329b
 host-parasite interactions, 655
 Th0, 84, 85t
 Th1, 85t, 671
 Th2, 85t, 671
 Th17, 85t
- Theophylline, 205b, 258
 action/effects, 588
 clinical uses
 asthma, 206, 340–341, 341b
 chronic obstructive pulmonary disease, 345
 drug interactions, 342, 365, 631–632
 mechanism of action, 341
 pharmacokinetics, 342
 unwanted effects, 341
see also Aminophylline
- Therapeutic drug monitoring (TDM), 123, 124t
- Therapeutic index, 97
- Thermal sensation, 507–508, 508t
- Thermogenesis, 388
- Thiamine deficiency, 604
- Thiazide diuretics, 354–355
 clinical uses, 277, 279t, 355b
 drug interactions, 696
 excretion, 352–353
 pharmacokinetics, 355
 physiological adaptation, 16
 unwanted effects, 355
 use in sport, 712t
- Thiazolidinediones, 381–382, 383b
 clinical use, 382–383
 effects, 381
 mechanism of action, 381–382
 nuclear receptors, 42
 and obesity, 390
 pharmacokinetics, 382
 unwanted effects, 382
- Thienopyridines, 304–305
 clinical use, 304–305
 pharmacokinetics, 304
 unwanted effects, 304
- Thioguanine, 611
- Thiopental, 105, 492, 495–496, 496t, 497b
- Thiopropamide, 211, 363t
- Thiopurines, 136
- Thiopurine-S-methyltransferase (TPMT), 136
- Thiotepa, 679
- Thioureylenes, 414, 415b
 mechanism of action, 414
 pharmacokinetics, 414
 unwanted effects, 414
- Thirst, 399
- Thoracolumbar sympathetic outflow, 140–141
- Thorn apple, 159–160
- Threadworm, 668, 669t, 670–671
- Thrifty genes, 385
- Thrombin, 29, 79–80, 294
 direct inhibitors, 300
 role in coagulation, 295–296
- Thrombocytopenia, 708
- Thrombocytopenic purpura, 302
- Thromboembolism, 426
- Thrombolysis *see* Fibrinolysis
- Thrombomodulin, 296–297
- Thrombophilia, 294
- Thrombopoietin, 314–315
- Thrombosis, 286, 296b, 298–302
 definition, 294
 heparin adverse effects, 299
 treatment, 298–302
 vascular endothelium in, 296–297
- Thrombospondin, 69
- Thromboxane A₂, 213–214
 action/effects, 214
 in inflammation, 214
 inhibition, 303–304
- Thromboxanes, 212
- Thrombus, 294, 295f
- Thymidylate, 680f
- Thyroglobulin, 410
- Thyroid, 410–416, 413b
 acinus, 410
 disorders, 413–415, 415b
 follicle, 410
 function regulation, 410–412
 hormones *see* Thyroid hormones
- Thyroid hormone receptor (TR), 42
- Thyroid hormones
 actions, 412
 mechanism of action, 412
 metabolism, 412–413
 secretion, 399b, 410, 411f
 storage, 410
 synthesis, 410, 411f
 transport, 412–413
see also Thyroxine (T₄);
 Tri-iodothyronine (T₃)
- Thyroid-stimulating hormone (TSH), 399b
 production, 412
 thyroid function regulation, 410–412
- Thyroid storm, 415
- Thyropoxidase, 410
- Thyrotoxicosis *see* Hyperthyroidism
- Thyrotrophin, 399b
- Thyrotrophin-releasing factor, 399b
- Thyrotrophin-releasing hormone (TRH), 395–396, 395t, 410–412
- Thyrotrophs, 394
- Thyrotropin receptors, 45–46
- Thyroxine-binding globulin (TBG), 412–413
- Thyroxine (T₄), 410
 absorption, 108
 actions, 412
 bone metabolism and remodelling, 437
 clinical uses, 415, 415b
 metabolism, 412–413
 transport, 412–413
- Tiabendazole, 669–670
- Tiagabine, 456, 549
 action/effects, 545
 clinical uses
 anxiety, 532
 epilepsy, 543
 properties, 544t–545t
- Tiaprofenic acid, 319t
- Tibolone, 422
- Ticarcillin, 627, 627b
- Ticlopidine, 206, 304
- Tigecycline, 628
- Timolol, 109
- Timpranavir, 643
- TIMPS (tissue inhibitors of metalloproteinases), 70
- Tinea, 649
- Tinidazole, 664, 664b
 clinical uses
 giardiasis, 666
 trichomoniasis, 666
- Tioconazole, 652
- Tioguanine, 681
- Tiotropium, clinical uses
 asthma, 342
 chronic obstructive pulmonary disease, 345
- Tirofiban, 305
- Tissue inhibitors of metalloproteinases (TIMPS), 70
- Tissue kallikreins, 218
- Tissue plasminogen activator (tPA), 296–297, 306
- Tizanidine, 551
- TNF converting enzyme (TACE), 334
- Tobacco
 lifestyle use, 711t
see also Nicotine; Smoking
- Tobramycin, 630
- Toclizumab, 334
- Tolazoline, 11–13, 12f
- Tolbutamide, 104, 380, 380t
- Tolerance, 15, 595–597
 mechanisms of, 595–597
see also specific drugs
- Tolfenamic acid, 319t
- Toll-like receptors (TLRs), 37, 78, 79t
- Tolterodine, 159–160, 358
- Tolvaptan, 280
- Tonabersat, 550
- Tophi, 331–332, 357
- Topiramate, 549
 action/effects, 543
 clinical uses
 alcohol dependence, 607
 bipolar disorder, 582
 epilepsy, 543
 ethanol dependence, 605b
 neuropathic pain, 521
 in pregnancy, 551
 properties, 544t–545t

- Topoisomerase, 631–632, 632b
 Topoisomerase II, 612, 681
 Topotecan, 682
 Torcetrapib, 288
 Toremifene, 683
 Torsade de pointes, 256–257
 Toxic epidermal necrolysis, 135, 707
 Toxicity, 699–707
 cell damage and cell death, 700–702
 covalent interactions, 700
 non-covalent interactions, 700
 testing, 699–707, 728
 types of, 699b (*see also specific types e.g.*
 Nephrotoxicity)
- Toxocariasis, 669
Toxoplasma gondii, 655, 666
 Toxoplasmosis, 666
 Trabecular bone, 432
 TRAIL, 72
 Tramadol, 518t–519t, 520
 Tranexamic acid
 action, 307
 clinical uses
 angio-oedema, 344
 bleeding, 307
- Tranquillisers *see* Antipsychotic drugs;
 Anxiolytics; Sedatives
- Transcellular fluid, 110
 Transcobalamins, 313
 Transcranial magnetic stimulation (TMS),
 579–580
 Transferrin, 311
 Transforming growth factor (TGF), 37
 Transforming growth factor (TGF)- α , 209t
 Transforming growth factor (TGF)- β , 69
 Transgenic animal models, 93
 Transient receptor potential (TRP) channels,
 507–508, 508t
 7-Transmembrane receptors *see* G-protein
 coupled receptors
- Transport
 carrier-mediated, 101–103
 drugs across cell barriers, 99–103, 100f
 epithelial ion, 63–64, 64b, 64f
 neurotransmitters, 147–149
- Transporters, 21–23, 21f, 22t
 Transposons, 617
 Tranlycypromine, 567, 568t–570t, 577–578,
 579b
 Trastuzumab, 685b, 717, 718t, 730
 clinical uses, 684
 and HER2, 137
- Traveller's diarrhoea, 369
 Trazodone, 567, 568t–570t, 577, 579b
 Trematodes *see* Flukes
 Tremor, 341, 485
 Treosulfan, 679
Treponema pallidum, 627
Treponema spp., 623t
 Tretinoin, 686
 Triamcinolone, 401t
 Triamterene, 356
 excretion, 352–353
 pharmacokinetics, 356
 unwanted effects, 356
- Triazolam
 characteristics, 533t
 clinical uses, 534
 unwanted effects, 537
- Tribavirin, 646
 Tricarboxylic acid cycle, 610
Trichinella spiralis, 668–669
Trichomonas vaginalis, 666
 Trichomoniasis, 666
Trichophyton, 649, 650t
Trichuris trichiura, 668
- Tricyclic antidepressants, 567, 574–576, 576b
 action/effects, 7, 192, 193b
 acute toxicity, 576
 clinical uses
 anxiety, 532
 neuropathic pain, 521, 522b
 smoking cessation, 602
 distribution, 111
 drug interactions, 576
 mechanism of action, 575
 pharmacokinetics, 576
 unwanted effects, 575–576
- Trifluoperazine, 367
 Trifluoroacetylchloride, 708
 Triglycerides, 286, 290
 Tri-iodothyronine (T₃), 410
 actions, 412
 clinical uses, 415, 415b
 metabolism, 412–413
 transport, 412–413
- Trilostane, 402, 683
 Trimetaphan, 163
 Trimethadione, 548
 Trimethoprim, 616b, 622, 625
 action/effects, 610–611
 clinical uses, 626b
 drug interactions, 693
 interfering with folate action, 626b
 mechanism of action, 625
 pharmacokinetics, 625
 resistance, 619
 structure, 661
 unwanted effects, 625
 see also Co-trimoxazole
- Trinucleotide repeat neurodegenerative
 diseases, 489
- Triple response, 211
 Triptans, 201, 202t, 469b
 Triptorelin, 683
 Troglitazone, 381
 Trophozoites, 657, 664
 Tropicamide, 159–160
 Tropisetron, 366–367
 Troponin
 muscle contraction, 59
 myocardial infarction, 253
- Troponin C, 249
 Trospium, 358
 TRPA1, 508, 508t
 TRP channel ligands, 522
 TRPM8, 508, 508t
 TRPV1, 508, 508t, 509b
- Trypanicidal drugs, 664–665
Trypanosoma cruzi, 664
Trypanosoma gambiense, 664
Trypanosoma rhodesiense, 664
Trypanosoma spp., 655
 Trypanosomiasis, 664–665
 Tryptophan, 194, 466–467
 Tryptophan hydroxylase, 194, 466–467
 T-tubules, 59
 T-type calcium channels, 50, 51t
- Tuberculosis, 634–635
 Tuberohypophyseal dopaminergic
 pathway, 394, 463, 465
 Tuberoinfundibular system *see*
 Tuberohypophyseal dopaminergic
 pathway
- Tub* gene, 385–386
 Tubocurarine, 156, 156f, 164, 167b, 469–470
 characteristics, 165t
 histamine release, 211
 unwanted effects, 164
- Tubules (renal), 347, 349–352
 collecting, 350–352, 351f
 distal, 350
- diuretics acting on, 354–355
 loop of Henle, 349–350
 medullary counter-current multiplier
 and exchanger, 349–350
 proximal convoluted, 349, 349f
 secretion, 120, 120t, 696, 696f
- Tubulin, 332
 Tumour necrosis factor receptor (TNFR), 72
 Tumour necrosis factor (TNF), 71f, 72,
 432–433
 Tumour necrosis factor (TNF)- α , 208
 action/effects, 209t
 innate immune response, 78
 and obesity, 390
 oxidative stress, 480
 Tumour necrosis factor (TNF)- β , 209t
 Tumour suppressor genes, 673
 Turner's syndrome, 397
 20th century pharmacology, 2–5
 21st century pharmacology, 2–5
 Two-compartment model, 127–128, 128f
 Two-pore domain potassium channels,
 58–59, 58t
 Two-state receptor model, 13, 14f
 Tyramine, 191, 578, 586
 action/effects, 182t–184t, 193b
 drug interactions, 693
 Tyrosine, 512
 Tyrosine hydroxylase, 175–177, 554
 Tyrosine residues, iodination of, 410, 411f
- ## U
- Ubiquinone, 663
 Ubiquitin, 66
 UGT1A1*28, 137
 UK Prospective Diabetes Study, 378
 Ulcerative colitis, 370, 601
 Unconsciousness, 494
 Uncoupling proteins (UCP), 388–390
 Unipolar depression, 564
 Uniporters, 101–102
 Urate crystals, 331–332, 357
 Uric acid, 331–332, 357
 Uric acid oxidase, 332
 Uricosuric agents, 332, 357
 Uridine diphosphate glucuronic acid
 (UDPGA), 117
 Urinary pH, drug interactions, 696
 Urinary tract disorders, 358
 Urine
 alkalinisation, 356–357
 excretion in *see* Kidney(s), excretion via
 flow alteration, drug interactions, 696
 pH
 drugs that alter, 356–357
 effect on excretion, 120, 121f
 Urodilatin, 353
 Urokinase-type plasminogen activator, 306
 Ursodeoxycholic acid, 370
 Urticaria, 561
 Uterus, 427–428
 motility, 427
 relaxants, 428, 428b
 stimulants, 427–428, 428b
- ## V
- Vaccination/vaccines
 anthelmintic, 672
 unwanted effects, 707–708
 against viruses, 647
 Vagal activity, 252
 Vagus, 139

- Vagus nerve, 141
 Vagusstoff, 139
 Valaciclovir, 112–113, 645
 Valdecocixib, 326, 698–699
 Valganciclovir, 645
 Validity, 92–93
 Valproate, 445–446
 action/effects, 543, 546
 clinical uses
 anxiety, 532
 bipolar disorder, 581–582, 582b
 epilepsy, 543, 547–548, 550b
 pharmacokinetics, 548
 in pregnancy, 551
 properties, 544t–545t
 teratogenicity, 704t, 706
 unwanted effects, 548, 704t, 706
 Valproic acid, 521
 Valsartan, 234, 274t, 275–276
 Vancomycin, 622, 633, 634b
 absorption, 108
 action/effects, 612
 clinical use, 620, 633
 unwanted effects, 633
 Vanilloid receptors, 43–44
 Vanillylmandelic acid (VMA), 179
 Vardenafil, 429
 Varenicline, 162, 597b, 601
 Variant Creutzfeldt-Jacob disease (vCJD), 489–490
 Variation, individual *see* Individual variation
 Varicella zoster virus, 639, 645b
 Vasa recta, 347
 Vascular effects
 of ergot alkaloids, 199
 of loop diuretics, 353
 of nitric oxide, 241
 Vascular endothelial cells
 bone remodelling, 432
 innate immune response, 81–82
 Vascular endothelial growth factor (VEGF), 69–70, 99, 267
 Vascular gene transfer, 723
 Vascular steal, 260
 Vascular system, 265–284
 endothelium, 266–269, 266f
 in angiogenesis, 267
 endothelin, 267–269
 in haemostasis and thrombosis, 296–297
 function, 265–266
 smooth muscle (*see also* Vasoconstrictor drugs; Vasodilator drugs)
 relaxation, 280
 tone, 266–271
 structure, 265–266
 Vasoactive drugs, 271–276, 271t
 clinical uses, 277–282, 283b
 see also Vasoconstrictor drugs;
 Vasodilator drugs
 Vasoactive intestinal peptide (VIP), 145–147, 148t, 336
 Vasoconstriction, 265
 adrenaline, 174
 antidiuretic hormone, 400
 endothelin receptors, 268–269
 ergot alkaloids, 199
 5-hydroxytryptamine, 195
 Vasoconstrictor drugs, 271, 271t, 272b
 Vasodilatation, 265
 adrenaline, 174
 bradykinin, 219
 effects of local anaesthetics, 528
 endothelin receptors, 268–269
 5-hydroxytryptamine, 195
 nitric oxide, 242
 non-steroidal anti-inflammatory drugs, 321
 thiazide diuretics, 355
 Vasodilator drugs, 271–276, 271t, 273b
 clinical uses
 pulmonary hypertension, 282
 Raynaud's disease, 281–282
 directly-acting, 272–273, 276b
 indirectly-acting, 273–276, 276b
 with unknown mechanism of action, 273, 276b
 Vasopressin *see* Antidiuretic hormone (ADH)
 Vaughan William classification, 255t
 Vecuronium, 164, 167b
 affect of disease on, 691
 characteristics, 165t
 distribution, 111
 excretion, 119
 Venlafaxine, 567, 576–577, 577b
 characteristics, 568t–570t
 clinical use, 521, 581
 Venous thrombus, 294
 Ventral tegmental area (VTA), 594
 Ventricles filling pressure, 250
 Ventricular fibrillation, 247–248
 Ventricular function curves, 249–250, 250f
 Ventricular stroke volume, 249
 Ventricular tachycardia, 247–248
 Ventromedial hypothalamus, 388
 Verapamil, 257–259, 671
 action/effects, 262
 calcium channels and, 50
 clinical uses, 205
 drug interactions, 694
 mechanism of action, 255t
 reversal of multidrug resistance, 687
 unwanted effects, 263
 vasodilatation, 272
 Veratridine, 57, 530
 Very low-density lipoprotein (VLDL), 286, 290
 Vesamicol, 155, 167
 Vesicular monoamine transporter (VMAT), 177–179, 179t
 Vesicular transporters, 148–149
 Vicriviroc, 645
 Vidarabine, 616b
 Vigabatrin, 456, 549
 action/effects, 545
 clinical uses, 543
 properties, 544t–545t
 Vildagliptin, 382
 Vinblastine, 616, 682
 Vinca alkaloids, 682, 727–728
 action/effects, 616, 617b
 antidiuretic hormone inhibition, 352
 effect on antidiuretic hormone, 399–400
 Vincristine, 616, 682, 683b
 Vindesine, 682
 Vinorelbine, 682
 Virchow, Rudolf, 1
 Virchow's triad, 294
 Virion, 638, 639f
 Viruses, 640b
 circumvention of host defences, 640
 DNA *see* DNA viruses
 function and life history, 638–639
 gene delivery vectors, 719–720
 host defences against, 639–640
 host-virus interaction, 639–640
 pathogenic, 638
 RNA *see* RNA viruses
 structure, 638, 639f, 639t
 Visceral larva migrans, 669t
 Vitamin B₁₂, 311–314
 administration, 314
 clinical uses, 312b
 deficiency, 309
 mechanism of action, 313, 313f
 Vitamin D
 bone metabolism and remodelling, 435–436, 436f, 437b
 deficiency, 437, 439
 preparations, 439
 Vitamin D₂, 436, 439
 Vitamin D₃, 436
 Vitamin D receptor (VDR), 42
 Vitamin E, 480
 Vitamin K, 297–298, 297f
 administration, 298
 antagonists, 300–301
 clinical uses, 298b
 pharmacokinetics, 298, 298f
 and warfarin, 301
 Vitamin K reductase component 1 (VKORC1), 137, 300–301
 Voltage dependence, 55
 Voltage-gated ion channels, 20, 44
 calcium *see* Calcium channels
 excitation and, 55, 57f
 gating, 43
 potassium *see* Potassium channels
 Volume of distribution, 111, 112t, 123
 Vomiting, 365–367
 anticancer drugs, 686
 dopamine, 466
 drugs for *see* Antiemetic drugs
 effects of opioids, 515
 reflex mechanism of, 365, 367b
 Voriconazole, 652
- ## W
- Wakefulness, effects of
 5-hydroxytryptamine, 468
 Ward-Romano syndrome, 256
 Warfarin, 297f, 300–301
 absorption, 108
 administration, 301
 and CYP2C9 + VKORC1 genotyping, 137
 drug interactions, 325, 332, 635, 693–695, 695f
 effect of ethanol on, 605
 elimination/excretion, 120
 factors that lessen the effect of, 301
 factors that potentiate, 301
 mechanism of action, 300–301
 personalisation, 132
 pharmacogenomic tests, 135
 pharmacokinetic antagonism, 15
 pharmacokinetics, 298f, 301
 stereoselectivity, 117
 teratogenicity, 704t, 706
 Water, body
 distribution, 110, 110f
 drug distribution throughout, 111, 112t
 Weight, body *see* Body weight regulation
 Well-stirred compartments, 99
 Whipworm, 668, 671
 Wilson's disease, 328
 Withdrawal syndrome, 595–597
 Wolff-Parkinson-White syndrome, 258
 Wound healing
 effect of glucocorticoids, 406
 toxicity of anticancer drugs, 676
Wuchereria bancrofti, 668–669

X

Xanthine drugs
 actions/effects, 471
 clinical use, 341–342
 mechanism of action, 341
 pharmacokinetics, 342
 unwanted effects, 341
 Xanthine oxidase, 117, 331–332, 695
 Xenobiotic receptor (SXR/PXR), 42
 Xenobiotics, 115
 Xenon, 492–494, 495b, 500
 X-linked nephrogenic diabetes insipidus,
 691

Y

Yeast-like fungi, 649, 650t
 Yeasts, 649, 650t

Yersinia, 623t
 Yohimbine
 action/effects, 182t–184t, 187
 clinical use, 429

Z

Zafirlukast
 actions/effects, 215–216
 clinical uses, 342
 Zanamivir, 645
 Zero-order kinetics, 128–129
 Ziconotide, 522
 Zidovudine, 641–643, 646b–647b
 action/effects, 112–113, 613
 drug interactions, 696
 pharmacokinetics, 641–643
 unwanted effects, 643
 Zileuton, 215–216
 Ziprasidone, 556t–557t
 Zoledronate, 438
 Zollinger-Ellison syndrome,
 362
 Zolmitriptan, 202t
 Zolpidem, 533, 538b
 characteristics, 533t
 clinical uses, 532
 Zona fasciculata, 400
 Zona glomerulosa, 400
 Zona reticularis, 400
 Zonisamide, 549–550
 clinical uses
 bipolar disorder, 582
 epilepsy, 543
 properties, 544t–545t
 Zonula occludens, 350
 Zopiclone, 532–533
 Zotepine, 556t–557t
 Zygote, 656–657